var title_f40_38_41568="3D view of insulin receptor";
var content_f40_38_41568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insulin receptor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A ribbon diagram of the structure of the insulin receptor kinase domain (from Val 978 to Lys 1283) as determined through x-ray crystallography. The alpha helices are shown in red, the &beta; strands in green, the side of chains of tyrosines 1158,1162, and 1163 are in yellow, the nucleotide binding loop is in orange, the catalytic loop is in dark blue, and the activation loop is in violet. The N and C termini are noted by N and C. An N- and a C-terminal lobe with a single connection can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Flier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41568=[""].join("\n");
var outline_f40_38_41568=null;
var title_f40_38_41569="Echo complex tutorial";
var content_f40_38_41569=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reciprocal complex (echo beat",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 140px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A ventricular premature beat is followed by a retrograde P wave due to retrograde conduction throught the atrioventricular (AV) node. Subsequent antegrade conduction through the AV node results in a normal QRS complex after a long PR interval.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41569=[""].join("\n");
var outline_f40_38_41569=null;
var title_f40_38_41570="Contents: Vascular surgery";
var content_f40_38_41570=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Vascular surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Vascular surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute aortic syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/16/37126\">",
"           Aortic intramural hematoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/24/9609\">",
"           Blunt thoracic aortic injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/19/25914\">",
"           Clinical manifestations and diagnosis of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/54/25449\">",
"           Management of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/45/8921\">",
"           Surgical and endovascular repair of blunt thoracic aortic injury",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Acute arterial occlusion",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/3/13368\">",
"           Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/13/13528\">",
"           Clinical presentation, evaluation, and treatment of renal atheroemboli",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/35/10809\">",
"           Embolism from aortic plaque: Thromboembolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/15/31994\">",
"           Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Amputation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/38/8810\">",
"           Lower extremity amputation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/43/23225\">",
"           Techniques for lower extremity amputation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Aneurysmal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/11/22712\">",
"           Clinical features and diagnosis of thoracic aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/11/11450\">",
"           Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/39/29304\">",
"           Iliac artery aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/7/10361\">",
"           Management and outcome of thoracic aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/53/38746\">",
"           Management of asymptomatic abdominal aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/61/11225\">",
"           Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/63/3065\">",
"           Popliteal artery aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/38/8809\">",
"           Surgical and endovascular repair of iliac artery aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/11/30904\">",
"           Surgical and endovascular repair of ruptured abdominal aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/23/37240\">",
"           Thoracic endovascular aneurysm repair",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Aortic arch vessel disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/27/20922\">",
"           Management of coarctation of the aorta",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/61/12245\">",
"           Overview of upper extremity peripheral artery disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/22/39273\">",
"           Posterior circulation cerebrovascular syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/39/36471\">",
"           Subclavian steal syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/60/3015\">",
"           Treatment of Takayasu arteritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Basic principles in vascular surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/30/41443\">",
"           Physical examination of the hemodialysis arteriovenous fistula",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cerebrovascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/16/266\">",
"           Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/47/8953\">",
"           Blunt cerebrovascular injury: Treatment and outcomes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/4/66\">",
"           Carotid artery stenting and its complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/27/40378\">",
"           Carotid endarterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/29/6617\">",
"           Coronary artery bypass grafting in patients with cerebrovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/19/31033\">",
"           Evaluation of carotid artery stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/61/2010\">",
"           Intracranial large artery atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/44/3786\">",
"           Moyamoya disease: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/36/7751\">",
"           Moyamoya disease: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/24/9608\">",
"           Pathophysiology of symptoms from carotid atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/22/39273\">",
"           Posterior circulation cerebrovascular syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/33/32281\">",
"           Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/61/30682\">",
"           Secondary prevention of stroke: Risk factor reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/39/36471\">",
"           Subclavian steal syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/9/18584\">",
"           Vascular malformations of the central nervous system",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic venous disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/29/11735\">",
"           Classification of lower extremity chronic venous disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/17/13592\">",
"           Clinical evaluation of lower extremity chronic venous disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/55/9079\">",
"           Compression bandaging for chronic venous insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/43/33462\">",
"           Diagnostic evaluation of chronic venous insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/34/30250\">",
"           Endovenous laser ablation for the treatment of lower extremity chronic venous disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/40/17031\">",
"           Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/12/13514\">",
"           Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/41/32410\">",
"           Medical management of lower extremity chronic venous disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/29/21977\">",
"           Open surgical techniques for lower extremity vein ablation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/45/34521\">",
"           Overview and management of lower extremity chronic venous disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/22/43365\">",
"           Pathophysiology of chronic venous disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/5/30809\">",
"           Radiofrequency ablation for the treatment of lower extremity chronic venous disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications of vascular intervention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/5/6231\">",
"           Acquired arteriovenous fistula of the lower extremity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/15/3318\">",
"           Arteriovenous fistula recirculation in hemodialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/32/39432\">",
"           Central vein stenosis associated with dialysis access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/13/13528\">",
"           Clinical presentation, evaluation, and treatment of renal atheroemboli",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/1/25626\">",
"           Complications of endovascular abdominal aortic repair",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/5/12376\">",
"           Early and late hemodialysis arteriovenous fistula failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/15/12536\">",
"           Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/21/16727\">",
"           Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/33/30230\">",
"           Spinal cord infarction: Clinical presentation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/43/40631\">",
"           Spinal cord infarction: Vascular anatomy and etiologies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/22/15722\">",
"           Thrombosis associated with chronic hemodialysis vascular access: Catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/8/29834\">",
"           Tunneled, cuffed hemodialysis catheter-related bacteremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/42/11944\">",
"           Use of stents for venous stenosis associated with dialysis vascular access",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications of vascular therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/12/27849\">",
"           Risk of intracerebral hemorrhage in patients treated with warfarin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/0/33802\">",
"           Statin myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/56/41865\">",
"           Uncommon causes of upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diabetes related disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/33/538\">",
"           Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/28/37321\">",
"           Management of diabetic foot lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/43/12986\">",
"           Treatment of diabetic neuropathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endovascular techniques",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/51/26424\">",
"           Arterial catheterization techniques for invasive monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/4/66\">",
"           Carotid artery stenting and its complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/1/25626\">",
"           Complications of endovascular abdominal aortic repair",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/29/9689\">",
"           Endovascular devices for abdominal aortic repair",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/40/39560\">",
"           Endovascular devices for thoracic aortic repair",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/27/31162\">",
"           Endovascular repair of abdominal aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/37/18010\">",
"           Percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/0/38921\">",
"           Percutaneous interventional procedures in the patient with lower extremity claudication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/8/41098\">",
"           Reperfusion therapy for acute ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/45/31450\">",
"           Surgical and endovascular repair of popliteal artery aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/23/37240\">",
"           Thoracic endovascular aneurysm repair",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/42/11944\">",
"           Use of stents for venous stenosis associated with dialysis vascular access",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lymphedema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/52/1866\">",
"           Clinical manifestations and diagnosis of lymphedema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/25/13719\">",
"           Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/42/11942\">",
"           Lymphangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/31/29177\">",
"           Operative management of primary and secondary lymphedema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/0/8202\">",
"           Patterns of relapse and long-term complications of therapy in breast cancer survivors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/1/33817\">",
"           Prevention and treatment of lymphedema",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mesenteric vascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/21/44377\">",
"           Acute mesenteric ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/43/27316\">",
"           Celiac artery compression syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/27/33206\">",
"           Chronic mesenteric ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/58/37799\">",
"           Superior mesenteric artery syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous vascular procedures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/3/35897\">",
"           Lower extremity fasciotomy techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/20/3400\">",
"           Patient management following extremity fasciotomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/1/37912\">",
"           Temporal artery biopsy technique",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous vasculogenic problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/48/6921\">",
"           Clinical manifestations and diagnosis of the Raynaud phenomenon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/34/28200\">",
"           Initial treatment of the Raynaud phenomenon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/10/23719\">",
"           Pathogenesis of the Raynaud phenomenon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/30/28138\">",
"           Treatment of the Raynaud phenomenon resistant to initial therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/9/18584\">",
"           Vascular malformations of the central nervous system",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nonatherosclerotic vascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/19/13624\">",
"           Clinical features and diagnosis of Takayasu arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/48/6921\">",
"           Clinical manifestations and diagnosis of the Raynaud phenomenon",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/33/18969\">",
"           Clinical manifestations of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/50/34599\">",
"           Diagnosis of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/3/20538\">",
"           Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/51/5945\">",
"           Management of Marfan syndrome and related disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/6/3177\">",
"           Overview of thoracic outlet syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/50/20262\">",
"           Pregnancy and Marfan syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/62/8170\">",
"           Thromboangiitis obliterans (Buerger's disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/60/3015\">",
"           Treatment of Takayasu arteritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Peripheral artery disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/0/1031\">",
"           Classification of lower extremity peripheral artery disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/31/30201\">",
"           Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/9/14486\">",
"           Clinical manifestations and evaluation of chronic critical limb ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/35/10809\">",
"           Embolism from aortic plaque: Thromboembolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/12/25802\">",
"           Epidemiology, risk factors, and natural history of peripheral artery disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/21/44376\">",
"           Indications for surgery in the patient with lower extremity claudication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/16/37128\">",
"           Lower extremity peripheral artery disease in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/21/32090\">",
"           Medical management of claudication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/0/38921\">",
"           Percutaneous interventional procedures in the patient with lower extremity claudication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/26/20905\">",
"           Peripheral artery disease in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/58/19370\">",
"           Treatment of chronic lower extremity critical limb ischemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renovascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/41/33433\">",
"           Chronic kidney disease associated with atherosclerotic renovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/13/13528\">",
"           Clinical presentation, evaluation, and treatment of renal atheroemboli",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/6/11367\">",
"           Diagnosis and treatment of renal infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/15/31994\">",
"           Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/54/8040\">",
"           Treatment of bilateral atherosclerotic renal artery stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/0/26631\">",
"           Treatment of fibromuscular dysplasia of the renal arteries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/43/29369\">",
"           Treatment of unilateral atherosclerotic renal artery stenosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thoracic outlet syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/61/12245\">",
"           Overview of upper extremity peripheral artery disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/44/8906\">",
"           Overview of upper extremity peripheral nerve syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular access",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/15/3318\">",
"           Arteriovenous fistula recirculation in hemodialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/16/23816\">",
"           Arteriovenous fistulas and grafts for chronic hemodialysis access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/26/27050\">",
"           Catheter-induced upper extremity venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/32/39432\">",
"           Central vein stenosis associated with dialysis access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/1/29\">",
"           Complications of central venous catheters and their prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/21/37210\">",
"           Creating an arteriovenous fistula for hemodialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/5/12376\">",
"           Early and late hemodialysis arteriovenous fistula failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/50/27429\">",
"           Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/15/12536\">",
"           Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/3/16442\">",
"           Overview of central catheters for acute and chronic hemodialysis access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/32/44553\">",
"           Overview of central venous access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/21/16727\">",
"           Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/30/41443\">",
"           Physical examination of the hemodialysis arteriovenous fistula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/11/36024\">",
"           Placement of femoral venous catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/14/3306\">",
"           Placement of jugular venous catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/27/1466\">",
"           Placement of subclavian venous catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/47/3833\">",
"           Principles of ultrasound-guided venous access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/38/42594\">",
"           Secondary hemodialysis arteriovenous fistula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/22/15722\">",
"           Thrombosis associated with chronic hemodialysis vascular access: Catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/8/29834\">",
"           Tunneled, cuffed hemodialysis catheter-related bacteremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/42/11944\">",
"           Use of stents for venous stenosis associated with dialysis vascular access",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/16/32010\">",
"           Clinical features and diagnosis of abdominal aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/12/33994\">",
"           Diagnosis of suspected deep vein thrombosis of the lower extremity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/50/27429\">",
"           Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/16/10506\">",
"           Noninvasive diagnosis of arterial disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/13/10457\">",
"           Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/8/31878\">",
"           Transesophageal echocardiography in traumatic rupture of the aortic isthmus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular medicine",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/35/2618\">",
"           Antiplatelet therapy for secondary prevention of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/32/3593\">",
"           Patent foramen ovale",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/52/41802\">",
"           Prevention of venous thromboembolic disease in surgical patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/23/27001\">",
"           Risk of embolization in atrial fibrillation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular screening",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/58/24488\">",
"           Screening for abdominal aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/35/34361\">",
"           Screening for asymptomatic carotid artery stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/43/3767\">",
"           Screening for intracranial aneurysm",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular symptoms and signs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/52/9034\">",
"           Approach to the adult patient with syncope in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/30/35305\">",
"           Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/43/23223\">",
"           Approach to the patient with dizziness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/4/26694\">",
"           Approach to the patient with muscle weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/8/31879\">",
"           Approach to the patient with sensory loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/19/25914\">",
"           Clinical manifestations and diagnosis of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/53/23385\">",
"           Clinical manifestations and diagnosis of coarctation of the aorta",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/36/34375\">",
"           Clinical manifestations and diagnosis of edema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/0/26634\">",
"           Differential diagnosis of chest pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/41/11930\">",
"           Evaluation of the patient with established venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/34/3624\">",
"           Headache syndromes other than migraine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/42/11942\">",
"           Lymphangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/30/41443\">",
"           Physical examination of the hemodialysis arteriovenous fistula",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/5/6231\">",
"           Acquired arteriovenous fistula of the lower extremity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/16/266\">",
"           Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/47/8953\">",
"           Blunt cerebrovascular injury: Treatment and outcomes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/24/9609\">",
"           Blunt thoracic aortic injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/57/12186\">",
"           Severe extremity injury in the adult patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/40/19082\">",
"           Surgical management of severe extremity injury",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Venous thrombosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/26/27050\">",
"           Catheter-induced upper extremity venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/48/43786\">",
"           Overview of the causes of venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/28/16840\">",
"           Placement of inferior vena cava filters and their complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/37/23127\">",
"           Post-thrombotic (postphlebitic) syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/6/27754\">",
"           Primary (spontaneous) upper extremity deep vein thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/25/43417\">",
"           Superficial thrombophlebitis of the lower extremity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/22/15722\">",
"           Thrombosis associated with chronic hemodialysis vascular access: Catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/4/43082\">",
"           Treatment of lower extremity deep vein thrombosis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-C1BE635E31-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_38_41570=[""].join("\n");
var outline_f40_38_41570=null;
var title_f40_38_41571="Eisenmengers PA";
var content_f40_38_41571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eisenmenger reaction in patient with longstanding atrial septal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows centralization of pulmonary vascular flow with aneurysmal configuration of the main and hilar pulmonary arteries as well as arteriosclerotic calcifications in these vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41571=[""].join("\n");
var outline_f40_38_41571=null;
var title_f40_38_41572="Pegloticase: Drug information";
var content_f40_38_41572=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pegloticase: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/29/40403?source=see_link\">",
"    see \"Pegloticase: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11302844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11302849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Krystexxa&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10806144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme;",
"     </li>",
"     <li>",
"      Enzyme, Urate-Oxidase (Recombinant)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11302955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Discontinue use of oral antihyperuricemic agents prior to initiating pegloticase and do not initiate during the course of therapy. Premedicate with antihistamines and corticosteroids. Gout flare prophylaxis with either NSAIDs or colchicine is also recommended, beginning at least 1 week prior to initiation and continuing for at least 6 months.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     <b>",
"      Refractory gout:",
"     </b>",
"     I.V.: 8 mg every 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11302956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11302957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Creatinine clearance did not alter the pharmacokinetics; dosage adjustments are not needed.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11303005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Krystexxa&trade;: Uricase protein 8 mg/mL (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F11302850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11302846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM227568.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM227568.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11303884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer diluted solution by I.V. infusion over &ge;120 minutes via gravity feed or an infusion pump or syringe-type pump. Do",
"     <b>",
"      not",
"     </b>",
"     administer by I.V. push or bolus.  Administer in a healthcare setting by healthcare providers prepared to manage potential anaphylaxis.   Monitor closely for infusion reactions during infusion and for an appropriate period of time after the infusion (anaphylaxis has been reported within 2 hours of the infusion). In the event or a less severe infusion reaction, infusion may be slowed, or stopped and restarted at a slower rate, based on the discretion of the physician.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10806146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic gout refractory to conventional therapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11302909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Bruising (11%), urticaria (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antibody formation (antipegloticase antibodies: 92%; antiPEG antibodies: 42%), gout flare (74% within the first 3 months), infusion reactions (26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Chest pain (6% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Erythema (10%), pruritus (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (6%), vomiting (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (7%), nasopharyngitis (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Anaphylaxis (&le;7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined: Anemia, diarrhea, headache, muscle spasms, nephrolithiasis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11302855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Glucose-6-phosphate dehydrogenase (G6PD) deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11302856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity/anaphylactoid reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Anaphylaxis and infusion reactions have been reported during and after administration; patients should be closely monitored during infusion and for an appropriate period of time after the infusion. Therapy should be administered in a healthcare facility by skilled medical personnel prepared for the immediate treatment of anaphylaxis. All patients should be premedicated with antihistamines and corticosteroids.",
"     </b>",
"     Anaphylaxis may occur at any time during treatment (including the initial dose).",
"     <b>",
"      Reactions generally occur within 2 hours of administration; however, delayed hypersensitivity reactions have also been reported.",
"     </b>",
"     Infusion reactions are varied; symptoms range from chest pain, pruritus/urticaria, or dyspnea to a clinical presentation of anaphylaxis (eg, hemodynamic instability, perioral or lingual edema). If a less severe (nonanaphylactic) infusion reaction occurs, the infusion may be slowed, or stopped and restarted at a slower rate, at the physician&rsquo;s discretion.",
"     <b>",
"      Risk of an infusion reaction is increased in patients whose uric acid is &gt;6 mg/dL; therefore, monitor serum uric acid concentrations prior to infusion and consider discontinuing treatment if concentrations exceed 6 mg/dL, particularly in the event of 2 consecutive concentrations  &gt;6 mg/dL.",
"     </b>",
"     Since oral antihyperuricemic agents may blunt the rise of serum uric acid levels, discontinue use prior to and do not initiate during the course of pegloticase therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gout flares: Therapy with antihyperuricemic agents commonly results in gout flare, particularly upon initiation due to rapid lowering of urate concentrations; gout flare-ups during treatment do not warrant discontinuation of therapy. Gout flare prophylaxis is recommended, using nonsteroidal anti-inflammatory agents (NSAID) or colchicine, unless contraindicated, beginning &ge;1 week before initiation of pegloticase and continuing for at least 6 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart failure: Exacerbation of heart failure has been observed in clinical trials; use caution in patients with pre-existing heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; G6PD deficiency: Due to the risk for hemolysis and methemoglobinemia, pegloticase is contraindicated in patients with G6PD deficiency. Patients at higher risk for G6PD deficiency (eg, African, Mediterranean) should be screened prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Oral antihyperuricemic agents: Use with oral antihyperuricemic agents may delay interpretations of ineffective pegloticase treatment (ie, serum uric acid &gt;6 mg/dL) and ultimately increase risk for anaphylactoid and/or infusion reactions. Discontinue use of oral antihyperuricemic agents prior to and do not initiate during the course of pegloticase therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Therapy is not appropriate for the treatment of asymptomatic hyperuricemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunogenicity: Potential for immunogenicity exists with the use of therapeutic proteins. Antipegloticase antibodies and antiPEG antibodies commonly occurred during clinical trials in pegloticase-treated patients. High antipegloticase antibody titers were associated with failure to maintain uric acid normalization and were also associated with a higher incidence of infusion reactions. Due to potential for immunogenicity, closely monitor patients who reinitiate therapy after discontinuing treatment for &gt;4 weeks; patients may be at increased risk for anaphylaxis and infusion reactions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11358648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the adverse/toxic effect of Pegloticase. Specifically, Allopurinol may blunt increases in serum urate that would signal an increased risk of anaphylaxis and infusion reactions.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Certolizumab Pegol: Pegloticase may diminish the therapeutic effect of Certolizumab Pegol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Febuxostat: May enhance the adverse/toxic effect of Pegloticase. Specifically, Febuxostat may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegademase Bovine: Pegloticase may diminish the therapeutic effect of Pegademase Bovine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegaptanib: Pegloticase may diminish the therapeutic effect of Pegaptanib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegaspargase: Pegloticase may diminish the therapeutic effect of Pegaspargase.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegfilgrastim: Pegloticase may diminish the therapeutic effect of Pegfilgrastim.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2a: Pegloticase may diminish the therapeutic effect of Peginterferon Alfa-2a.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: Pegloticase may diminish the therapeutic effect of Peginterferon Alfa-2b.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Pegloticase may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May enhance the adverse/toxic effect of Pegloticase. Specifically, Probenecid may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11302851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11302852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the benefit to the mother outweigh the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11302853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11302854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Krystexxa Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg/mL (1 mL): $4620.00",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F11303004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Uric acid, serum: An increase occurs during childhood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Males: 3.4-7 mg/dL or slightly more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Females: 2.4-6 mg/dL or slightly more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Values &gt;7 mg/dL are sometimes arbitrarily regarded as hyperuricemia, but there is no sharp line between normals on the one hand, and the serum uric acid of those with clinical gout. Normal ranges cannot be adjusted for purine ingestion, but high purine diet increases uric acid. Uric acid may be increased with body size, exercise, and stress.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11302944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pegloticase is a pegylated recombinant form of urate-oxidase enzyme, also known as uricase (an enzyme normally absent in humans and high primates), which converts uric acid to allantoin (an inactive and water soluble metabolite of uric acid); it does not inhibit the formation of uric acid.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11302946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: ~24 hours following the first dose, serum uric acid concentrations decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: &gt;300 hours (12.5 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Median: ~14 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dalbeth N and So A, &ldquo;Hyperuricaemia and Gout: State of the Art and Future Perspectives,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2010, 69(10):1738-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/38/41572/abstract-text/20858623/pubmed\" id=\"20858623\" target=\"_blank\">",
"        20858623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sundy JS, Becker MA, Baraf HS, et al, &ldquo;Reduction of Plasma Urate Levels following Treatment With Multiple Doses of Pegloticase (Polyethylene Glycol-Conjugated Uricase) in Patients With Treatment-Failure Gout: Results of a Phase II Randomized Study,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2008, 58(9):2882-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/38/41572/abstract-text/18759308/pubmed\" id=\"18759308\" target=\"_blank\">",
"        18759308",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whelton A, &ldquo;Current and Future Therapeutic Options for the Management of Gout,&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 2010, 17(4):402-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/38/41572/abstract-text/20562597/pubmed\" id=\"20562597\" target=\"_blank\">",
"        20562597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yue CS, Huang W, Alton M, et al, &ldquo;Population Pharmacokinetic and Pharmacodynamic Analysis of Pegloticase in Subjects With Hyperuricemia and Treatment-Failure Gout,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2008, 48(6):708-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/38/41572/abstract-text/18420531/pubmed\" id=\"18420531\" target=\"_blank\">",
"        18420531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16076 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41572=[""].join("\n");
var outline_f40_38_41572=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302844\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302849\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806144\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302955\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302956\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302957\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11303005\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302850\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302846\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11303884\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806146\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302909\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302855\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302856\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299831\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11358648\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302851\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302852\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302853\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302854\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322866\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11303004\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302944\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11302946\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16076\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16076|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/29/40403?source=related_link\">",
"      Pegloticase: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_38_41573="Acute rejection vascular I";
var content_f40_38_41573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63730&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vascular pattern of acute lung transplant rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADrAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3Mn7uT+tcb4pW60TWY9csrc3EMoaO6ZnyIcKNh2Y5UkHLZ+XPTFdTqNqb3T5bX7Rc2pmQqJrWTZLGT/EjY4NSQxOLZYrmX7USpV3dAvmZ9QOOnB4r5ulPkd9z6Dm5ZXIdK1Sz1S382yuIZgvDiN87T/nvXI/E9dMuI7G2uLGG51KWUQwTIoae3JwwC4+Zc9eoHGak1rwZcLrI1fwxewafelBHJBNEzQSADHCowK5HBxnIA70vhHwZdWHiTU/EWu3dtcatfFSRaKwihwu3K7yT04x0FdVP2NP94parZa3v67W/PsVHljJTT0/H0Op0LVLfUbKJop1lmWNfNXOWVsY5HuQawfE3w90XX7qe6YXFndXKBJ5rSVomlAxjdjjt2GfXNW/CVhd6LE2mzxNJCGeRbkEYck559z/SukHNYSk6U26Tt2JbdOT5Wcn4f+HfhbQjG9ppMc1yjBxc3bmeXcOhyxIB+grrcjI9ccU0HHbNGcdc4rKc5Td5tt+ZF2x+R2oPT0po6/8A16GJUcKWOQMD/P41NhCnPp7UpO3OcY9TTeOgpc5z2FACnofSkx1oPTjIPsKCeOaAQjAkgg0ki7l2tnB9DTiR26mmkjaT6dTQM4zx34KtvFD2kszJthfM6OcLNH6NjrtPzV59pnhSeHS5dJlvIddF5J5plW53R7TjAVl5wAAQo747Zq94j+L/ANk8S39hY26y2NirfapWXdnttA75JA/SuJ8I6gml634avoLzTYtNt1a4uhJ5irHEznDRp94sQSM84PBwK9vC0a8abu/Rb9301O+jzqN302Oh+I2r3bahYaXoFxd2thp1j8zq28s6nONmeDjofQ+1bvgbx1o1rYahZWklw2rGNZlF0QqzuVHyx8fwjqT6E9KoR+F7Lx34jn8XaLqr20d3aOFsLtAkkbBSm4FSRsPUkZwSas+HdHuNDbToNV0E3dzbxCe51VZVMcCE7RCjgfNkHI6nkD6aVHRdJUpbrps79dXvr/wC17KVLld79jK8SeJfFujajCxluV0+aBbh76ZJHSEsCwVccYHAOc9eemK9C8LX2gfErQINQZIr26sWa2a6WAxPDMUG5os8gHOR2PpVmz8XaLq8V5Y36JBp3mGzMlyQttI/Qx7jjDegPXjBNcDe6RL8O76WTQ7b+0dEuLhUKRuHe2zy3mYwV6YDLj7oyc9eeS9suSUeSa2fR/Pv8zF/vGoL3ZLX1L9t43ufAusavpPilZJdOghF1ZOmwOqZww5I3biQR6HcPaul1Xx9pk3h9rrRdSgt5p4/3N1exMIISf4n9SOQF9faqVtH4a8c2sJ8Q28keqaa8kCfb3EE4Q/xjnDKQRyR1B+px9XvNA8PWcuneCoIb7Uggt7lhIZBbwnOWyfl356cHpmo9nGpJKUHz9Xpy+vX+u41ThVk1Z83b9fJEtlF8R9Rk02e41147KZlSRbWwhUFQM+ZnqqN9c+wzWwviPVPDXiyTTNXtbq702REktr4gASucbo0GeoJGQT2OO2eCI8faklve2EtzNFpLiOFIJF3zpjqztxk9zg4B5HFdGfE/irS76XStSgs9c1B44njs1ZY2KvgsA38RUHqMg9cVpUpcz5bwej0WlvO/l3eg3QtdWVl0W/4jNMnt9Dvj/wi+r6XeJ5jzXFvdQFr4FuSN3bHT8fXmr/xO0OG3ltNZ0y3K6ilx5irCwj3k8kk8ZPHc4/GtfXPC1jqmnyXWl6fa22qy7XlHTzR3RyOvTtirn9raRrawafqqNDeHrC6lQGUckN0A74NYKr70alO91vtf8LXX9XH7T3lU1fch8R+HLLx3odq9zNNZysqyMbZwWRivKn6biPoaw/AHg2/0HxPfSXKgac0Bh+8CkxwFXC8kDaDnPeobbTdW0HXIX8O+I7XUYW3vdWM+DJMucjZjgso46g13vhzV4tb0mG9hTyy2VeMnJRgeh/Q/jU1JVKVNxhK8H010+T9N9vmQ5yjBxWsfyPO/H/hS40bwrv0ZpLu3tWPmLPmSVrZmy0Gf4hkgg9Rt70lzJHq3gQ6fuyNOkV8TfMXtSSm4dyBu5PtXqN3bi7tpIGLKJF27k4ZT6ivK4Wij8eQXli+Gvbg2vlSN5SXLKCsmFJOCVPTgfKMAdKqhVlVjaWrWt/8/wAdTWhUury3jr/Xqdp8OteOveHMzoYryxlazuIz6pwrA9wy4OR7+lZ/xN8TWWn6Pc6YZoPttxGQySuFCJjJyTxkgcD3ya53w79v8AalqVnf20lxpkCFrS5Vh+/gyCC+DwynIJxjketcfdaRL4y8eJd3lvPdaDqrzSabc4+SNlHzI3odyBfT61rDD0pVXVb9zdeu9vXy8rGcKSjPn6br+vIz4vGch/soGexZN2y7gRThnkyVVMckBduW9Seta+iXms6rNPpWpWEK2kdqLoyF94ADgE7ScHAbgH0yM1g6VFb2upCM6LJDcRXTQF5gA8a4AR2TA4YHHHTsa+iYLDStStLnyYrWZLlFjuHtj7DgMORjtiu3G1o0Ipxjo/66ep0VK3skk+p5FHaeFNB0fU7y9itrq8vHjgCTwfJDwdgAA5IBJ4GSevc1R17R9eWfT5WuYrWZ0dk/dNidiMKQozuOCODzxmvVdH8C6Tp6ESma9YTCeI3Jz5OOQAOn1ro75rj7HP8AYQhu9jCDcu5RIRhcj0zjPtXA8wUJXp6+vpYzliYpvl1v8jhZ7ex0vUDr+vK0U1tawlYpZV+Vvus4z90nHIz25rG+Is41vVrC50e/uFjs96SiDYVulZQwHJxgZwSfUnHFQXNhqXiHRQdbmhuL3y/LnJXBnKk5Kqvy7Q3GR61iatoyQ6ffWmow3lnbRgSS7AYmdMnMYHUZHXHUfWtacIqSlKV5L7rbaXNIU9VKT1XQ2b66vrPQ9K0TwxHH5Vpg3TGItljh/wByckZAzjnn0ri1vvFdxe3AsWtdSvN6mS4u7VbdrRiT8jjG189OMnjtXo/giPWrf4Y6ZPbWEUN/czpsjQFtsB+RHHUqduOfxJ61xmp+HE03xHDMdPv7XylF80oYyQeaZGCuxGRvBGfpg9jW1KrCM5Qdr3eujbfn69LfPTQzg1JWitfX7/6/UzNX8Y6dJ4Wa5gRLfU0iMU1tk7GlRl3sRjDdcjGOOue1z4W+GhrGq6drZkszp1lK80sdvCA6SlTgOxJIAzkKOnFauheElv8AVNOl1ObS77Tbe6klnDvmWZiC6hccMdzZYZxgDI7V0/ia+i03w7d2Phi2ttMYN5nyIqITn5j0xn360Vayt7Gkrc3XtfTtf/LuFS7fsou/n/T/ADPI/G2gpaaYkUeq3l/cRyzeRFLIGeRXIUqoznjGT6iitN5L3XPE2k3AsEuJdNkje7vZYNsEq4yCpBwMkY57j6iiuyOMlQiotKT8/wCvmTXpKbWn5I+k7eQSwwyDgOob6VMMZ6fnWR4fmeSya0coJ7Nvs5deQwAG1se4I/GtUsyyrn/Vn5ffPavluWzaOOsrSsh/4+5pcZOMYzQOvtThyegx2pmQxCzbl2NGFbAzj5vcYP1688HjpTyM/wA/rS9iR9OaUClYY3POMcdaXGfTn3o4z7H0prhyoCFQc9xnApWAXAI96XqR2H+e9IAQB3+v9ad1PA5NAwHbIzRgZznp6GjGOufpSnqSRzQIaQSOGIo+vanc9ugpMDPanYBvHrWX4mmng0W5ktv9YEOOa1QDk5xg9OK4v4q3t3Y+Gw1hKElZ8YZchh71pRg5zUTSmuaSR8wpbXFv4mvbzUILtkEpaRI5Nu8Mefc/5Ne22Hhnw/8AFHw3pGrWMF1pc1kWgVZFXPDZww5BWuB8JJfX3iF7OZQ97cpkkdFXPX1r1XxPeXfg3Q9D0rSmtYW1GWS2kMituPy/w46HBbn1Fe1ipS54wpu0ujv0tqepWTXLCLs7/K77/ocddWc/h6/YSI89pPOtvYyBgXeLy/mlbBG0M2QAB0GMHgl19qt1eX3hufW4IbXQtLBkS2kl8pppi2ASpJD9sfjwOlcd4k0EWkUFhqd88emJGzWET7vtBlCgktwTt7DHXjFekeD/AAZHq1lpb+IozrD6cyFQwKKCcOQQcFtpOOeDg8VtU5acFOTv5/hp0v0ZMmuXmnq1+f8AW36Hbazo+kXFnaWOry29nezAAQkCRX7BWjPDdhnrkcGvKtL1GaGz1LUNPtptMkllkhuJNQhk2O6DO7y8jJwvT1HOa9S8UrpVprL6m8yrrJRYYmk+ZBz90IDySRXH/GP+1rvQtC1J7R5pSZbbyUkKgGQfK7HooIBBPvXDgm7qMtpd/v26r1MqTvyqT0f5+XU47wHpdk/h/VtSlnlfUJ5GaF3QhQRz90ZZssT6/wA66jwb4V1HXdWvG8SWjQWdnHG8UMbGLz5sZCuy43J6jNeheC/C+neHdBtII2N2I181bi4Cu6AjO0MB90c4rRn8R6ND5S3Op20LStsjWaTaSckAYPqQcetFfHTqSl7JPXr1Xp2FPE3hyQWh41NceNjqFlPq1utjp9nc41CKe4EGm+UeACM/Nx2Geg6kmruv211c+HU8TtYQWlxo94vkteMRHNApCwsvqCGAJ7gAivQvG+ueGrLVdG0LxQkc0+ozZt4ZbcSxqRwGfPABzjPP5VlS+OfDmuaprHhvVYEe1hlNrcLdjCMBn5j/ALO4AAjBHB4pwrVZqM409tdO19bfiZwrXfNCPr/Xmg+H3xAbxFeXGna7awabqahXt1SUPHdqRyY27kHPSp/iVoJm0u41LSdPnutXUp8lsRvkxwGIJw20Z47574rx/TrMXmm6Xf8Ah6OLSbmxeWWxD5dUlDqQAWB3Ajdjd7V1kvijxrfXulS295YrHHErXtskQy56FyME4Ixxx7dsXUwfLV9pRaj3Tv09Oj9dzT2E4S5qe39aFzw/p+peJfD8kFzFq2meJNMV2sbi8g8gXII+RZiB8208evIINaHwa8TS6jPrGlatF9m1mK4JmtkQ7UdRh+eQM4B68knHSl8IT6zZ61JJ5rzpfSK720kpfavZkBPoex7YNeliCGG4nmWKKOV/9bJtClsf3j3x71z4qqo80Gk1La3R9flfoTXbg3F7MlHYjPTvXhXxU8L3Om2d7dQOWhF99vspgn723kJ3MoYHlc5PYjHHrXuYKgoCwGemO/0/CvG9Su/FF9r98b2TSo7SKYh4bjzCLWLOGHmY27tm08YJJ71ngOaNTmi7W/r+v+CThvid9V1Lun+MJr7whYrr1g+qXT4El3av5eVJxuAHzA44OOvORXUQ6voNrpGnNpd5Fa6ZbneER8KfqRnPOcjv3IrzqGxNyLW80xjeaev76zvrSRiispKsrx8lW65X7pB6c5rBWNb+PUYvDNrA2q3jFJokTbAsiknIRwArbepHHOPWu6WFp1W7aa3fS3qun6bWOl0YSXufD6ndeJNW0S58QX93caY66c1pvk1iGfMjkJxtixg4yByea4HwzFNZQR6PK0/9oWlwl+Hmd4o7jcCUwUPXaQec9DW/qWkXdtZW+ianPa/aH09zKizCJ3kKZ8uM42nPQ9hmt7XLOx1DR9HtPFiywSWKiWFLWQJcW0YwNjBeOmMYzke9XTlGilGGqfZvpezS/PZdhK0bLdW2f9f10E1f4t2uiX4+0/6dbOGVjCy5SRRlhxjnB6V2t5OPFHg6aTR7y5svt1oJElRcSxb03D8cHHBryK30G38PeLri91rT7bUtB1WYRJLFuMUiOSAT2R1PXpg5rsfBN/beFLi/069uZY7K6uQbNJCNtu7ZDRD0UkAjHvx68+Iw9PkTor3lr691bujGpSXxQX9f1uHhGzmn0y0gSSV7eO3WOKdpD5jgEA7h0xgbvXP0rz/Uk1fTtUutQ1c3940s8lrM9vM0yOS4AYp90NjgDI4HSo7bUPEWl6hrH9h20+n6DFPKnk3ClonfJI8t8cNweewx1rG8Razrlrew6nc39wlu6qXeGMgyuDkFFJ57fOccflXdQoPncm1Z/f6M6lG15WVl/X9eh9EeOLu403w7KLR1t1ePyfPJC+SMYyM8A4yB71xnh7X7rRorbzraZ7BIz5oyCSCcllUcAD0AxSaMNH1PwndHxpfl7KbYZre9uNjZBDKTtIIOR04zWP4ouNNmW4HhrVFtGtk2tblflt125BUngoR3Ga8+lRUb0pq+urtp9/8AXTqZUYR/hSXzNT40XV9YaJpOr6Xplnqlhbzec7S2+WhDYKMpGCo7ZHtmsXwfay+KPDw0/UsvcXsRvI2WEQoiFseXkcAjB+oNYXg/x7f/ANlX1rq99pkmlkCKOV4RKkcm4chDjIIJ49Rkd6970W3SDToEj8sx7AQUAA2kcYx29qdZSwVL2TS30a+/sZScqOv3f5niptpvCukp/wAJTpsOlr5xjjFo5lMsQIwwwTzluh578UV7qY0ICsitsIZdyg4I6Ee9FYrHp61Iu/lK36P8zOWJqO1mcz4OR01dwhUQKjYCrgFc4X+tdTp+p2OpPeRWU6TSWkxguEAOY3HY5+lchYs3h6HR7RcyXGpTRQNJsLC2XqAxHTK8DjqTnArYtIo28fX72k7hUtx9pgR8I0hxyV6Egd+vNZVIqTcvLT8jTF+/Nvtf8GdOPYGnD8+Kbn6flTgeegrmOAdzjn86ZNIkMLSSsEjRSzuf4VHU07qMY7Yrzn4265qGj+HLeLTZBDHeu8M8g+9t2/dHpnJyeta0KLrVFTXU2w9F16kacd2dJovjXw/rE8kNpqUSzIcbJ/3ZcZ6rnhgfauiK4OccjqK+MWcq68nORg55r6w8C6wuueE9NvQ6vIYhHMEH3ZFGCMdvX8RXZjcFGiuanex6OZZasGlODunob+Pb2oxx8uM4oyeOlKM9jmvNseQNUHGXPPsKWlGMCkPT37UBcX+dBBxyCKReV6nP9aU8iiwCY68V5Z8ekZtH0iQ3DQQpdfMAeJOM7PfIBAz3r1PkA8k4rF8V6Pput6LcWetRpJadTu42kdx6GtcPUVKrGb6GtKXJJM+frq8uPD+up4h0WLfp15Ev2bzxtKMxBMbY6Y556e9bcut6r478VaDZ3NnJYkXRaLEZf5Y1yZQegHPJqxp2o6d4X1MWMSPqGkTHYyXGJVC57Zr2fQ5rC606G70tUEEq8Ntww9j349K9OtX9mlLkvpZM9CtW5LTtr0Z57418Fz38tmUt5mvWkVft1mSjKoPOST8vHU16A9vDpOmXcsCpEywlnkHG5gv3if61pdAfpWf4htheaJeW56SIQeAcjv1rz3WlU5Yz2RxOs6nLGWx88Q3moW+kau/iNLMW0Mgu7e3E4uLhlOcfNu4Ukg8jr0FXrXxHq2pCa38WW23T8RwW1gGDOS2SN4yMMdoUZxjkYzUOpaHceF9W1DUGudPm0QW/kSXUcAEnmY+TcoGAVOAOmQOTSXvhrxO1pM08sd4upiPM+0JDaKuGjkVAuQcHtnlu5wa+icqcvebWvXbte3Z/jsd2miXy/rc3tG8WeItOsZPD97pcAe0dox5ZOyaMnj96zYz1zgAYGBg1xWtG21i+eaztLm/mjvAZIHZwYCSdoAYcp2z7CsXwn4j1W1u204XLXccsrWsd08B3pNtOxRuzyTxXW2hmlv5vCviWG+vNQ+zM8k5tzGZEI3Dnrlcbs8fd9jk5I0JOWl3rp+Lt/wAH8Bw5bXS3/P8AH9SSSC10+WG8nv7RNGEe2K3bloZhnO1j94/e6dfQd9TwxaJrlvFd3WkLaapJHJHDDdSlftCngBG43bj0zxnIrJh8IzXsM8Go6h9oswA8V1N8ptRGu5n34yGOOQPXmuotTYX+lLdPGlyEBkt5kf7r989mAwRj1J6VjWmmvdd/P+rfP0NG3a1/kSHRI7eSS3+2pJb2aGBXtz9nRuASF5OSDxz3FSQNBAHIS3jcgEggDdngAkcmmlzFbQvddJHyxBC5GefofwqLVbORrJ4raaZY48yFgpZlUDcSB3JA4HX86wUeb4mNdmyzPGXmEdpI2zeVjV5fLkRiMZ3KcA8kflmqvhfWrnw9ZXFhYHUtStI5ZFdrmMs8TAAkbSBujY5+YA/jWTHdardWmmX9tpV7p1vNJIGtrwKszxjGJMNjCnPoeQQOMGtC81GGEQDUJowDgAxPgqxPAC9f0/Gn7JuNt0/mKMVWSa1RvXXj/WZbmzGhaFDLauoeaW9lKlScfJGifN05Bb17V53f+ILaHxJq9zHql4mltcpLJpMLiZYJXOHyCMFCck8cE4PNdMlyHdUjGY3cqWWQDPfr3P0NRjQ9KfUnuRYwxzjO2REVW5BBOBgHj1zTpQp0rvl/rz/rQmNGEHeP9foZi+KPFGjeTpWixWsySJ54FlZLaLDydrMRwwPp7e9aSeNxp0zTeLPC9o0l5cq1zfWzkLCAqgMxfpxjhSBweMnFZXiGe8tEuwW+yWgg8xbtNrOJQc7CnZSM4OMA9Kt2ekabr3gm1uNYmH22YBpbIyFrd4wdyyjJG1tvUhuTkd8VcoU3BTlFWbtpv96t2/zM6lOC0V031/rp/WhHdzWevXN5d2LtLahDcw3k0gAlhU5Y+YxzuGDkYGAmD2p/jCZpLKKz1Wwubq28tFVI8OdhAKurL25BBBqhL4m0ewKwWenrO8qSWcen3cLIsm7KOYRjIBzjjPOfSspF1PVLT/hHdPu3hXTQimWyl3eWgPALbV34GBxwcDmrhB3Ta91d/wCvQ2jJuy00X4/13LpSy0bQJ7PVra5/sae5SKV0uizxtt+SVCBgHjDBhz0+l/xNpFhr/wBjsBdwvNbGJmillYHYoCkgDvx1/wD11zfhw6iqXoigWy2XomuEkAK3UX8W7OcbuR8oA9q6bxJpMtn9h1DSrT7fEZGWzuwCdkLcujMpwGQZwTwRzyaqVoTT5tX1v1sv69PQctXqtyLxN4kun1hfCOmWU6QSH7ROZ1yJht/9B7Fuv5UfC7TNe8Q2EsCf2fp9vplwYXjukme4CN8w2nPQdAM/h0p+n3mpaLamTU72zvxHcGOBxIojkBORyfut3I4HrU2reKfEOna7bCzuIYNNG4TM3ykSc4HPDeg6jOfrUOMnD2dK2vXzXXVdtPIzlTny3h/Wx0HiDwPDHYT6jrdxaTNYr9oaFNxVj03srHGfqMdetYV5FZ674TtpvD9v9okDAsEDkK4yC0m4knAyeeM4rVttY1rXHaa38T2ls0IKXOnahEiR3cXIYoSO3PYgk8034X+GdSa2m1C4C6da3Lny7BCfLRAT09M9T+FcicqcG6s9Va2/3Wsr+qI9pKN+d7Hkln4d1G1kuIRHb6hamJpVmLgh5Ac8j29MfjXtXg3xDe6b4KuLvU4bicwQiWC1CElRkL5at/Fyc+2af41sIdKubWGBvsGlCzcEpbB0eQPuALdUOeR681N8KNKvNM8PyX+u6lLdLcsVtxdKo2xbuMfU9vYUsRiVXoc0u69Xq/x9ArVFOirrT+v+D+p3lnK9xZW80sLQSSxK7QucmMkA7T7jOKKqXOsWkdvLJDILp0jkkENuwZ32DJAGevYe9FeVGlOTdlb8PzOKFGdT4Vc4n4f6/qFrbXsXiKG6YwSFbGa7iImkfB3oCedoOPmOAMkZxWhpeizyeKY72/ubhGS4MxeJzEJmZQQenKDlfesG2ecaayR3F/Fc20RQXEyvLJbogzk7xgjHY9f1qCTxWjjT7OYBXmlxJJPIyySuAOFG47FxycfSvTjQlJycOu/3f1+eh6eIpyU3KCtf7vkehSeNdNl85bGQysu9MkBfnHopwSPpUfw+8Yr4tiu2it3QWsph84rhZSOrL7V5F4f1Sw1/WJdJkto4dVjkkgQSogMiYwdkhHG7PT0717Xpb6b4d0G1Vi9rAx8pEm+ViyjG1Qfp2pYnDwox9mo+8/6+Z51SlCK93Vs6DoMcgYrzr48WjXHgUTDGLa6Rz/wIFf5kVtXHj3R7WRFnFyu9tiFU3ZP4ZA/Ota8t9N8TaLPZT4mtLhAGXOGXurY9QcGuanGeHnGpOLt/VyaEnh6sakls0fJkzR+XGBgYUZ+tfR/wStXtvAFqzqFNzLJP9RnaD/47XkGu/DDxHYX7wWtjJfQE5hmgG9SM8Z/un61694A1aa1jtfD9/HbjyYFjhljbgso+aP39j3r0cfP2tJezaa3PezavGvQSpNPr8jvCcjHSnY/A4600cDjke9I7BFG5sAkAZ9T2rxLHzA8/hSHjqf1ozxzj6460HqR1JpDF/pSY+lHFIfcUgDn7wxzWbr+ntqulS2gmaLzPlZlPIHcVpHvXJePfFB0CzRLdkF5LzvYZEa/Q8Z+taUacqk1GG5rRhKpNRgtTzm6+C90tvfTXXiq6WO1ZprMwxZdU+8yuOMnjAx9fauh+A/iOTUtDn0y/vJ7u7gYzQSyxbFlgzt/d8DhW6g9CfTFZ2jePtTt4xBJb6jrb30rRQCzjDuh7P83RevXjHPFa32a/0LxxG+laaL23MwE5eUq1tBLguy9mAOeOegHPb1KsanLKlXd3unp0/wAzrrU5Jyp1N1qj009QaOhyRkZ70pBBI4o6eo9q8exwHMw+DNJEd5Hd+ffw3MxlaO5kyqgnOwAY+XPY1tz2dvPZ/ZJYY2ttoTyiBt2joP0FWRz6UEZxjrVyqTk7tlube7M5rewtpItlnCJDKCDHACQ54Dk4/wDHjXAeNI7S21We5trmdp443aVIydynptyeuckAD3FSeOvGuv2t4lp4R0r7Ttl8qe4dcrknACE4BPckZxxXFf2je6ZObWWW7meW8NvbXLZZnbG75s/dCk9T3OOxNelhcLNe+3v0v+Z10IST5pGR/wAJLPeeH2mfw3qty97vjFusw8oQ7cqzJt3LuP3efm2HHSuy0eKaLRrSO5jit7lIuYUHCH6jg4Jxx7ms63ubaG2W7e8ie6llWJrhWLlyD8iD+EkdBxn0rWe6jWUWVzKFllXvnEhwSQD0zz9a7Kjd+VRt9/6nRFNbsz49Inlu7CW6W5u47cs5bftyzDb8xHXr0rH8f6fZTajZaTdSQG7lu0lktp53T91ggsnOCewHX0HWumttTj0xnaRXitbWIsAAojA56ADt1PHOfxqhe6PpniCB7UyyzWd9MjxzRv5ZAYjLISDtDdx04zirhUlGXNLby/qw227qwsGn2trqN1cTXmyTUpA3lzXYGSvePefvHOcZ9K5RtAnub67gmaCXVJVed4Yw5by1YbVVRkkuOcjOMepxXb6gtpJc2p/ssTTW7lLecN+6tUVdpxu+ZyQoAPXvUUUSXGpzSxqjXMgWFpgPmIGFCjvjAA/CpjUcdfL/AIb5f1sb0ak6bvHQ8+0Aa+0vkXNi+n2yJNgyo6pExXhsYMjMCBjg8jpgmus0a3mm0xSt/PqqefmC4eN4539trFjkMDwex9Kj1TXEtNeTRIUb7bIocdcpnOMDHJwKsalp+oFLaSxuAJllHnNIApkXGDyM47HA/MVvKbla9lf+rhKXPre7RZuI7q+tXns5I4L2LMTPsyBnPOM8/SsnTLfbYQ6fZXdvO9m2yQzQlUJ/iUgcKcnIx7Z6mtfTbq3liu1sZ0JgYpId4zFJ6MD1HH69aran9rtPLvLS6u7mLID21raoy5bqwJGQByTzWKbu4/1+RLlZnJeK9WluJ4R/Z2oJdwh7fHm+QFVicrI6kkE/3eAQfeuj+CGrSXt5IJNLijZ4fskLiTMZRf4MD0x/nrVXTPBunWcUlzPcPeGRx5tzdHCsQSd4HQ7QeeTVDwRruoT+KbvVPC9qbnSdPYQKrARQlSDvl+uQW9eR2zWtR050pU4dvT9e5lOzWr1aenpr2v8A8E674sQWel+HUXUZZPKWddrWpwUzyScA5HAH5VieBfGVtoeq3OnRQeZp8caieJi2TAzZMoB4ON+dvpxXaW3ibwvNf/2Lqzw+ZqhHlRzfvkZycdVAGM4x7968v8R2KaTJ5GinUdMsbW+ljkW5hUy3G1sZD4BaPk4U5Azzk9efC+/B0Kqev3MVLmqP2LV3/Xn8/l1ueh+OPCCzT6edC0dzbXURV4otixwnHD8nGSD1rMh0C48N2tldePxYX0KSpbafApd3M3LKZH6E4B46V2EGrXdt4Ntb8KdQnt7IsMLtWV0BA6dCcVm614jste8E6d/wk+gZTU7Z7hoy4/0c8qpVjyGIOQeMZrkhOskobxTt59dr+V+xl7SrJRg1ffuV77xrNPe6ZP8A8IzbR2cDOJJryNDLGcZAhGcZPI4NdJo/iuy1Z4ZngMg5aCfaE5weMHoeDXlnjWyuLP4caRCtpLPZR6k0tzdxuz/ZYlRVHmY5yRnngA/WsrxNqutQWt+/kPpem2zRtbXUCAiVGA2fKepxkn8e/XZYSlVSUbLVr+vvKdKm00r3V+vr/XY961nX9PsdO865KMJV3QxyADzmKkhVzwW4PArxwfEbSb5tQudUgvpZbooEsJhtgQrgK+QcjkYCgZ680eP9XW58PW2i66xvwkSbL7TU8z7LdKud3OMqwOCp6fhWfdx2UaWlzBD5moNbSPGQu1JJQmPMk/u9cDsCfxow2FhSi5TV79uy1/T1HRo8qvK/9f10Nuy8WrovjPTpNQsLMadLE7C4X/XK+3JIHYDpggDrRWD4E8BeJ9ciN/qcQs7UMQtvMxX7QjH5uxOOhyeCTRWeJhhJSSnLVK2n/BJnCjKTbl+h6Z8LfHNx4qv9T0TXHS7uLdWPmJamNJYwdjoylmOQfzB9q8u1+8tNUu7y/tNJOoSxan9htFdGja3RGBBBB5wOM8deeleg+JfDFj4W1i5uNJYaPpF1o9zbs8JP7u4kfk5J4+U8HPB6YqCTw2bj4OSS6o0k89ji8inQGGWRUGOSexHPv1rahKlCXtIaKTSXlp/na/8AkZxSjaeydvvv89vmYGsw2Nt/ZXiCcS/YIZSjIqFwzL2OzJBJxkdOO1SyrqF1NB4l8U3TfbrtS1vFMGHkqxO1UUjC4Xbnjkk+9W/h54usNQ8C3NrA91btBqMLyytcmDY0oJjAdT83zIFIPHPIpvjSz8Vzad4b/tPRtR1i5HmyXF1CrOUdnwF+UYGAPTnPtXRGfJPlm7WbV7621en6/I3hWVSsk7WWiZXutS1ex8n7OkVrJcOU8+4lQnA6yKDkN9MH3FbPgrxPcSKHkKxanbyiC4JXYjjOSvKnGQe2OcdBXL+JNFupPCUOqzfZZbGGdZLVGhaS5XYpMqMjHbngcdKbf6n4V8TabHb6sZ7e7nEd0YlYwtuIGACARnGAcit5QhVhZRv3t/X9MqTjNtW12Po60n86JXU/NxnHrXnvjHSo7HWVawLQvOpuVYj5Y5FPJUk9O5Gf51kSeObqx0C18h3eNNx+Qb5p1AwIx3467sZOKpS69Fq0s+oX975ggU5t2YuUHBMaqOvUdvqRXm0MHVpS53sc1KjOnNt7Hq3hPUp9T0aGS/aA6hH+6uvJ4XzB1wOwIwfx71s8H8K8es/HB0vw+506ymRS/m3V5eJ5TbSODHH1JAAHf15rX8C+PzqOp3Wn6uyRJEoaCVzulZf70pACLkYwOtc9XAVEpTS0X9f1+JzToTTbS0PSweOT+NA6H+QqvZ3MN9b+daypPFkjKdiOoPp+NSxuJFLIwZcn5lII9K89q2jMNh3U9Pwpoxxjv+tLkdc9Kbn8xUjRm3tzJDclTJsQjcp7Zrzb4jWLpq8epTGSWMoGKt90rjB4Hp/+uvWyAx5wceoqvfWVtexiO8hWRBkgHg+4zXXhsSqM1Kx14bEKhNSseK/CW9W48Zx2oRl2ea4wOgCng113xhsWWyXVLPUp7G+jtpLUrE5+ZGIYPsz8xUqfwJ9K7HS9C0vR3luLG1SByhDyFifl68kmuN+JV3p2s2Npa2c9vdm4hdkeKXcjAnao3Ieu7P0rq+sKviY1IJpL/gm9evHE4hSgtDpPh5rY1zwjZTtdJdXNuPstzMmQJJEABfnB+YYb8a6MjJxjnrXIfCrRYND8HwxRZM87tNcNt2gydMKD/CAMD6V1/wCVcFdJVJcu1ziqqKm1DYMdTQvDDnB60cA9KRuwrKxmeC+I4bO28eB7mKaRIYzZRwzBj5GckkDptYHANRQvcW2sQaXYW4Nl5Z23EkvmbVH3QFByD7kcdK6T4w+INc0bUYxZarb2tiI1laF0BMy4OULEHGSCOfX8DzFhevf29q0NgdMu75tghaQM2CfugjnGOeAMDNfQ0rypRnLa3f8AH5fM9Sm+aK0sSW8clzbDVBClto1jG7WysAjmdm2KwQgB8hiQwOBk5wRV+S+iWxtJ9IszfpuKkW5yIyuVZixHTPHp6E1y/jXUILfxZHZDTNTtgZYrVA7/ACTIp+eSFOAA2QAQTwO1ULDW4Hhj0vS5BbC1v0htJBhYpWxx5gJyQxOTjPvW0cO5pT/4a3yf9ajjO65r/wBf1c77ULQR/vL6KBJCg+7IHwG/hJHUc45rIsddsJGubGzYB7NxAYhGSqnJHG3ORwee2KoXNzqGg6dO9yvnarC5ka2Llo/l+8UwT90dPz5rasYDqnhm+u9Oj/s6S/tnfzQFBLONu7I7/wAvSs2lCN5aruac7t5kGmwSP4puJJrtlhjjIlijfptGTuHtjgj1/CmTXOqtDPqWjSstrBJGU2hcyFTlweN3Q4AHWo4rNLW50y3kmaXWH04Ce5C7flVuQccE4AXceT17Vk+PNXjzbRSzSSRsGmmWAln8ocYAyB82T+C1cU5zVtfl2/zK0e5vXEV34v0+W60fUHslvZc280MX7xlVcvCuSDkjnaDyFINN0a81S80lLmaxeO8jiAljYlY48EgbhjCkgAntzjisPTXnnl0W10pYFuEmiksLKObJVCwIkPPD4LEn069K9/0trqRrs6hbQR3HmsnmxD5Zk6g8/XnqK5MXU+rKySa7dV0+d/0OepP2Tuz56uGnMN7aaZpluqXEcv8AaVwqNLjI4KnOAec7eg4Peug+Avgy984+INTkY6e9v9nggYn/AEjB4dlPQKOB6/z9msb+xuS0NlNauU3CSKORSVI4O5B/WrjyBVUtxkhQBj9K56uY1HB01G1/6/ryOerX51a2p4t+0fJqTaKYLKMJCLckKGAygb5yoHtt49CTXI/CzWbCz8OXGj219Pcm522sokgVQvmjazIoG4qP7zdwOlfSN7bWt3CVv4beWGPLt5yhlXA5PPTiubsNK8JXxa80OPSoZYldTcWaxr8uMnOOCuOc/rUUMXGFF05wuhRqxupdlby79/v32POtM8LWKjUJdJtLnWNZ0N0kt/tCCOCUhzhlwcnGM9QPY1i3thNJbtqniHT3k1GbUG1GS3S/VvLYj5iqKSNhwPlPPocVp6UbieI3KeNLHVbYHY9ra28qoF3nGGYAkHByO3XpTNL0i31nxhfzC3W3V41hW5DljvxwAM8DAAJA7V6MJODlKT28mmttNbb76I7oyVSSqz19f6+a/wCGOn+EaXer+FPEsU05+yXV0wtWbGY3aIb+B0AbbgfX1rjZNPt/EPit9J1fRNQa90zTltppQxVH2YBI9jjIb07V7L4I8PQeF9EFhbytKzSNNIxP8RA6fgBWhqsFrtS8uoBK9uytG2DuU9Bz6c9K814y1acoLR7dOlrnKqyjOSWqbueZ3HiWDTbTSNNhup7GaaRoPtlun7ovtCYxn7oXaBnnI3Vx1tp2raVqN9b6fbTXaXkr/bZL2XlJGYESqTycYzxnqeelep20tzeagYdPs7JLd3V5AIdxJHBY7h8vH0ro4tFtYRCAZGSHiMNg7fx6/n2q/rKofZ33/r+u+hpKpCn01/E8e07wJqVp5drpN1cy205828lAwzk84yccHp3/ABr0HRvB6RPE+opCIYyGW2j5BI6Bif4Qew7109yZomto7UReXv8A3qHqVx2/HvUyxIkjuM72Azz19OOlctbG1aq1f+ZnUxc5RUVoiK7tvtRjM0kmFbcyg4D+x9qKn57D68UVxqfLpc5NWeQ2XxnWW0S61nRrQQiVitsHPnAK2FZMghiTx0HI61Qu/iWLq81PS7yO5tEuX+1OmrZaOBO4Plpu2nsmDk8d6k8SfDJvDk0GsaXFd6lDGpWeNLopNCjKQxj46YJPByPpWLLoem6V4ftY9Tke2t9Zmkjhf7UzyyRpjynLj5Vb5mHHGMda+npU8JJKVNXv/wAPt5L7z0JwpO3Jb+v19D1D4Q6HpcHgc2sCw3ym7d5HntsRPMp+VlVhkqPlweDx2rgl0n4qah4mu4r251C0gnLo80chESq3dSOgA9DWaNWk8O6TZaXousXem2s0kmVgfzJGkAA+d8EDZgHaMHnkE10Pg/4k6xpGuppPi64m1CN5orU3EqrG0DN0JAHJ55yegB65znKhXhz1YWd7vXffp0J9jUjKU4pNefl/X5eh6Bqt7onhLQdMg8Yam0zyoloJpQWaVlXBbjtnkk+vJNc9Z+F9Gk1W4ZL6J578eXHI8C7tvBwSe/QY4rotf8P3Gv8AiER6npsE9jaMJLaSXaQSeGAHXPTqMV5lqmjfYPG0qaLe6h9nS9g+1L5YkSK3cncUZuMgEbhyfcCscMouLUZtStd7NeXp/mZUHZaS1fY9MsPAtkl6k8o3PEzbEdR6FcgZ5BBPNZvij4YaNd3CarZwjT7q2gaIkSGKJ0I+ZyRyGwcbj+PQGsVfh1bbLu9fxdFNqc0zGzv95YQJ0I4bkgdOgBrqNJ8G3Vmktxa+Jr67muoxHPLcgSpOoGMlSSOncY/qYnUcHzKs/ua/r8/IiU23dz/BnjusQ6PoVtYW9+ZJ9JdHhSazuRKgAw67WzjLHqWGcD6V2Wj+BdV0rxHp9rpFuIdIu1a5u9QkXzxKCuQjbiHRhxjnv35rr9N+G+lRxTJrITU45ZlmEJj8qFSPujavXGO/vXY6ldfYrG5uvL80wxlwgOMkDpntV18wvaFHXdO+z7P5eZVTEPSMDyrxXF/Y3imy0Swivro3sBnmkJCRhMlVj4++SwyfQYq34D8O+Ioby2TXpY7jT7OWSWGQo8bK5YHIVsDb2HGRRpFzqfjLxVo1zqmjwJpsUEjm5tZ3khyCdoDkAMQ3XHr7V6kOFA9BgVjXxMqcPZdba/iKrOUYqM9/67dQPXPGaO3TIFY3iTxTo3ht7OLWL1IJrtttvEOWkPAOPbnqa4LXfGuoPe2kUJlgdHkaL7GgcyqDgM6ufu49ARnPIOK5KWFqVdUtDGlSlU+E9VUE4CjJqlc6pp9sqtdahZwK8nlKZZ1QM/8AdGSMt7V5Vf32uP4jE2p3s/8AZhDLGrSYWKVf4/LwACQehPGegGK5bRPCnifXPB8A0q0EWo6ddTyNFq0GGediDvUvwxwu3kYHB78dMMDBJSqTSX/Dmrw9o8zZ2Pxe8b6FJpJ0SO9uWme5Ec8luWQRbRnaz4Iw2fQ9DxxW78ItL0xfBOnXtta2jtIzuk8cZXgMQCAwBHIPYZ696880Xw1f6nqq6P4jitrea9mWac6ZcKZEYfM5fqAAVB3L/ex717R4u8R2fhnQbjVr/c8UYGyOLlpD2C+vFaYhRhCOHo3beu+/9foVV/dxVOHXXz/4Y2eSff1NGe/v3ryfUfixdvDYXHh3Q1v4pXPmiafy/k4xg9jnd2PTpXR33jqHTr7w9Dc2zyW2r3b232oDAg4/dhgOpJIBI4ABNcjwlVW0/pGM6M4ayR2p5HPf1pORn0xSE4zu4x1oJBIPtn/CudGRwfxj8PHXPD1s0H2WK5t7mPE8w+4pPQHt823qK4LWrGC08R3Wp2+nNf3lyoslTz2hdozwSJOikn+IivRfi7o+oa54InttIt5Li8injuFgify3k2k5Cn15yPWvKvGUdzc6Hp2ptFc2d2jq7RsuyaMHJKqoHLZHT2ycAGvYwL5oxi31at6/id+GacLMz77RP+Eb0y+sbdJjKYWvdPvpomka1ts7ZNzqduT820AdRk7d2Kq+G7e31CSGaLTy9uFMtoXtAiNMDy6yhiwYDqpJHTI4GOz8TaYdG04WVp4it7/SrqytnOjXd4u63SMh3nijyC5YB8gY6nO7AAxvCNvoX2G3uNGRmj3CNJTAUI5zlRk5znr14ArtjXbpOT1f9fd/w7W5VCXN/l6bG9G8dvq8VxdXsVvdybvsy4AZt+CqFu33WYDqeewNXtVmjtdKuJJCZYLdM4hBY7l6KyjkduOOvWqekzQa5dgR4zbOBczCLcYiB1xj7yg4JHOCa4e41P8Asrxfc6dBNPOJ7/fI0qmNTK+fmUZzyuBg5GBnk4NYQpOrPle6Nup1+tw/2lMCfJS2mt1swIgVPlyD5nz1z279eveseR9BOsWen6d5Uk9rG1son27GOfmhyx3MfmI28/e61tf2u/8Aaemabp88LxOs/wBqYfMVRUPyZ7Nk5xxjAH15/X/LS3g1PRLWw1K/tZ2kUxybm3OuGJIwSw24wecn2qqfMnyvb/h1r/XUE2np/wAOVtN0638RfEyBLNbrThp7xM88MP7sRqwwqqOFByFHOMc17J4m8SXH9ow6ToCJJdz7vNuhINtuBn7v95uDzjC4J7VzPiHx9aw+HoNK06CyTVZoIzqVpG5QWYkjy5Q4wzrn3x35rM+GVh4d0PSbO6inlu9S1q3uDYpKrZdLZSXBz64x9Mgd65q6dSKqVI25dEt76bvy0v20OaTUv3s1bokRWVk+nJFqdhcSWM0U7CGGMr5d5yP3pJAJDHeA3oPQ12Xi3xjqGmG1tNL0ePUr9lX7QiSnZDIQCEGOT6knoK870mz1zUJLRxAl1FFMZLzbDmRlABURjuMnHbAGMdc6ul+DbzXNV1IzWup2thqE/n3d1eMYyWXO3yozySSc5Ix+lFWFNyvVadv68n5nTOEHO9S1l/Xz8hPHniG51CxOitFL4gv54Xee309/LtISOsZYfeIAJJYms+OBYrSJ7qyttE0632h5FiaQyKI8tsxhig5GQMHHfmvStI0208AeDJXaW1nvYI2Mt6YUha5lLEopx7sqgZ5AFcn4Sh8S6/chL3VoJYVRmu5Hm8yWKbOUURn+DH05z6YM06sVGXJpFdddfNLb8O3UwhUik5LRf12/4JjadZ2rxRXOlako8OSqWeJ7EICB1+diTj34rEvtYay17+1fCtnc3dybYTJMuWt2CttLEfxbQOmQM9c4OfW7T4d6bBpd1ZTX+qTpdZ80+cFHPYLjGOe4NZviHwf4Y0HStKlvb06RpOm5SKQuS7OzbjjH3i2Dng8dhThjKbnbV9Nt/W272XmWsVFtpvfcktvGt7etpUWm2hee7j2yCWE4DgZLBQQQpz/Fir0Oka5rjrNrN+1nZknFrArIzAeoOdvTvk1uaD/ZKxztovlMJD+9kRw7SMOxYnJxnp2rGmTxXH4zN9falptp4PhVj5Y2qz8cF2YZHPvj2rhc1zNU0o+u/ovPojn9ol/DVvXc6i0toLK3WG1iWKIDoOp+p7n3p880cEEk00ixxRqXd24CqBkkntgc1ymo/ELRNP1Szsrj7ftumKJcxwb4twyccHceATkKRjHNTad4w0vW9RvNN0uQyT22FkEsRCsGHBUngjnoawlh6rXM0zLlk3qmS23iPSdT1TToNNu0u5ru2e5h8oMVWEHDSE44yRtGSOcit1CSqkgjIzg9qr6fp9pp1vHDY2sVvGieWqxIFCrknAHYZJOPWrB6HB5xWdTlb9zbz/rsQIcDPXiikY5BwSc+9FZ3sOxheFnfxN4O0W81q1MF4U3vGHyUcEqc/UDOD64rO+J/gtvFWi2/kTsl1p8hni4yWTGSgx34+X8q4D4eapdaL8T7k6leM+mawWjEsspVYpQSyKwb8VUg4O7HWvfF4Ix1zn8a9Orz4OsnF+a+fT9Davz0pr+up852XiWHTvD2/wAu/WG3VPOJjAI3EhSMBQzbgTxjHJyTVBV0t73SEvtXn1C11CaIiLbsL5fhnc4wR6kbux6V6l8T/B15cRwan4amlt/Jl8y8trfALx9WeJdp+fjkdDk++fHpdJudQ1S71LSJ9OmjVibGeZE8uaFh8ocDIEsWcc+nsK9nDVKdWHNF2v8An/WunQ6IYjmd4rf5/wBdNT0/VvF2t6rfasHRLLw5AXMLQfNNcRpx85B6NyQBjjHXqeXsvC1rK80lndTy2eogTCDJXL9QQyFWQj0APHXNQ6fqevaboEVzNprXktvIuCt3581y2DhmVeCnJDAZ429TyZNK8SW+qyromu2cEUlw7zvdaRciNI2x8yOjZaPoOCQ2fWlGEqcWqasvK3T9fncSUUlBR/rzN6HRZLV5pb29e4MpBMEcaRwrjoQuM7v+BcnqKsabf6tpPiFJkn1O3LpulsryHEN5FnPmRnswB5wQRwCKz4NWhX/RpILuzC/KJLiWN0YYJ5IbIPHUZzntWs11rM3hq9jt3sJIEK7FaYzRq5PyndwRnkEjIG78Kyk21aVtdP6/r7i56q0tj0vS/EGk6xd3FrpmoQ3NxbqGmiTO6IHpuGODWk6h42WRcowKkHkEHtXjv2G5ZPtOmanLYahNFF58NndNDLKUORHl1Kvgk4IIyODgcVPPqPiWw1GCe31aeGVY8SWepQeakuecuAVYH0wR09M158sEm/cl9+5x/VZa8rudZFcyeE9QNobDUrjRZNvlTwxqY7Z+cLgHgHgDA+tX7bxfpk13DbSLcW88knlfvEBVX9CwJGOozXnmr6hf3+rDVbuZneOJY44Iy6wwEHJYLkjJJ6nJwMZrOvI9ZuLqKKzutJsLHGZry9dCm/nCbSwPPGcc88VusHGavN62/r+uptLD+7zVN/I1/EunPf8Aii/v72SG9t43YWMMzI/kuB1GM/KWxn/Gueg0q9vk0q+1t4UurIM6xWzLhJW4fc2MlWwrbc8cjpXRJCdPsd92Y76/DDH2RWS3Y57s3zEe2P8AGqlrNqEWpXr6o8Ajkw0bKMZHQZXuMdzW9O8VaL2/rQ3ir2XY5/xjCjJIt3cpp9pNbm4upo2y27cFDrHkbsqNuOO1ei6rc2uufB0m3updSsvIjiln3HcyIQTvwc5wOR3/ABrz3xpZTazeWMOl2L37PH5csNucyeRKuNwB4I4DDtxwRya6nR/hTfJZXG/XLrSheWaWNzaxETiSJCACxJ2hyARkA43HHuV5U1Cm5ys072/rX9DKvyprm6C3uvXVj4f0+70bRppNIlCtG9tGJknVjgvKwG7g5Hl47cmrXjnQItR+H8EetKN+WNvHGDBHbu2CpYDJ2jB4H5Vt6z450Dwhe2fh+Pa91BEivDbhY0t48ADPQAkZIUfpmuuvLOC+iiF1CJog6zIH6bgcq31rz5VnDlly2V736v8Ar8TJ1GlGUo6P8T5ltxbeH9OmhvJZJrMTK4tJSif6SMZeGQt8ynJO3jr9a6zStXv/AArqQ1C+vLmbw/fszy2NzBumtJGGVKKM7cf5zXpHjnw5odz4RvortdPsIYWa8juLhQIoZuztnjBOAR36YryTS7DxLrdmlrf+IRdw2kSpI9vGYZoQcldjBfmUjAwfqPf0aVeGIheSsut/08/xN3VVdvTQ9Z0zX5J5LM/2gPLmCyAXEOzMRbBJb1GD689ar6J480i/udQ+zRmCytBcM8ki+WCIiNxGT3ycVyl7fX9jp8c2n+Ze3sLx77aRSMqCMM2BkjHHBOMVRi8IaRdPqUl9JNLFqMimS2ibaFUFWHAHHIHvxXMsPSs3P5W/pESoLU3LnxF4h1ST7VaYj0mW1WWa2ScRzRq/CBcHeWYZIAIJ6+lYt5e2Vtpun213ZanaJcDCWNqTJOIt2STI7EJzgEluM0uoWMVrq0Op2yj7TcTupVmJ3HYqRqAf4VRDwOcfri+K9ZS61dtEstJg1G4FuJLiQTBVj5C4xgjvjnpn8a6KVNSaUVpv2t+NvnuWocq00I/FM9s3iBI9MsYl1y5jENvKymWVIwCNoHToeSRjFaVw82lNZaZaeU96I3YJI4AjCrkuzDrzxwOSeKpJd299rkN5prtDNYw7ZJXh/cKqvkAuwC8HnA4OO4ArDmgkl8Wr/aTWtxrCzCGaWFzKNpBJb0LFScADv24rpjC6UdrL5/8ADGy00R0HhwG10vT5LrzVvdQlleYkBQVOc7lxnOB+YrSi0vTr2+llnAZbWB8XUkexYMnkxrzjJ46Zxn1rkWuJvEtpb3Ogb2FhfKiR72wsKjAdlHPU4JHTNXtF2Wb2dhomLhLQzw3bXDEyRhlyFPTzG2lQCPlA6d6yrQlq07P8v62RXNfQr23iXSdC0m//ALKt5Jbi8uFuxDcRqszF165A+VCFyF+nSu88E+AdF1ixtPElzZXdhdahaeXPYSOGQHPLqevzAAjHIz1rlotL03XZ7t/Fmoadp6wosMlwsjeYYixMK7SMBs5478+wr1fw9qsV/qN1ZW1rNb2+jsLVTIPvEDb1x6c8etc2Lm4Q/dXT6vy7efTzRy1ZNfC9VuQab8PfD2l6jYajBHctNYRsiG5uDKpUg/f3ZzgE4HSt3+z9OvHGoJEm42rWqTouwpCW3EL2XkA/hVTxjYNfaI7pcz20lm32tGhbGSgJwfY1w3hyDxH4s0u4v7m/2C8kdGtpS0UdvFj5VQL94EHBP5150YyrRc5z201/r1MYwc4qTlotPTsR2MHi7wzb6k9ulre6Msxlim0xldpQzdCnLA8nODj0q54N17Wr7xlbf2vqsMWnTQSKlh5iPmTedoDjOWwOmcjpxU2n/Dl7GKWS3vlinMYiFvGpSBxnJB9j7jr1rjPFejX+g69pN3emEm2m3W8pZ3PPb5Rj/wCviu6DpVm4XTbvrbXb8/M6404V04Jpy72sa2q+IrrxP4d1KDxVZWVjZJOHEZk2FAkgKnexHJ4GR1yRitvwddaDZasdLmha01W6RrmMjfi5BXLFmHAcDOBnkZx1GfP/AO0vtkV5aXaWUt6WkltQg80uNpZQUIKZBGeME+grufgrp17FoiTazA63Ss7w+bI5eKJsYDBjjJOSB/CPrTr0406Mui7L0/4Gv+dicRTVOG1r/f8A8MemKMIBuJxgDccn8a4/UfAlrqfijUdW1O+ub23uoBFHYT8w27ADDqPqM9up65rsutYHjrV77RfDN5d6PbxXOpAYt0nOI93JLMfQKCcZGcYryaUpqXuOzehwRck/d3OY1tNI8NeKhqlrct/wkNzbxpLZRH5J0UcHb/yz3EZJ5JA4xkmvIb7VdI17x5KurTXmp6hOxiE3lmRFkVuIo1DACPOeR+uc13cU0HiPT9Ys7bUGOugokl9bsTc20uQd4zjCEgr8vQcZ6CpLP4cNa6outweLQIJVjN4scCnzyiBZFXbhQWO7kc/Nnnv69CccP/Eetrdfwsrpf1sdV1T0S172v9xLpN3pd3q8+gNDs1RYkawubg5SZG+9tIPUYI+oOfSo9P8ACmv+HtLkl1Wf7XOHaQXFufnXB+UFQBgkAcjI5p0WheDvBHmXkWmyS3jxyNF5U7TzxB/vL0wq4OAcFuT161TtfGmla81jJLfeXqa7o20+Qlop48bSHU4IbBxkY6ZxxSXPJ81JPl63XXy1fz8/I0jKd79H/Wh6JY+L9Iexhae8ImCBZPkLEOByDjvntWzYX9tqNrHdWM0c8Eg4dD09iOx9jXhviK4jtbWc6TfWegQTyBZHncsUI/uZH3yOCeuBXovwy0zUtN0u6l1jJmvJUaNiuHkRUAEjqOhbr7d65MRhYQg6idvL+v8AMxrUowWm/wAjtM/59KKxdd8TaLoUgTWNRitnKq+1lLbVLbQzYBwM9z6H0ormp4erUXNGEmvJXOSUlD4nY8m1bTbTWPKkliNzayW+YXjIdXZeU2ADdvJBXjtwRxXv9pJ5trDLsdN6K2xwQy5GcH3ryTwVo9nqGm2HiHTb620zw3GzObZYtwmQYyHDcK24dvw6g16B4T8X6P4qs/tGlTOVDsvlzIUfI9B6V14tuok46qOnp5euh3Y2anZR1tudDnBz39a5PWfhx4Q1i8a7vdDgS6LbzLbO0DFv73yEAn3I5rqx2pwP4Y9K5KdSdPWDa9DzzjrT4c6Lb6hJN5+pyWzxqgsWuiIEIOQ6hQCD2PODk5BrdtfDeg2in7PomloWI3MLVCWx0ySK1h196Q9c05Vqkt5Mt1JvRsy9Q8O6JqMAg1DR9OuIRL5/lvbrt8zGN2MdccVw3jTwjIL2/uNOEcdnqEal4vPECx3CECMoWO1WJIKkY54x6+mYHvSOiOu11R14+VlBHHIPPvV0cROk7phCbg7o4nw34XuTo8UesQxpc7RuVtrMvygHLY5JIySOMmsXW7aTw9KkM1vc3QvJ2ZJzIq+SAoURouB164JbJzyOtemXdxDaWstzdyLHBCheR2/hA6/5714musSeN/iv4eS6kWC3sybqztSTvwuWMrKAQCegz/dFdNCdSo5VH8K1Z00ZSqNyk9Ed3H4W1csxj1OGxiI4jHmyMAeqsA4UkDjvV8eCdL2IJDK7Kc5OBn6DHFdODTCJPNU71EQUgoV5LZGDnPAAzxg5yORjB5ZYiq+pj7ep0ZkN4Y0kv5jWpEmMbhIw/TOM0SeF9HktGt5LJCrdZDnef+Bfpitodck0h4B7VHtZ92T7Wf8AMzH03wzpOnatLqlta41CSIQm4dyzBAANoz0GAOKb4u8SWfhXQn1K+O/DrFDEOGnlY4VBgH8+wFbR6+1cN8X/ALT/AMIpm1uLKBlmXD3jqkYfOBktxgc8dTx1rSivbVYxqO9xx9+S5meda0ND0BZdQbTNuo6pcuRA482WaZyzcE9gXOMeveuv8J+T4B8CSeJfE5vLWe4ij8+ykkLMshOFGCeHbgn0HHY1w3guC2vPGnhyTVLZ9W+zQsf7ThmJjSZCxzsIwwAC46dOnp2Hxbvm1m2sYraKC602CbzLjzujMvOcd8DO0dcnoeK9WtFynGg9nu/0/rU7J87/AHMdI/oRePfGZ1zwlaRW+jv9gu5MalDfL86RBhgRgH5iTghh0x09LWjITYRRwmNoniV1jC7Q6g5+YZ46DjPUVh+EZ01azkvbWWZ7GebNvHMu5rdF4CcZGd2fmHLZ5qxLdafqdhdHSbpIoTmASohV1cHBVhwcD0zzmj2cYr2UVaz/AKv6foXCEYq0CDxnf3tmlumnGOL7UNkMwOAtwMkK+cgq2SBkcGr1zf3VtPDE8DMn8TD+Dp0x15yP/wBdYl1rcNvq7aTcISLREeZ3jwEPAVumMnOfx+tWdQ0+K61K31SyuLiK6UbW2PmOQDsV9eOv19q39mlGKkvn+Rqo213NxVa5WRLOMyyzDMcxlKsgXGSAPunPJ5zjjtWDoei6PYWlxcaNJIbq7VVllVuGZTljnPGPXHOatwpNgmM4DDnIzz6D8OaF122EX9hxtZybXEMohAieFhyxfaByeMtz0POay5ZRvGOw5Kz0KWqaBqOqpZx3uL1IAPNYsYo41JJG5em0KVHcnr61z0t1ZaXq1/qV7p7QsvBnhUsqyOMApzgnjqOPSs7VNQ07VLGeaGzdtJlvkjv5rczLPJcbSEEZLECPCt94E/MeAQK3dRshaQfZjZXEnh6CychFUyOzxuCAG65IPTPTJrqinT0ns+m3m+v4ERnffYSHTU1DWdPuLF5Y5zLGbnSkZWOW/jABGCQdxO3gEnNQxQanY3r6tNp4u9MncpNqMrYSOMhl+Vz2BzjkjOBxkVY8LLNJFJqMd211rM9tIsrQQDzIYTHtMTY5BUHA7jA9OI9FmltfAuoeFNdsLvF06TWUSowVAGBLszY68HC8HBPHeZOSdlrsreXW22wNyXwodHHHoNjNPD4cn1KytfLCI9wssTheA6x4LIRuzvb2A7mvb9K1qyunsrb5ob2e2ScW8q/OoKhsH3GR+IrxnwPrEsOkw6Va6dPeylmtVmu441dOeHRTnAUkKBz0r2Dw1pT6JoqLdYuruCFi07D97IeTyTkjPpmvOzCy0nv013OatFcqb36I17+0j1CxntbgSeTMhjcxsVbB9COhryex1LXvAV9JpN1aSXWjtOBDcCAFYYsZMmVO6RiAflPIIIGa6240/W7+fw3rUGsm1giHm6pbxxEpOg3EBR2PJX1PHpW5pGp6T4o0dbvTZ4NQ065yhJXIOOqsDyCPQ1xwl7GLTXNF7rs/8/0M4z5Pclqv1OG134kS3CWcXhURCSVXla4vbZyrJGpZ1RAQQ2B39e3WtP4deOT4qtil9FaRzOf3ZiY7ZuM/cYkq3XjJ6HmuX8VTW+mCfS/CPh43OlQmb7elparLL5rjaWTPO0YAyMZwRyKqSaKfDN1qKaTqVva6vHpouILZXHnNJkgs6kbEAJ49vxrsVGjKlZKze3f52+Xl+nQ6NFwttK2n3/h6HsYsbPz/ADhZWomHSTyV3/8AfWM1YAC9BjJycDHNeaeCPEeuT3RfU/tN/DLBGQsA37XwN5Ax0BOMY54PtXotlcRXcG+Bi5U7WB4ZW9COxrzq9CVJ2lqclWnKD94n5xiuf8caTZax4buYtTOIof34zkruUHGQOoz2+laCazp0lnf3UF/aSQWLOly/nKqQun3ldjwuPevMvG3i7XtXOnw+ErMx6YxFzNdySon2tRysaE9FJ59SMdO7w9GpKouXS3Xa3UKSblePQ5++1mKXTtfHhaxgufE7rFbyjyyGDk9W3H5mA3YGcE9R2rf8H6NresQk+KLiNrhAfLMEQjSM7fu7VAGc5yRn61zEmsTadq+nRTR3EJd1N8IoQFQkAJLuA3Mob5dx6Y59D6V4W8QKLN7O1hW5uLY75h543sD1fHr1/KvTrKUIXgt+vbpv0/4J21IuLco7nAeM9G1XR/FmmNFHfS6GJFFy1vOBJIWUAsFOA2Dk4ycY5xwaz9Z8I63pUlzrMi6bMu5rm41SDEaz2ijoRjKueAQB1AJJ5NdwlofiTE/2+xvtHWCQ+WwkCzLg+gPKn146cV6HJaRS2klncxxT2bx+U0LpkOuMHcPf0rKeLnRUYuzkt/T1/r8jGVVxabf/AADw/SvFazWdxbtpJkto1N1BNMgZGwMAqcZ6kOOnJqbU9U1zVfDE+r6b4iuLG1cReZM7+UqbSBg91OQQT/EfXNdx4t8KtB4as7Pwpp9mv2VtqwyM2RGWyVU5yeSetc7p/gHULtJrPxDp8K6a42NFa3Aw4BBViezA57VccRQl7601622Xl3enzNlUpyhzPfz/AK0KfiiC/uLG/wDGFxpazag8MNqsNtllkhP3z3BQg9cY60V2N/qejaVY3fhdo7m3it7JVXYDIpV8qEVs5JHvjiiuvASpyjL2kVbpdtafK/r8xU25rdr0X+ZxnhrUrrT7STwr8QYbOCFfltJvKKhgfu7lUfd9H6jHOe3Q/C7SNO8NSvpt2p+3Wb7RIGOw7l3Bh3YMD972qz8U9R0jV/Ctwls+/VY4ZDBOmEezx98sx+6ODwD2rlvCut3E9x4StbVpr5DpoUyNDtkiCllDPnnk7QPbn0rnipVqMnblTvdea6r1/rzc3eNrNN739enW3c94GOM/rQPUdfSmICqKOMgdqd+P514p5Y8H0PFB7cUADAx+VBGBn16UAAPqKRRlgFBJ9B3pM5Hp9Kw/FGjTaxazRvf3MdosL/6JA/krM+0j97IPmKf7IKjrnPa4pN2bsCVyC9kOteHdQt9SfT7W4V+UE4lEW1wUMm0kjJxkVi3es2/hyLFhbaXdXpjZbjUDIvzTDOUKr8/3hjHA/KvOLvSz4bsPD95G3hvTri2dJJBBsUXEYb7/AJygtnGBkP1BqS/0n+wxPOdS05ra/uJLm1uILpWkCO5cBs9W+Yr3zivVp4aL91vR9DvpUdeWb0d/S/3/ANWPWfAXid/E9jctc2yW95auElSMkoQRlWXPPY8dse9dOc9iPyrwjw1d65b6nrN14Kjlv7wWiIbCWIJAr7gu4tu+Yj5iBx15OBivbtOF0unWgvyjXwhQXBjxtaTaN2O2M5rixdGNOfubPp1Rjiqap1Go6LsWc5pMj8KU/wCeaTuOMn6VynONkyFypUEDq3QDvXkXxsutH1K+03SddsdQe2jdmiuoGdUWYjoVxtdcYyevJweuer+J+rS2mipp9vpMuqf2k/2SeOKXyzDGw5bPX+nrXk1/pWpQa61w1z9kgmj+xwXrO0zQqSEijEYP71wBwemfm/hr1cBh1f2snbe39f8AA+86KNO/vSWhFqMehabZaYLzUdT0yxmjVIrSWMedNAjl3jGxgEJbpKffitDw/BPqF3bSW19dXHh0L51vBfRx3G11IOfNX5XKnOCfmBAyKk1qz0q4utP0y+u73+2CrfY3CtvmZQAQ0nGwnBJP5ipvDuseZp1vNpWmwWkMc3k3lhEFUxgrjecAAOcAnIya9BycoXX47fL17nTye+9TS0bT5tNhu/tN8b26lmMvneWsYA6KoVeFCr0A4GTUVzpn2iG403T5jZNdONzWsYLEMQWPOMMcCp9MefUrmSC1m8qdiI42bDHJxjjp9B1pPAur6X4gutTtbDUrhodJTLysmC8jMRuVunVenfsBjNYubjeXX+rGknGn7r/r/M3VCWvl+H47a1i09dttO92nmSMgU8MwI4BJI9OOcVz72iW1rLaYS4gB2IuOGTPHH0q/c6lcyaXcpbxQG6Cs0cz8/ORjdIxJ471zfh+fUple31O333YIDPEoIdyQAFI+Vgc9vTtVQg4xcvv833LgraGhbww6VFPFIL25iitZJo4LQhpIiANrcnB5bIB64HXFcBa6frGrSafpvhGJrO9uv9JN2/7qR2XO4TZyQOcgDjnv1rR8UWcuk6tezadpwmtZy1xeXSOWkJ3kbSSSAvbgdzzxUsfiK886yMek2jx28KTfaFtSPsKhPlLPjLKTzzk4wOa6IQmoucXe5E25RfnoMuLS2tdQmuLTXbOGTTbIG4sIkdI5G+UOwJGHJJBwdueMYA4ltr1vFuu6G/h3VNRtpTH5E1rHIIpNw+9gBuQASPM4+70GKv8AwZ0i28US3Fxf6Wgm5e9uSxKXCl+ECdFJwc47ZPpXsWl+DNA0rXZNYsbER37IYlbezLGp6hATxn156mufFYuOHk4Su5JeX9W69zGpWjHTf1K/hbwRo+gWWnR29szXFlJJMszSEs8j53M5438HAyPSpbrwbol1dx3V/aC6uELHzJHK4DfTA47HtXSDjqOD7UhAIIIGOmOxrwnXqOXNzO5yqpJapnnGkfC6Gwvrtf7RI0aWaWRNPigAwrY2q0hJJ2kt9c16FbQpb20UMZOyJQi5OTgDHWpeO1Zt9rVjphf+1biKzQttiaZx++4ySoHNFStUrP3ncblOem5Dqmh/bNS027h1LUtPFluBt7OQJHOrdnXv04I/Cq3h7w3BoGqXUmjtHb6bdkzz2wXJec8eYGzwMY4A5P4Vcm1yyh0l9QlfMUSh5ktyJ3iXONxCE8DqSO1S2+rWU+jJqonEWntF54lnHlhU5+Zs9B3/ACpXqKNum36/8ETUrbabHkuoXFxpsly0OuweHRLfC5ubqZRukGSBEG7csT0PA9uc/wAI3Oj3evm/jvrrU4klG64uYBBJcQjgbl/iXccZOM46Zrp/F9n4R8VSXc8N9Y3V1YtD58bswhJdS0Z6bWJAJyMjAOe9ZFt4S1HVbrTbqxV9OtI35RlRw8QGQqqh2lGJyOg5z1FetSqQ5HzvlfXp0+96HapRled7XVn6nca34Ysr+4S50uWKzdWLXUsNwYwF2n7wU8eueMde1cX4cQ6T4g0//hC9bt9cS4uNl5H50kylP4m8xs42g5Byf155nxH4pjufEOo+HPB8Caf/AGjLv1K4nbes6JksFGPlRue/O7HGa9A+HNnaeF/Dmo6te+RDHM4RWSIK21eNgAHTPQe1ZuE6NFym97WT6377/LXoRaSi+bXp53f37f5HLfEfxNomoanD4I8KtcQedeM+oyadCqxMzZyknGGz/F1HY5xgOOi6vr141hcWt3a6bblZLQ2MoUOAo3KxGcKCFwBzVG01W11/VZbrw/oq6f5sn725DLChPYED77fTnvW5pfiK+XWZ7LTp7CZbaASeZHN5sil2wWY42564Xt361cYypQUYLVau/fua+wlSVnv/AF/X/AMm8WV/E0UsNxPZfZZo1vori3BNygOQqHGSPvdOBnP1jsNF0zRLfW/E2matf3Ooy3AsmiWMExSOwxnByQoO7HoK6Dw5pes3l3eTXpa4lncSJNJ95MMeM9NpXHbPX2rVltNE8AeGmsYrlmm1G9IaVmBkMrjBKnoGVenfPvU1K/JaCd3orLrtf5CqS95RW9/U4G+/tqx1+w8Pf2rcyiOGS5FxDti+0SAnavmr/qxjGeSeR612mheN9WitoT4ghtsmDLqjASh+dpUkhWBx0PzZOQSOK8p1CxfR9QuLq10qPT4pY1J1eWR5RCpYBsISctkgbff0rqIzc6zoutImm2NxZWt4okGvgW8LdRGY3yueeuCM7hnqM71qcJQXNb121v5eq08uiCpGOqn/AJf1t6ep7Vpt4uoafb3KKyCVA21hjrXnHinU7j/hZcS6BfGa9sbN1vIWmAjhyAyYj6MeSCe3FQ6v4t8RaVFpdpqXhwadDERL9os/NuLZlTp/q2DBT/dOevNaXhHw69/4qvfFV1E1vHeWhh8thh5y75LscDGAqgDHI5+vnwpKi3VltZ26+Vvz9OpzRjyLmexS1WTWtb1Kz0S/jUW+4Tm8VkDxHaVOYwM7efvdMjFFejRadZx6jJfRWyC+kiWF5xncyDoCaKzVeTVqcfuuP61OOkHZFfRfCPh3S7C5ttH06K2gutwnMbNvbPX5icjnsMCrdv4dsYZopAshZHEhy/8ArGAwGf8AvYHrXAad4k1XTtb0kLf2s3hksY7syxhplLcK+9RzhsDp0656j1YfgR7d6VVVaT953v8A195GIjOm7N6dB+O560o69qbk9O/vTh2rnOYUcnPeuN8R65a+ENetZbgateDWp1jZBJugtAMDeAegOegPQGuvkjDkEs3HQdqz/EujQa/pgsbqe5hi81ZS1vJsY7exPoea0pSipe/sy4NJ67F+6mgtLeW4uZo4reJC8krnCqo7k+leX+JviXoWs6fq+iaS+om6a3IWcRbE56ZJO4A/Toa77xLYw3mgXOnzPEkMsJjHnS7QRjAySefrnrXgstrFY7pEZJ/LyZluIDC0Z/uHn7ox14Jz0rswVCNT3uqOzBUYVHeW6I7LRrXWdO83xJamzsraYFIhLua6A6YweF/DucHipbSxv73ULtNaNndx3ch+ywRoGRkCk7NvYAAADsR61taPHL4keG0s4LeC+T95H5A/concE89T82CfWvTvCfhKDQws9xL9s1HBHnFcLGCMbUHYe9dtbE+xT5t+iOutVjSbct+wz4baXd6R4ZSDUIoopGcvHGqgOkZHyrI3Vm6nJ55rpyBuz6dKXrxn9agvry2sbWS5vriC2t0GWlmcIoH1NeLOTqScu55E5OcnJ9SfOO4A65rB8Ua9HpUAijKm5foufug9M+57CuX8deNpJ9C8rwRfp9uuGULfGLKRrySEDDlzjA4OMn61yui22uXloNSP2i7jDJO17dc7sACSTb0BAHAwTXbQwbtz1HZdup00cO/jqKyNXXotKGtvG+oQX89ixe6thfOhtxjgnPysQeq5x2461zuuvocN5fxXd2dS0soklzFkN9lOcojGPB3Z+YY7cHjNYfjOyb53WK3K3k6M8KII5rskgqBIx5fJJwPr2rrLeziGgx2FhCtlKUWOV0kIZHx8uG6EDDYJ5OPSvTUVTjFtt/1+HlbyOq0muVvb+v66lrTpVvjPdzqHgYNCgQMmF45O4ZyfpwKmlsbOAyT6fDAk14d13JuJNxhSFI5wD0z+PXNZFhDJbaBqFtpuqSNeRSFvMmYTbJBj903oDjBzW5ocF3fRW0V3Db2t3cRtvg27UVhguBjPHzDp1xWU/cbd9AbV79hng/TInvZL03MsEVsxERX5SHGCcNyDgfzqG+u1vtQuVS1js7RZN0caDaJHYkmRgozvOOT+HFZ1hFrUWuXf26SK1swqRRWEXIjZDkuR0y3XJySD7CneKL1NKS3vZZ7eJLhjEs9y7bYxgMTtVSWA64HPPvTUb1N7t7Gj1k5yZPqeo6faz21tPNFE1w2URs7nbIBYYHTnvzVLXNQuYoLq00y5jgnVQ8FxA/msTu+YKoGQwHQ/U9s1hXcs2l3Uc19cw6xqVxf/AGSz823YJChjBYGRWBTHmJgjOMH3qp4mgsPCTLeSXER1O4Zp106CYgIWOHOepj4bj649RrCnHmS3/V/11fmR7RddipbXMz6vdxXZurDTIIlghBjeNkY4Vdz4PGepyTzx3qHWZdTTS7NdSW6tNTfMKCONMzR5BZnz975WC7RwcZ710um+alxpQ0KzRNKvIFeVp53Bg24G1VYtuxt27QCX4+tbvw48PXt/44+3a/bRXkNhGGgngfdbW8wAAUZY7nIIJHGCBx0xrPExp+9Jbff/AF3JlLli2zvPhdoEmg+GAl15/wBsupWmlE/DRrn5EA/hAHOPVjXXgMR3rzjxT47u9A8RRaXHFHfTja9wMYZw5+VYwP4wuMnuccVoeNYYvFXhnVNM0ZGu5cxSNGjBSHDA7WyeOBznjP0r52pz1Ze0l1OaVCbkpT0UtbnblcE8YxSNjP8A9fpXM+B9K13TLMf2/qhuMoEjtOHEAHA/edW44x/OofGsvjRL3Tk8GxaM1u5IupdRY4jxyCcc7SOPlyeay5Fz8qa9ehjKKi2k7mr4t1C50rwzqN/p8SzX0UX+jxv0aQnAz64znHfGK8mkh1E64uoXd29+zW5jkEp2SI3U7cZVQ42hgACNowcV1XjfxJYS6K8plLS2AMsyhGWF32EYR2A3fMcA471y9gks+jaRq0ADw38UrtIrAqsitgRAD0ALZPPOOMGvRwtNwhzNb6fht+p24anGK97dh460XWNJuY9T0yK6TTkaB7O7gcC4tg6nd5nBDqM4K4wwOCe9V9N8d6vBrlxYXWqadr2mJF/punXNots0CAc+WQCuPY5Xtxwa6rw/4kv9IltLSTT5LvTppD5sxuFDWinqVQj51yc4ByBmvQLvT7O7Eq3dpbymVfLctEpZhjGM4z0pVK/s1yVYJro/61X3ozqSs1Gor+Z5z8QNc8J3fhFIzZW19HMokis4rlLNm42sNw9Bx0PA4rmtJm8L6R4f1C98OxXlld3enrY7Jb1JbeKPcSxDA8Hrknr26k16dbaN4UvLfUvDsOmWcsEGEu7doidu4Ej5jznqQQeO1cz8RfBfg6z8I2091od0llpRXYukgiRUZhuyDneM8ktz7ipo1qStSalq/wAH5Xt/W5HPTT+F6bXZy2j+HLrWtDL2FlAJFUiRbKVWdsg7WHOTxjBPHHHHFU9etrjRdJ07wNEi6nCQYpUSTfLHLIxYnAHyhBjJOOvFdP4r0jw7a6QdPh8Q6tZxXPlxtbWa/MMqGXzFGCoK4GGwBnHauX1S7/4QPz7yGwmha8HkrPcXIcwhQMIRjAZgV+8TjnB6kdcarqy766J6a+vz6f5HbB+1d29lpf8AHfsinYaUNKEukazHBDGWWJEW5+R1A6LzkEkZPfJPANbXgzwhpEeq3MWkXUSXTbo0nac5lRSN6qOM4yCePT6VUt49H8J2djf+MrW+EmoynydKif8A48yx5dyDlj90qOwPc9Ol1nRrTU/E2lyaFFZq9hFKIHlvGScyvjKlSCNu0ZB+tVVrT2TdnfXpdfP5f5iqVYSsoff0X9f13PStPsxY2ywqxztxu9/YVw3xG0CbxHpENtc6b++trhJt9uwjW5m2knbnnbgcsSOeK5WDVfGXhzS7q415Z11YndEb6djFCg+8wK53Dn7o9M10CfFfwtrelanGZb6L7IikzJbZSV8jBjJJ/i7OBxXnrD1qc1Uh72u61/I5XB05r7V/6/4c5rxC10ljE2iW0GsXD3UNtLDbnzUBbnb6Z+UksflXFL4v0mLR/F9rZ6vrD3EVzeCext/IBSCBBnLsQepB6DnGcDitf4fXH9v69dXMdtPFJaTljLNAY4Z5WBJZQO+GJx34PetnxprWjabqkY1FbfUr2T92FY7Ai7uFIB5OeOa3lVlTqxhbX8dbW/Ly3N25TqcsdV/VzI0j4q6bpdqsWrG4luJpZ5ttkpkFrCGwnmZOQzHsM9ulQ3PxltZDqa2mj3wWK2eW3nZd+WUfedB0Udev8639W1XRrDT7cT+FjM16RElotqCWOQO/VfQj0rtLWBbeC2SG3jtFjQKsUaqBGv8AcGOMfSuSpKivedN636/5fcYS5Ie81q+//APG/DGoeP8AV9AuNUin1S/uo+BBcRpZibOGHljHzLg9feivXZtWs0aUXE5TysBvMU/L+GMgZPWitI1pVG3Ckrf16GLc2kkrei/zTPL5zp1hq01hJdpLqYRVXa3yXcTDcCAOMgHcOe5/Hvvhl4jXX9Iu4P8Al60q6ewnKkFX2/dcHPQj+RrkvDGkWl14itIHsoYJrODynMaq67MltqN3G7I5yccVnz2cvw61i6ttFsZ7q2vNRW+uJzJibygMiNcDDHLFcEHg/iOqrGNePs18Wj/z/wCAjsxac+WHXV/jb/NntgxjjilyOeegye3HrXJ+D/Hmk+J3t4IBPaalLB9oayuFxJGu4jntjjI9sGty+08XFwZBKqyNA0SZyMEjg/TPUV5bpuEuWeh5vK1uaQPOKDjGTyvTAryzwlF8RLq08u6kg0o2t7tmikQEyxZ5MZIIxg5x+WM1vQTXvg64SPVbgXml3MhAmB+eJv75HYHuBnHX2raWGcW4qSb8jX2N3aLuzmPFPw98ReINR1DUI720t7qS9xH9okLq9qM7RgA46jj27d+t0TwHp1pZ3VvrMs2vrPIJB/aRMoiH9xAScLnJ6114IYKykMCAQR3HqKB688+1KWKqSio3sl2JlXnJJN7DIoYoU2wxJGoAGFULwOg4px9aUjB96Q9+cVzt3Mxfx4rivirYPqfhYQWmorpt4lyjQTnBJboQM9Dg9a7Tp0/KvHfifd2upeNtGsWmljjs5Q7zTSLHaqzY6lhlm44QfpzXVgqbnVVumprQjzTRx2t2ms+ImWbQ762ki0sR+fqjOscUU0fySyHOAoOM55zyRnNW/EPjvVLm7kbRL+xufC1jBBDHHFFtluZThX3Z+Zdx3njjGB1zVJ2a6N14a8OWWn2OkNP50stveG7eaJWbaynlSWY8+m0VoefpPhnw26m3SWG2i81zwxkOOpPqTtBPYds8V7jUNOZXtstNvPz9DvhBytOXT+rl3WizyQfZRaPM+FklunCiOI5LkZPXHuOMntVvRbi3vI0ls5jPZysRbj5gjEcbxkA9/TGMVh6ZqB8RwxT6vPHZ2tvOrQRQyiOKclAWVcnLB8nrzjA45Fbel2hsrlnvNaa7u5yFjt5AAYgTkKvfbnp9OMVlNqMLNmvvXJ9A0Z9PguDcjzbt2kaVoyP3p3lgfXOPy6Vbh1EXMKPpd3plxYwPItwyPuuRKRiKNAPugnOSeMKepqTzJluAsgR4mba5DbSp7Y96sJY21rPFMLeKGS5IPmbQvmlSQCT7c9axqSu7y3Zm49Cg1hdLdXeqzXUpllgMbW+5Qqc/eC+p6D0zXJ3Oo2VlDe3l7dTQXLaeGk0523vGVO1GYdA3IYZ7ZPNbEcepXi6tdWLKbuKZlhjuRhdnTcB/Ec4xn8KqR6NcW76hdJpWm3t29qRbTywL5k8wAy0hI+bnLZ5AyB06VSno2/Tp0/r1NJrlfKZWk+IJbBrq71BtRSPMNjLGJWMbjdlXRQCc5APvuOetGrwDWEe8msfsDWrFX1CTEnmRdRIAoyMf3RuxinG+udT06DSI9Hv7zWLhBNqUWlAtJb8jhkGAdxx/EMVvR/DzWRq+nLaeGobK0S3G64k1QZiZlyyMqckZ4Iw3f5q39pTpvnk+V+q6fNb/ADMnUhGWrt/X9fqczpmnapq15Jp+geIP7Se4izbAI3lxITklmYAg8Ecj9cV7db+G28N+BpNG8JiRbhUPluZVDmRjl33EYz6ZA6CvKdPsbrwX4mJ0rxFp0EzToLizI2GRFAzGRJlhuHUKWAIyD2HZXXxD1b/iYuNDMdtbgvDJG+9psdUA/Pnjp0rkxqqVnFU7OO/b79iK0JyastEd7pNgII4bi7jhk1ExqslyYlEzADgMwzkjocHHpU3kxWUY+x2SgFuVhVUx6n/PNYfgfxUviPTbeW4iW1u3jDtEXBPXBHsR3FdOevXj0rx6sZQk4z3OOacXaQ1h1xXBeP5Xa92Ocwwqh2ckYbqe/OePxrr9T1nTtMYLqF5BDKV3iMks7L67FyxH4V5r8UZ5tVtND1TwfelkkuGguNQtoxMsSjkB1bGBnPXHtWuFg3UV/v6GuHupKVtCFr8WcUssekaZCkSGVpbppJ2Cgc4ViFPH6VkzQebrJu7kuzxc2sa/JBagjEmxFwoVgFOCMhlJyc8atvBqZOmxGMSWc7CFLmJMjAwGLDkJ6Y7D1rA8Q+JdM0XxNf6ZctdI+m3XkQeZEZWus+g9cke3T1r0qV3K0Vrr/l/X/Dnc/Z3vLpruWvENsb3S7uyE9zbyTLujmRuVPXK85zjt9a7/AEiO88T/AA3sraPWLq21ExJDJfx58xnjIDE4IJ3Y55715HfHTLx5bW6vTd2+iyxyx35n3iSQ5+R2HzNtJAJwCenbmaPXtWh0mDQNXvbjw9NqF7G1pf2UavA0eNpSTB3Kp+U56nv61VbDupBcr1TT/rv3aIrWcVNbr+tj3SaOGwszGL23g1B7dU+2TopeUooHmOON3r+NU77xNZaToEepX90JcqATaxsTK5/uJ1/w71wPjO1/tHQzZaHAuqX5tVht4hPjzog/zMpBwBkA4zztxXL/ABBWax8O+HbC3uHshaRHzwlwE8mTYm9TJjJwX2YHdua5KeEjUaTlq3+H5+XqcyoqTtfU6XX/ABbHrk9xcaNp4vb6wUGSKMkSZbIKKy5YnbnJIHToMVz8muI2jXGp6n4anuIvMWOS21X5UXkfOWIxwcdqyvCsCXdxrslhNJPpjeWWuLeQBkfbtYKSD6A55H41u6jZ6zf6XLpsmqf8S+WJWj8+FJJM7l3FgRtJIAwecE13KlCm+VLt1d/PY6lBcvu7ar+v6sbH2Hw+dKk1bUZRZJqspuEmvrlG8wDkNGoPKnPAx6Ctbw0YdAjkuJD9oWSLzopfs+JZEJ4YN1C/gPpXmHjFNKgvtFstTsp76C3Xy4rxYmDLkDC7B8vB525A64FamjeJWu9buNE1e4upmijbzb024EcoHCoAPugg4U88noKU6EpQuno7/d5f18hNSatUejt/w39XPSvC3ii38VyajY6dZvbXFiqyJdvHviDN3Vs8nnpxWVb6J4X1LxNdeHI7PV47u2j+1y3Cny48kg7cjHJyD0xUUni+40q0t7Dwto9nZ2FuyjbdOTheS2CDy2c8n1/CqHij4gSf6Jm8ltrZpCga1jIVveR+gUZ9Qa5I0ainemrJ7a9e7/yM/Y1E3y6J+f5npj6jp2lRx2j3itNGNqQAh5m54UKOSelcJqeieC/EepXdxLNcwaoq4dDJh4CcglVGcMD2Ocelc3oslu1vJeW8pnW4LzS3bESMR3HmY5C4I5zgcZ4ocWFpaNcG5s47cFVEm1YVwepZ16k9j+ppxwns23zO/kXChye8pWN3wzO3hG9bSLO+u9S0RI3JjvF/feexz8rn7qBQDgZ5JPesnUvGUmieHItH8HmythaJ5UfmXSStbrnJaRm9M9ACeccYrH1DQItT1T/Tdcu5rZ41ePSYDsDAd5MHOC2Pf9K0tE+GWh3WpLHqNtqZsniCxRQbVQtnJZioLfnjr2rX2dBe/Vd+r03tffa+7/zM5wpw97l/r02/rYx9J8Ia94iuLYWsRj02eVX1PVZrthPcdDlQ3zBTk42qMgjJ70V7jp13pUDNpVjeWpksIo1eBHDNEmMLux6iiuSpjq1/c0X9f0uljnlUlJ3X5X/My/BXgtdBMM735um2YUKm1cH8TxVvxn4X0vV5rTV72ORL+wBVLiDd5hjPVMA4IyeMg4ycda1PDOtQa/olpqNuhi8wYkgdgzQSDqjY7j/OK1gSOcnJ6Vh7er7Ryk9dn+qFXqTc1KW6PnSzv9N0H4qR3Xhm+vLySZJIpYJlZ0EgyNrNjds9MZwR6V2dv8YmtGtm8S6A1mjzfZ5RbymSS3fJHKEfMuBnII/E11Hja1v7O2nvNA0yC4upY2SRUCRuwPVg5HXH5145rXg3UE8HWlxc3kslndagr6gbxvLmt4zgqDyeBjJxnoOMV7MVQxaU6i8t9dE+34XWpsnGpG7V3+r/AKf+R9LJIJEjaNt6OAUYcgg8ivMPG3iewm8Tw6YomluA3kRRoA25mOCAOwJAGSTnAPAqpY67qvhm91mG41Jb1UiR1guLjItQ33DGABhdpAx06HPrS8FeCr3UNV/tC9izYFd3nykCSWTOG6chdvH+TXHSw8aN6k3otvO5WHoxpXqVXp09Tq/htq9zcI1rE4vdPSRoxIpz5BXqmfTPY/hXfY56fjWb4f0LS/D2ntZaHYxWVo0jSmOMnBdupJJJPb8AAK0h06jmuOvONSo5RVkcdWftJc1rB2/kaTJJOKXOfekySawIM7xDdz2Oh3t1ZrEZ4Yi6+bnbgdSfwya8Qto9K12C33tFdwbjcw5LBk3Lhn9cnn6V7N4umxoN9Gv3mTYf+BD/APXXkEM82k+H52fTxAYiy28dvtaUxDAVmwOmSTtHQe+a9fAK1N23bO/Bq6atuZjeHUlstY0rTrqO1uwqrAtszZt4QwZY8dFZtuWbOT7ZNVtYwdV8RWkmoTzXBtVAMbPFsQFfNKuFOMjnoRhiCetb/h4TWtzJHeKBdCBbqSTZt3PKM4YdiFCiny2TWB1H7XeyLbxiSZEVcs5KA+XnJODzyeBxXc6jjKz1/pf5HU4JN3ZS0XQ9DU2p0YRzaffTG/hd3IdW24AC9irAqQOOhFUTNplxr9rqLw3ljcW77Y1uF8tLjtkhhke2M5xzisbUrzT9X0K11XTzBa6jo8kduj3AMSSxncdpI46kZzjHJ4zioLGz17+yb271MfaI5pQVsLolkdO8sMhJO0dMA853Diq5bP8AeN9tf67enyJi7e7/AF6nQy+JtSS5Bgt7K6YlFgsLYGS4lRiMykjhdoz8x5JwCMZIu61e6ldaTeahps8d28ZUWn2VBKevzNg8Fh0yOnPU1jvfeHIL6zvGtJBLaoPMU/LMhC/djCNtxliOc8da6awVj4etpFtDbWvkskVqId0gXOSMZyTgDGfXiud1ocycF95pySjrIzLbU7rxBpF7bW1leWyqip9tuCVkZ+N6rnIwAG5+ldxp3hTUrbxtYM0q3WiRQbLhQSBGyr8q+mT8u4Dr3rg4tX1PxNLpuk+H7Izf2rHJbTzu4lNjDkAk8/KQp3Ak8545Jr3Hwjox8PeGdP0h7uS8a1i8szy8FzkngdhzgD0FYYurKirKybvpv87/ACOOvW5fdiaP+jWkSZaG3iUCJBkRoMnhQOBU+KxfGFrYzeHrubUbB9QjtENykMfDllGQV9DXM+AfF+oeKJ31F1gstCWBd0Vx/rY5DgLhuhU4J555+leZGi5Qc103OVQbjzLodrqmmWGq24h1OytbuNTlRPCsm09iNwOD71h32meFfDOnXN9d21nY2RBSVipZSX+XpySTkjj3ravtW06wsxd3t7BFaFPN80NuBTIBYYzkZIHHrXiPj7xVZ+ITp9/cX0F1o+mzGO/0hH8pJpCx8sl5BtDYHrkcjA5rbDUqlV8qbUev9bDpxk9r26le/wBTTQ7O9i8FaTeNYWku2wnmmaV5Wwd0gVvmVA2wAd8H3r3XRPt50exOreUdSMS/aPL4Xf3xXi/gTwvHbeNW8S6prE/2ecGeK3P7wSAD5VMgJ3BQR0HYdq9gPiHR/tEcA1CB3kYIChLKCeQCw4X8a2x/K7QgrvdvV/15mlWL0gk9DyyB9O8WfE/UJNcSbT5NPubiygMU6o042Kq7gRlhgMwA6dTnmrHhW2tbbXvEX/E9RtHksJrWS9llG2Fkl2gktw33hkn0A71Q8YT+HPFnim+TTopIrywmRZtUgCSMswHVYXHzYxjcMZx3rxdruHw7qdxpP9sWmpaT9p3vCsRUXEYYNtcsuVyQD3x2rrp0XUioptaJWNlFqPZNeW/3/wDB8j6l8D/a7M6n4e1OSzlNmUeAxfemhcZ3sOmN3pnr7Va8T+BtA8TX1ve6vYl763x5dzDK0Ug+pHX8elcF4E1PUre80WXWraIWqqsNveWSMITG6ZCMf7v93POc+tdb4P8AFNtfare6dLdwPKAJkUPnYD/CffnNcFalVp1HOD1XYirTkm5r1N7Q/Dmj6Bph0/SdNt7e1zvaPbu3t1yxOSx6da8yl0/+0/Hd3Zya3dqlpOYbyMWgBnkdQV2Ochdu4YOOfSvZSOOK8o+JmmxDxfaai8cSlbctG6x7Dv8Auncw++SvHI4GKjB1JSqPmerW++vzJw93JxT3KlqrfDrxFdR+JL+SPw80ZFlcwQu0jA/xP5a4BDccDGSDWP8AEHw/Dc2GhaboN/Z6jCtz5xhadHlWFgCsrqTuYlsjpyeteteHGtbNbeFgiarfW6T3KrLuDbECqTzj7uAMDnHtUsHhjRbbWJ9VTT4P7Snx5ly4LMfz6fhWscXyVFN7r0s7eX363+QlWaleW/5njl2mpWt3rBeCz+z2gMUMNrMyTTylQ2HYgAAgrkAYwfxp2mXUN5HFBPIg1dIklnsxIDsZucKR0+n9K9O8WaFJNc2c9npJun8xjK3mCNU3Y+Yg/ePAH0rl9f8Ahgt7Pf3cEGmyXhQeSJ1OyVgCAGPUAdO4+nWuilioNJydjphiI6O5z0+paWFt22eIJ5TnzFihjCxEEjADOGYj27Guk07S/D10n+l+JY9sZ+eITIR+bKP6/WvP9aXxlaWFvZjTJ7HUbZ1WSc+W4ZcA/uiflKk8EegAPeuu1Gy1S60N7rRZLG8vI5FP2Rh5bGLGG5PyqQeeTjH5VrUjorTsm97p/oW5t/aaRoW1vaeGvD2oanqq6drd2bhzaLaMZC0WcxqfRvXgD1rmdftfEXjTTbW/ksre3sIZPlikjVxCB1Gztzxk8mtCbS9U0670eeR4hYXkTyyEBXO7b/q9wHIBycjrx71Nba1q2kfDUPcWpk1O5v8AyJI0YZigZj82QeSEB/QnvWSvB+0i1KV0l5dNvluJe7aS95vr5FK6tvK0sW1zG4tHjMLxwS+Sdh4K5BHGM5HpnrV3SdK8Gw2tsdStIUmtiI7e7dvLMShgypktzg9zk+hrT/4RyfSINS8SeIdQjayt7IPawGzDCznYf6zIDMWGQAAD1Ncnpuk2+pz2Ota3ZTahplnpAkunurgBRMucyshUMfXkg9gOKlVFJN82i3a766ev+ZE6sKl9NuozxPoOkeHL271DQNM1DU9UF0ZnuDe4UB+WjVRwQAc5PT3xXRa7rF0+gxDS9Zt7WK4J+0zs4KQhl+aM8cse2MexrkG36dqFvqT3SXBntkuGtnuwqRiUExgKMKWK8jcxqroFrq+seInu9cgexkuJksZrd03W1wv95R2IHzbh0PIPNaujzRXO727/AHWt29PyNacYwtK11v6+f/Du2hL4NsJm8ZWNro9zfXmmgeZcSqrRwxkZ5Y/xD0HfNFerTa7DpmnPHounGSC32ri5kKB16Fg3O4gc+p+vFFcdapUrtcqsl3av+JFV1a83UUfyOH+GGtS6d44g0+50ybT5NV80yRJGWSRgcrIx7Hrk9MGvZ4tVsZdYn0uO5V9QgjEs0Kqx8pTjG442gnIwM5xzjFeT6LqfjC1uG0q60C4/te3h8tNQQBIJOS2CFBHQBQcj1OKTS/EGv+BLqzHi+e7vZtdLypaXF75/2d06gOBtXgjgZHIxjFbYig603ONr22Tvfz9Ld/8AgEYqHtZJ6a7dL/p+XloezHBHTIPUGs7W7DSp9GuIdVhiOn43yKRgcfTmuHTxpqXibw/ex6Ko0bVwwWFv+PkScj7uBx6E9uKlbXprrwzcaVqc5l1+0jVrnbHsDH1APb3Hf0rCOFqRau7O/Tdefb8Tmjh6idnoad1Z6JqejavqukaBDeajNACIJoijXBQARDHp8owPYVq+A5teuPD0M3ie2SzvnJxbjGY16c44HrjtXltjf32g6Drc1lNcSi7uDJIzSb1iRhhmjcHg98duK2vhDJqGlyW2muZbjTLiNnRpJxIYO6D1AI9f1ror4WSpyd7pPS+9rGssNNQltZHrJIwMYo/GjPT3rk/Enja10TxBb6R9ma6vJoPtG1ZlTC5IAAPc4PpXnU6cqj5YK7OOEHN8sdzrDjsOO+aYXUOFZ1DsCQpYZP0HeuSj8ZSurE6HOhXu1whA+uBXPeIjYeI/EOh6jdzanYLp8qyOsTHa5GSFIHUHP1x061tHCzbtLT8fyNVh59UaXxc1S90/TNOi06CWaaeZ2bylDFURMsRnqSDgCuO8QQ6pbeDPtmhmeJkhAm8tj50EfBY7hyevOO2e2a3fikumeKdHtjb3k7mKR45Y7eURvtbGcg88kAZ9Ca5Xwj4luZ7S0sTpx02KW1mh8t8t5WBt2tnnlPmGfQ16OHg1RjZapu52Ya9NJta+Zo6fLJB4asJp3WZ9oM8qsZCwwSTnuenXnrWRrGpagzS2stg0FlPCZLPUI2BjuATtaL/Zk5IHOQQOMHNa+LuTw4IdP+y208bKFaQF4GGec7RnGP8A9VcQljqmn2WpW00l59gmkM91YErcR3BLDDRAENGyH5g3Xp1xg9VOF227Xv8A1/X5bmk7p6a6nXWXhm8svCpiKJrGl+Quy4YBTdBj8qEEna+cDvjb1rJn8LWMOhIJfKsr+2Zyy3ieatsGOWVudjgHjkECui8M+Kn0e3nUIHth+9nimjKArg5bJGOx55HFdhL4S0TxLpcNzpl9cLp13G2xYSrRsjDkDI3DkepwR2rlqV50ZNVNE3v39V/wNfQiclTdqm3c8gXSLO5v1bTtVS3vYLcym6MSOs5ZuXUZGPqBgY5wevRafDa6h4iMV1qd+hjhms5dPjUH7bIse4GNgfkI3Ak8Zxj60/GGleHtK02XRPC+i/briyvEe5/tCWVd+QSPKcEKW4Hy+w4Jqr8P7PRdx8QS3OoaBcSu8UySp5kfn5GyUt1VcnnjqeoFb6OnzK6XTT7u79NPQbm6ivr/AF6HqHww8AxeDRqNxJLHLe34jVvLBARFH3Dz8xz3xmtDxz40sPCU1jHewSzTXIZo9rBVGCB8x7flUvg7U7y4WW01SWKSVJGWKVJA/mYGWGf4sAgg+n0qh8RfAFn43utEnvLiSD+zpW3Kh/1sbYLKT68DH1NeNJ89e9d/1Y49I1b1dV1sa9v4osm1uy0S5SaDWLqMym1IEnlKAT87KccgZB+nrWV8RdH1W9tdLbQrk2kNtM7XCwwrIw3AYkVOMspB44611ttZwWpVo4l8xYliErKPMKL0BbGTVgZBHUH1HY1lGooSUoIzjU5JKUUeTeE/BTajp0d1Hrgt7owzR3VrarugkkJ+WcoTuXjblfu8nGM1QvvhTrL6bY2Ed7YT280rNqUzo2XyeGHcuB0PsPxyfHVnPp3xdknsoxBrN1sfR7tj5cUQMZMgfBBfLBwB0JbBz0rqI9A1vW9TsvE+m61e2d/NEEnjjP8AozhCq8KcbMkOSDu56V6cqlWnaopKz1269v8Ag+R1qc7ay0ffXp9/9eoupfDm90vSdCsfDl0buGF2gvUvpGUyxucmQFSNpUZHHOMY5znmFvLPSbjU/DEGqzanfQyGK5vJ4kXaCuESIE8sozlnySR+fuWo3lrptlNd3twlvaxAb5pTgLkgDP1JH514pqng9PD3je9vb+5gvF1hhNavIApyM7kA7kAjkdjWeGryq3VV/wDBf/AJw9SUmubb+vyOTn0loNHll0fXbU6nZgSvfSxh3kZOQjdQCCVUE/Q4rO07WtCntZbrXtCjGqTxef8AapkUxlgxbMi/3SMnIGSeMV6x4a8HeHrnUxs0+5itxFLCbdWUw7HGMtn5g/Qg88jPtXM6f8EdW03xC7trttc+HoldlF0pLkejJjacDOTnsCPbu+tUlJqb/T8vyOh1oKXLO/T+v8+/5V/DGr3Ws69LceI9Qz4eureL7LZTJ5JkQch0VeRggAjphuvGa6q1i834n6XcCxhs7COIBkjgC+ZMyFSJG6uRwM8jAH1rK1PztQaS10/UIoL9k8iLUIYVSaJMcKrEgoGC+xx3ru/AehQWdtHcXDvc3GEVJpBjdhRyOeSTnJ79a5a04xXPtpa3qTKXs02+qf4/kdmw9etYni7R7bV9GnW4i3yxRu8JBI2nH/1h/StzoPem4HQ968eMnFpo8+MnF3R8za/c6al9YagsjQ6tvewls7glWlgDHlMHBBwyqDj5h9K72x8Tp4cEsV1qGoPa3caxWouQxSNscYBG5GwccnA2/jV3xn8O47u/i1O3gS9WHBS3f5WjYNu4I6jPauZ8LW1xPe6vbx29+8kLedJc3aFQZC2MRg8ADGB64r3OalXp33S3+89FyjUjra36lTWdWvdH1S70+wg8QLdaTC1wslrcsxcGTaIXJyrjGOeepxmvQ7HW/Et4NOtY7SESXMMdw00yEMkbjILgcAjocd/Ssj4c6bGfFWs3Vwyzw30BKwlGCoSRvDckMSOMkDgfLxmvT0RY41jQbUUBVUcAAdBXJiasI2ja77/15nLVnyys0eQ65qHiseKrfR/F66WdL1GdYLE2kHmYOeZMk5Xg4Oa9M0HQrXS0kiQb/OOJN3OR6e9aRVWcFkUlemRkinRgKyZyQDySc1zVK/NTUIq3e3UxlVbjyo+Y5rzXH8Xma5mH9maesiz7Jm8v592DhumABjHpx6V6N4egm1fxNZx30xXTYoIbm1hRB+8k2/OGI5ByQcHt0rk7TQ7oeLNct/EEUDzxXAezgfDGOEsSCmP4WJXn88V6v4S8P3FnO97qqIt2fljjBBKjpkkcZxgYBPTmvTxNWEaata9vz7f1od9ScYxbT1f9aeRzPxEbT38Y6PPG1w+qr5lmY8yeVgjzCWAwCcdMZz6HAx3ljp9v/YcVnLAHt5YdssUgyHVhyD+B6Vmx6HdT6zeT61dwTWa6lHf6UiA+ZGVjIKvn0JOMdvrgdEzKilmYKByS3AHvmvKqTXs4wT2/XX9TilUulFdDwDxNos7/ABA1MJqFta2liYQ9t5G8NESGjUKeFChfvdeeK7/wXpNxe3sOq3UXlWkKkW6k58wkYDD/AGRk89zius1bw9o+syxzanpttdSqFxI64JVTkAkEFlzzg5HPStB0DgKcgDGAOK1qYxypKmlqlb+vX8DaWJTjaK1e/wCWhwHirwfY2mmxXdnBq93cWdws9vBbMXZX9cBlwBk89s9DRXoLEfeHT1FFYxxc4qzdyFU5viimeV/FT4gIgGm+G7+V7q0uPLu/IIBjkHRckYOOc4+nrW18OvFA8RpJpXiFrO71SMu65jUhwvD4BHUZHT19K8k0qDTfEa69daZaKkz3iTzZ3bsFyWYZJHRm4GP5Vl+LLjUrDV7XUPCk8Np5U7RxtGQrxyIQHUnGecjOeueM17f1GDg6UdJLr1vv/XkejOjB4ZQteW+iv93VnqXxljtIbux0/Q7FbPWZEedb2zKxup2kbW24PIwQx6Z715touqKPD9oINfVJokJuI03u5V5NpDOe2cDGepz0213ev6faa/4vjl1PUhANds0tYIo0VCJ8AMM9eHGcnqMCuw0D4X6ToPh+ewtJWklnJee6nxkk8kcYwOAfwpxxFKhRhCb10f8Anr5bephGsqHJftr16/keTpaX1t4m3xxyxwTQm2trIy4W7fGPkUcEdMj/ABr2r4aaNqWnaMra3bQw3uAiBDlgn+0Ox9hxR4Z0Hwnb39tqeny2d5qaq9vFcmfewx98RrnA9yozg9cGuy7ggVx43He2XJFWRhicU5xdNLS/zGnI46V474907Urnx1De6THCbx5vsscfLOyJHuYgds9QM9K9jJ5HrXBeJLl5PiFZ6bY2UlrqMli00Gr5DAEZBi2sMDIwN4IOcDkCsMHN05tpdGYYefLO/kzhdBtNcvdYvIvE2paTHZttgWcScySk5KBeD0yu3A/HnPqdp4btLV7Q2aqY0UK7b8YUDjA9/T0rx+4v/DVxr4t76y1rSvF1xdIjTX6LI9khxyqdFVhnGOecjI67cnjLxRL4evL7w3Yww2mnTkOjuJJZYA33zvX72Co46ZPXt6GIpVajXJp+C/p9PyNpc04pxf8AX9MxPjRaa3oOp3M0FpBeaHc4ntyiHzYGAw447g/Nn0PPeq/gXVv7Z0y8hjijt79YAA92SyzMMnc3fODg+grtfhp40u/Eep6tpfiEb50b7XZboNpjgKk4m42rjK4HufQVzBS00rxveTabfXd5Gl7Jpi6dCFCNcPl3d2P3VXqcA9AM9a0jOSj7GpG0or5M1p15KLpTd7f5mw2jyx6HHpN2PIkkXzJRE21JQSdzI/p6H2wai8Q6OmqeILHWvDF9b6fIHt4dVS/ZYztUbEfceu4ccck4roZIoI4zAHhlgLgxWojLssjdSmPmGe4HWuZ14aYLLUrV9dg06e6UW2LqDap+bmFxgkZYAgj5gRnntnGo279fTTXf+vLdmiSk1rYz75tQuPFs2ka7H5OiypN9rke78zzIMEJLBgeoHBHBypxXc+APF3grS/B2n29hrSw2cDtAPtqGKTzM5Py88EnPBI565zXAaPper+GbCW2aaxurORpWN75geXT5HUAJHyR2BOQCcqcDGazNS0O+1m0h0ifUrSOfz2+xujl5LtMfMzlukmOeOMngAYrSrQp1lyylaPlt11tr+fr3M50/aL3r6eh6V4itLbT76W9nvll0K7lAd4p02rIw+UOxyEU/3qw9f8T6ZoGmzyaVpey5kKxW08E/2mSViMgliSCg4wecHBGKq+HvCtx4StNQls0ilnaxT7XDdSKWlUAMFWInByMY7547mneFfHZ8U6wltdWNr9kW3SS1nuFUGJ1Y7gAeDlVIwP7tZRpfaXvRjv0/AqLdtdfn+h1XgWCPXNQ07WZLrdNYlwscqlJldkw4cdGJBGc88Zr0rp+FeEaffa3rHjPW4vC96bS5EaRspjAVGY53hsHjAYBq634ieI/FPhi20mPTYvt0ghXzplt/M8+UYBGB0z6DB5rjxWGlKpFJq72XbqZVacqtRRTW33Gt4cstVtfib4pmure+XSrmKF7W4mug8TEABlRB93knr6e9dr1wB1I4FcPYeIPEUmvaTpt9o62he3W6vLl1Zo0BG541IOAVBxznkVk+KvH+qxapFaeEbWyvJmODJcvhI0IG1wON2TznOMdjnjF0KlWSSS2XXtoc6pTntqcP8aPENprfjCDTtNeKT7Di1lmEWHSXzDvUN1IHHbqDjqc+s/D3X4dV8I2suI0kgiIZYh8rbRncB7+nrmvIfAvg/TdR8dXNteX0l5qHmm+u5IUliEYJB2q4bIO7o27OcVt6k3iqyvL/AMK+HrG7i1B5JZo9UaIpFKhO7PmYwhweuep7Zr0K1GnKEaEHqtbvTTqdtVxnRjSejiu/m/8AgDvEPxHl1iwgt9R8Lu3h+6mWO4aeVonGGyuD03HbkAZJweKLm2n8b+LbVbeyMGnaNElrGsZO+CJ1+do36b1wowefToSbGu+Cr2y8J6XbXlrcaldSt5l39lZ5Ps04GUeM8tnkjdn9K9U0FJ00i3a+t47a9dQ1ysYUBpD1Y47nrWdSrSoxUqK79fx/QylOMIJw26f52/Uz/Cnha28OQuI7m5vLqRgZbiduZCOAxA4BxxkelT+LpvJ8LavLkxlbdwGx3PAI/OtrFZXiKzm1DSL6zVYTHPAyMJCTuJ4249PevMc3OpzTZzRk5TTk+x4G9+zJ4Un+0RWumPcJetd3cwK2xVirL6HHPrXoMXxTt38RLYS6az2Ij8+S8jZituoGSWJGCAMHIx1xXnuj+A4dLURatDGzE/vIC+9Ix94HH94Z7djzzXceFvDY1+W4muL+0vNDuIT5cSAeYZA21lIwVaPAyD94E4PTn2cUqEleWqV/x/M760IRV56+n9I9WVlZFeNlZGAZWHRgeQR7Gkz2zzXE+HtM1Lwz4nntrnV57zRLtSbeGb7tqFUYwTwuMEED5TuU4B69VeXUyXVvDaCOR5Tk78hQoGSQw6nFeLOHK7Rd7nnuNmRzaxYRakdO+0B71UEskMfzNFGejv8A3V96kiubTUYX2SpKitzyOCO//wBeq+raFp+q2epW19CHj1KHyLgjCu6dhkc8dqXQNH0/RdJt9O06P/RIF2L5jb2wBjknr9KPctdN3FpY5fwbprWXjDX7uyNlcaNdxoYpbeQNL5qnBEgPIOOB247dK7kcgZGO+D1rn7vw6F1H7dpzRRTPw/mAkY9BjpzXPxp4vi1a9stVu9Ph09l/0KeIzMX5wN6gggjvzjPrW8o+21UtUvy/M0koyd+Y78gjOfXg0HGOxrjfDui+MILlDrmuWbQoxwLRpHZh23eYMf4V2ZPP+NYzgoOyd/Qykkno7nmfxUlbT9W0y68h5IbsC0maMYIUk4YnPQEqCPRiecV6FYFTY24Xaw8tQCp3AjHr3+tYvis3l/8AZNN06wWZ55cyXNzE3kW0Y/jyCNzdQEHJPUY5qtdT6L4A8KRWNq8UKxRyfY7R58PcScsVUsSeWbqeBkdK0k+alGPW+n9f18jaUueMY9TL8ffEPSvDepW+nG4WPUWmjilna2Mq2qOM89MsQOBnHc+lU9V8X2cEltDrOpParM6rCJI2CStkfeYZUdecnHFYdnfyalpvmq0M0kjApPMolO4EBjJ1UEMcYyfu8VpW3kWEIfUHsN1t882AFTzAQVYqW2gdOD7kYOK6lQhTSUlqt/8Agaf1+J0qkop2PUemP6dPqPakPHPp+lIrblRscOoPUHGRn/J9qXvg15bOAacc5/n2oqO8uIbS2lublxHDGu53IJwv4f0orSEZv4I3+V/0LjCUtUmc8mjaJomlapqvhvSob6RYJZHt7eXeJ3VSSmBkZI449a8hnaC7isrtJE0m4sUN9d22pODPDE/PoN5wBhcBsFT6mtO8lk0/TpbKwdrW1cNI0cJ2DcF4PFcV4osYL9jqV6rz311ofmzTSSMWkdMqrHnqAi/lX0GEoScnzSu31/ryv/wT1nQq4de1jK+/5M9C8C2lpPqOkajqVgx0iSaXVLK8lJVbeUEBQ2einORk9RXrvibSV8QeHNS0lpzAt/bvB5qdV3Dg/TOM+2a5zQ7G21jw3La6nClxbSWaq0TcKQFJHA4GMDGPSuk8MSPLoNi0js7FMEsck4JH8gK8zEVXKSqLdP8A4K/4P39TzMX785OR863Wp674VNnef2CLTUtNZbVReqcsAMeZCgAUqemcnqMd8dDP458Z/Zrq4S7hLQKRtiUBkY8HKd9uc8+ma95ns7e/jSK8hjnjQ71V1yAw5zXF65p9onjnS7NIES1uoJnmiXhXIU4JA7jArsp4ujW+KmrpPz0WptDGRk/3sbv+v69TjtD8aeJPDHh6zu/FUs+oiVgskrxsRH82MsQuUzkc8jP1Fbdl420HXtUiS7W50zVYWEcF5CgkjdTnKK/IHcHIBGfrXa+F1A00xYHlhygU8jb0x9K8Pu44oJpZ4YYUne5aJpRGu8qHyOcZ7detFKnRryklHlflt16FUoQrTcbWt1R6f8Q/7Hn0i/W407/hJbzEV3Bo0MoFxw+0SJt/ebBkk9R1963vB1vaw6BZSW1vcW6tEFeC4kLyQn+KMk9wePyrx/4yWFsfh/ZeIhHs1v7O1t9rRirmMlQV4OOjMPXk1h/su67qlx4ol0qe+nk05NOeRbdmyoYSDDD35NZ1MNJ4bnjLRP8ALT+n16nE7Rbp9f8AI2fiP4b8SWVrf2kDRvpEipE7iRleaJW3D5c4cjABUYI6k4p+mTza34hgv9ItP7O0iGFrhvPwks7AKivgcMzbWz7H0xXvhOEfHrg+4ry3xZZwWXinUPsqGNfkwgY7F3IC2FzgZ9hV4fF+2XI1qk/0T079jroVud2e/c6Ow1WHSoVhgsfPkdi6yJhC4Y9emR6VjHxToHi6AWev+HxPbxzFmSdRIUkX5Q23AbODj8e9ZWkXU82mxNLKzMr4Uk9BnHFXbi1hjHlom1WKIQCRkHkg1l7KEW+a9+6ZUqEG2pIp6/Z6Nd6hcRaJHpDR3FusNxp8l15ZvYADnEbYYSJg7Wyehrj7qPQbLxdY3ltawPBbwRsLye5QtEEGFDof4xjAbGcd/Tb+L2k2FjFJJaWsUUtt5LwyKPnQtu3YbrgnnHTPNc3ruj2F9ZWN3dWyvcXVvHJO4JXzG2A5IBAzXoYVKUE7uzX6evb/AC2sdFKjGVNTet7r/hzX124uPEEeiNHrVlfu92ZwL4iVtuMMIm2gpypwPbhuKteM30u38OMLtbewuktg8LRAq0bp/EoHU8gkjufrXCafHHc+FxqckUaX1lHJBbywoIiihsDhcAt8zfMfm5zmuz8ZaZaaOPCEOnRGFI9GMi/OzHdIXZySSScn1/Cm6ag4JPS78ttTNPlqKMdG9TO8NSeI/CfiG6t5IzfavdtDcteRAbJPMC7k5BxjvgDkHp1r3PxJqc+n6VJJHeCznSIyyBYxIxUYBCAnBOWA59a8z8U2sWjeBvCiaYHt/tNuLiZldi8kheNixYnOcse9df4yJn8NaDqMvN6qiQSjghjGGJ49wDXBirVZwlbq1620OdpTVNvrdFPU/Gt5BKbK+0WO40uSIx3M63JEi8YKlAvJP+yaqTv4Mn0ixSMx6PFa4jidhjCk9NxySM+v6VwmrW6X9j43W6LuIo0mQCRl2vszngjvXHGaVPFdhpfmyPp93p9q00ErF1dmgVmPzZwSeciuyngION4u1u3pfrfubzpQpzUFdPT8Ue63fhu80/SCbC9hntZFaaW5acRBAFGJCehG0H6eprQ+Gvi298URXbSWtpHpsYUWr21wZWGOCspIHzHhhgcA4PIritFHnbNBnJm0eNS62sp3oD5ee/UZOcdK9V8JWlvZeG9Mhs4I4IjCshSNQoLNyxOO5NediUoQcZ6t7PbT79/Lp3OfEJxj7+pr88Yzk0YwOPzzSZ+97dKc/B49q85K5xjcHv0pMevPpT2AA4ph6j6/0pWGjzn4reHLO60O+kgvjZ6vcoTZxi4WMzTLhuCxGeAcj0rlbHxmNNgh0HS9Kmv5NJgiW4VR5MczsOQh+9tBz8oHuelYvxEuJZPip4pEreYLO3tjbCQBhCTGSSuehyT0rSl/drqMqcSTTqXPruVQ30z7V7VKi3SjGo7rf77foz0sPBSUZS1/qx2/iO4g8WeHLCGeCazS6B85PN+dGA5jDL1xwxzxgYIznHP+E/Esmi+KvFWkvP8AaLSCOGTS7bZsjhjIIwHzwjEJ0yM+nQ5Hw+upm0HxgrSEqVsrnH/TRwwZvqQq59cVtfCqKLxR4Jlu9ehhvLg3I+d41B+VgV6AdCT+dZypRpRnGXwq342f/AFVpqF4y2TL/jTxbHFomnT6laz6dC9yqy3QZljU4PCSAdc8ZIA4NS+FtWj0a7uYXurmbTppN6tcHcyk9T65HfqCB2PWTwBYWmpeH7y31C3iure7u7qWaKZQyu3nOM4PAxsXAHAxxXO2ztLptuZGLEMDk9c7sUo0oPmpW2ev9fIKKjUg420PYnkVYfNyGjCl9ynIIxnNcxYa3LfrfX12wg0yGPZ9nC5kcsAQ2c8c9BjvXO3Go3cPwt8XPDcSRvaWczQOpw0R2g5U9RyTXn/w91S9fwRpAe5kfcTMd/zZcSOM8+wFYU8I3Gbvs0vvMIU1zun1/Q7uXxUPBlpp7eINUvry+1G1lWFb10WPzoydodhgLnKrux7nvXQeB/GcHiPRbC4lNol/MCJIraTeiupIIB6kAfxDK5zgmn+JdH0/UNHs5r2zhnlguVeNnXJUkc4/w6V474DgjuPjB4hmlUmSytz9mIJAi5AwAOMYJ4961p0adeEns1d/8BL5/gS4qSv8v6+4+hrqeG0tZri6kWKCFDJJIxwFUDJJ9sZr51v9Eb4geJ9R12S8aXTJLtliJVgWtUACrFn7ozkFscnp0Net/Ewmbw7p1vL80N1dRJMh6SKFLYPtlRx371xeg6jdL4UvCkgU28/lRbUUbU3AY4HoTSwcXTi60fi2Xltr/XQ0o09OYyp7vT9P8Myaho9vC8unRxyRRR7lIhMgDLgZOCFJ3Nn5ue1a/hHRtF/tC+kcRzQ67breLDcAfP8AMGGUPTo3HrjqKd8Grh9V8T+Lvt4ilGIUx5aqNoLqFwABjHGOlWvEek2Meq2l3HbqlxHaXOxlJG3YTt4BxxgV0zlabpNu71vvur26dTe95ODPVtoK4UBUwMBeAB2ApscaxoFUHA9Tnvnmq+iSNLo9g8jFmaCMk+vFXV5P414UtG0ee1Z2MnxPpy6p4e1Gxkmmt1miI86FsOhHzAj34orV/wAaK6cNjamGTUOpcZpKzv8AfY//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph of acute vascular rejection demonstrating a perivascular lymphocytic infiltrate within the alveolar wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of L Kobzik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41573=[""].join("\n");
var outline_f40_38_41573=null;
var title_f40_38_41574="First degree atrioventricular block";
var content_f40_38_41574=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   First degree atrioventricular block",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/38/41574/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41574/contributors\">",
"     William H Sauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/38/41574/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41574/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/38/41574/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41574/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/38/41574/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) block is defined as a delay or interruption in the transmission of an impulse, either transient or permanent, from the atria to the ventricles due to an anatomic or functional impairment in the conduction system. The conduction can be delayed, intermittent, or absent. The commonly used terminology includes first degree AV block (slowed conduction without missed beats), second degree AV block (missed beats, often in a regular pattern, eg, 2:1, 3:2, or higher degrees of block), and third degree or complete AV block.",
"   </p>",
"   <p>",
"    The PR interval includes atrial depolarization (the P wave) and subsequent conduction through the AV node, His bundle, bundle branches and fascicles, and terminal Purkinje fibers (",
"    <a class=\"graphic graphic_figure graphicRef76390 \" href=\"mobipreview.htm?30/21/31069\">",
"     figure 1",
"    </a>",
"    ). The normal PR interval is between 120 to 200 msec (0.12 to 0.20 sec) and tends to shorten with increases in heart rate due in part to rate-related shortening of action potentials. Children under age 14 tend to have a PR interval of about 140 msec. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37687?source=see_link&amp;anchor=H5#H5\">",
"     \"ECG tutorial: Basic principles of ECG analysis\", section on 'PR interval'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrioventricular impulse transmission is delayed in first degree AV block, resulting in a PR interval longer than 200 msec (&gt;210 msec at slow heart rates). On occasion, the PR interval may be prolonged in the absence of apparent heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. As an example, first degree AV block, with PR intervals as long as 280 msec has been reported in 1.6 percent of healthy aviators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17749?source=see_link&amp;anchor=H1#H1\">",
"     \"ECG tutorial: Atrioventricular block\", section on 'First degree atrioventricular block'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The remainder of this topic will discuss the manifestations of AV block due to conduction delay at different sites in the conducting system, as this distinction is important clinically in terms of prognosis and the indications for implantation of a pacemaker. The etiologies of AV block, as well as second and third degree AV block, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SITES OF FIRST DEGREE AV BLOCK WITH A NORMAL QRS DURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While first degree AV block with a normal QRS duration (",
"    <a class=\"graphic graphic_waveform graphicRef67882 \" href=\"mobipreview.htm?11/45/11989\">",
"     waveform 1",
"    </a>",
"    ) can result from conduction delay in the atrium, the AV node, the bundle of His, or in the specialized infra-Hisian conduction system, the majority of cases with a normal QRS results from atrial or AV nodal delay. However, involvement of more than one of these sites has been reported in 20 to 80 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Atrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally difficult to determine if first degree AV block is due to an intraatrial conduction defect, although it has been estimated that this problem is responsible for approximately 3 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/6\">",
"     6",
"    </a>",
"    ]. PR interval prolongation is common in certain atrial diseases, such as endocardial cushion defects and Ebstein's anomaly of the tricuspid valve, and the conduction delay in these disorders may be due primarily or entirely due to intraatrial conduction delay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Suggestive findings on ECG include widening of the P wave and a decrease in P wave voltage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     AV node",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AV node is the most common site of conduction delay in first degree block. Conduction through the AV node is approximated quite well by the atrial-His (AH) time determined by His bundle electrocardiography. The normal AH time is 60 to 125 msec. Over 90 percent of patients with a PR interval greater than 300 msec have slowed AV nodal conduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/13\">",
"     13",
"    </a>",
"    ]. Among the causes of first degree AV block with a prolonged AH interval are increased vagal tone, calcium channel blockers (which block the inward calcium current responsible for depolarization),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    (acting via its vagotonic action), and &szlig;-blockers. PR interval prolongation associated with a narrow or wide P wave but a narrow QRS complex strongly implicates the AV node as the site of the conduction delay. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link&amp;anchor=H6#H6\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\", section on 'Action potential in slow response tissues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bundle of His",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the His bundle is documented by His bundle electrocardiography. Given the rapid conduction velocity in the Purkinje fibers in the His bundle (1 to 3",
"    <span class=\"nowrap\">",
"     m/sec),",
"    </span>",
"    the time of traversal through the His bundle is less than 30 msec. Slowed conduction can result in split His potentials, but the PR interval is rarely prolonged. Drugs that block the sodium channels, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    , can slow conduction in the bundle of His by impairing phase 0 depolarization (",
"    <a class=\"graphic graphic_figure graphicRef78354 \" href=\"mobipreview.htm?33/3/33852\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infra-Hisian specialized conduction system",
"    </span>",
"    &nbsp;&mdash;&nbsp;This infra-Hisian system consists of the bundle branches, fascicles, and the terminal Purkinje network. Most conduction delays in this system occur below the bifurcation of the left and right bundles, resulting in characteristic changes in QRS pattern and often axis (as with right and left bundle branch block). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10344?source=see_link\">",
"     \"Right bundle branch block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39784?source=see_link\">",
"     \"Left bundle branch block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The PR interval will be normal if one bundle is intact. If, however, conduction is equally slowed in the right and left conducting systems there will be prolongations in the His-ventricular (HV) time and therefore in the PR interval. These tissues consist of Purkinje fibers with sodium-dependent phase 0 depolarization; thus drugs that block the sodium channels can slow conduction at these sites as they can in the His bundle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FIRST DEGREE AV BLOCK WITH A WIDE QRS COMPLEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;First degree AV block with a wide QRS complex (&ge;120 msec) may be associated with delayed conduction in the AV node or bundle of His, but most often involves the bundle branches (",
"    <a class=\"graphic graphic_waveform graphicRef75567 \" href=\"mobipreview.htm?9/62/10213\">",
"     waveform 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/7\">",
"     7",
"    </a>",
"    ]. Two levels of conduction delay are present in about two-thirds of patients studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/7,8,14-17\">",
"     7,8,14-17",
"    </a>",
"    ]. As an example, right bundle branch block (RBBB) alone is associated with a normal PR interval. When the PR interval is prolonged, there is also a conduction delay in the AV node, His bundle, or left bundle branch. Similarly, when first degree AV block occurs in a patient with bifascicular block (RBBB plus left anterior or posterior fascicular block), the prolongation of the PR interval is due to a conduction delay in the remaining fascicle or the AV node [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/8,17\">",
"     8,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors suggest that His bundle electrocardiographic studies be performed in these patients with several areas of conduction delay because of the common progression to complete heart block and syncope. A permanent pacemaker can be implanted if the HV interval is more than 75 to 100 msec [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment with a pacemaker'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL DETERMINATION OF THE SITE OF AV BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several clinical approaches to determining the site of first degree block, including electrocardiography (ECG), noninvasive evaluation in response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    or vagal maneuvers, and invasive electrophysiology studies (EPS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG is usually of limited value in indicating the site of AV block, but there may be some helpful clues. A PR interval duration of 300 msec or greater with a normal QRS complex is most often due to block in the AV node (",
"    <a class=\"graphic graphic_waveform graphicRef67882 \" href=\"mobipreview.htm?11/45/11989\">",
"     waveform 1",
"    </a>",
"    ), while a PR interval of 200 to 300 msec is less specific. Rarely a balanced conduction delay in contralateral bundles and fascicles can produce a prolonged PR with a normal QRS duration and pattern.",
"   </p>",
"   <p>",
"    As noted above, first degree AV block with a wide QRS complex is most often due to disease in the bundle branches (",
"    <a class=\"graphic graphic_waveform graphicRef75567 \" href=\"mobipreview.htm?9/62/10213\">",
"     waveform 2",
"    </a>",
"    ). When seen in the setting of an anterior wall myocardial infarction, this finding usually indicates bundle and fascicular block. In comparison, an inferior wall myocardial infarction is more likely to be associated with delay in the AV node, since the node and inferior wall are usually supplied by the right coronary artery.",
"   </p>",
"   <p>",
"    In some cases, marked prolongation of the PR interval and a wide QRS complex are seen together (",
"    <a class=\"graphic graphic_waveform graphicRef54122 \" href=\"mobipreview.htm?6/17/6416\">",
"     waveform 3",
"    </a>",
"    ). Such a pattern suggests combined AV nodal and infranodal disease.",
"   </p>",
"   <p>",
"    In cases in which the PR interval is markedly prolonged, the P wave may sometimes be obscured by the preceding T wave, giving the appearance of junctional rhythm (",
"    <a class=\"graphic graphic_waveform graphicRef69975 \" href=\"mobipreview.htm?30/53/31570\">",
"     waveform 4",
"    </a>",
"    ). However, variability in the P-P interval usually makes it possible to identify some P waves in a rhythm strip.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3285434580\">",
"    <span class=\"h2\">",
"     Noninvasive evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vagal tone slows conduction in the AV node but has little effect on the infranodal conduction system. As a result,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    (1 mg intravenously) has a variable effect in patients with AV block. Its vagolytic action can directly enhance conduction through the AV node and shorten the PR interval, but worsening conduction can also be seen via acceleration of the sinoatrial node. The former effect predominates in most patients with AV nodal disease. In contrast, the increased heart rate can, in patients with infranodal conduction delay, encroach on the refractory period and exacerbate the conduction delay.",
"   </p>",
"   <p>",
"    Exercise, due to the heightened adrenergic tone, increases the sinus rate and accelerates AV nodal conduction. The effects on conduction will be similar to those with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Vagal maneuvers tend to slow conduction in the AV node. However, this effect may be obscured because of concurrent slowing of the sinus rate, which allows more time for both the AV node and infranodal conduction systems to recover excitability and to conduct more normally. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21224?source=see_link\">",
"     \"Vagal maneuvers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3285434588\">",
"    <span class=\"h2\">",
"     Invasive evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial pacing, during EPS or by means of a previously implanted pacemaker, can worsen AV nodal conduction and, less commonly, infranodal conduction. His bundle electrocardiograms provide the most accurate way to determine the site of slowed conduction. Some reports suggest implantation of a pacemaker if there is a prolonged HV interval (usually over 75 or 100 msec), although there is not agreement on this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12326?source=see_link\">",
"     \"Overview of invasive cardiac electrophysiology studies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22328?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Bradyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies of first degree AV block in young healthy men suggested a benign prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/5,21\">",
"     5,21",
"    </a>",
"    ]. However, this view has been challenged by the findings of several cohort studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective community-based study of 7575 individuals from the Framingham Heart Study (only two percent with prior myocardial infarction or heart failure), a baseline PR interval &ge;200 msec was present in 124 people (1.6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/22\">",
"       22",
"      </a>",
"      ]. Compared to those with a PR interval &lt;200 msec, individuals with first degree AV block were significantly more likely to develop atrial fibrillation (adjusted hazard ratio [HR] 2.1, 95% CI 1.4-3.1) or to need a permanent pacemaker (adjusted HR 2.9, 95% CI 1.8-4.6), and had a higher all-cause mortality (adjusted HR 1.4, 95% CI 1.1-1.9).",
"     </li>",
"     <li>",
"      In the prospective Health ABC Study cohort of 2722 patients (mean age 74 years, 52 percent female, 41 percent black), the median PR interval was 168 milliseconds, with 339 patients (12 percent) having a PR interval greater than 200 milliseconds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/23\">",
"       23",
"      </a>",
"      ]. Over a 10-year follow-up period which included heart failure in 369 patients (14 percent), atrial fibrillation (AF) in 537 patients (20 percent), and death in 832 patients (31 percent), each standard deviation (SD) of PR prolongation (29 milliseconds) was associated with a significantly greater risk of heart failure (adjusted HR 1.16 per SD, 95% CI 1.05-1.28) and AF (adjusted HR 1.15 per SD, 95% CI 1.06-1.25) without a significant effect on overall mortality (adjusted HR 0.99 per HD, 95% CI 0.93-1.07).",
"     </li>",
"     <li>",
"      In a prospective study of 938 patients with stable coronary heart disease (history of myocardial infarction, greater than 50 percent coronary stenosis by angiography, exercise-induced ischemia on stress testing, or prior revascularization) from the Heart and Soul Study, a baseline PR interval &ge;220 msec was present in 87 people (9.3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/24\">",
"       24",
"      </a>",
"      ]. Compared to those with normal AV conduction (PR interval &lt;220 msec), persons with first degree AV block had a higher risk of hospitalization for heart failure (adjusted HR 2.3, 95% CI 1.5-3.7), cardiovascular mortality (adjusted HR 2.3, 95% CI 1.3-4.2), and all-cause mortality (adjusted HR 1.6, 95% CI 1.1-2.2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As such, the presence of first degree AV block in healthy persons as well as those with underlying coronary heart disease appears to be associated with a higher risk of morbidity and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;When seeing a patient with first degree AV block, the following approach can help determine the level of conduction delay and the potential need for treatment with a permanent pacemaker:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estimate the level of AV block using the clinical situation and the clues provided by the ECG. A PR interval of 300 msec, particularly in the presence of a normal QRS complex, is generally indicative of AV nodal disease and requires no further evaluation.",
"     </li>",
"     <li>",
"      Although",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      and vagal maneuvers can provide variable findings, the effect on the AV node and conduction often provides a sufficient level of comfort to conclude that the conduction delay is in the AV node. (See",
"      <a class=\"local\" href=\"#H3285434580\">",
"       'Noninvasive evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of a wide QRS complex in conjunction with prolongation of the PR interval implies that there is a significant possibility that the conduction delay is below the AV node. Given the unpredictability of progression to second and third degree heart block, we consider His bundle electrocardiography and the use of a permanent pacemaker in patients with marked prolongation of the HV interval (&gt;100 msec).",
"     </li>",
"     <li>",
"      There is an overlap of cardiac conduction disturbances and other cardiac diseases including infiltrative cardiomyopathies, cardiomyopathies associated with muscular dystrophy, and other dilated cardiomyopathies. Therefore, newly recognized first-degree AV block should include an assessment of patient symptoms and exam findings to exclude these rare but serious conditions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32007?source=see_link\">",
"       \"Etiology of atrioventricular block\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment with a pacemaker",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general principle in considering the use of pacemakers for AV block is whether symptoms will be relieved",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    survival prolonged. We agree with the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    device guidelines which do",
"    <strong>",
"     not recommend",
"    </strong>",
"    a pacemaker for most cases of first degree AV block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/25\">",
"     25",
"    </a>",
"    ]. Prior to consider placement of a permanent pacemaker, any reversible causes of AV block (ie, ischemia, prior administration of AV nodal blocking medications) should be identified and treated (ischemia) or withdrawn (offending medications).",
"   </p>",
"   <p>",
"    Patients with first degree AV block and symptoms consistent with the loss of atrioventricular synchrony, a situation sometimes referred to as \"pacemaker syndrome,\" are potential candidates for a pacemaker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41574/abstract/25\">",
"     25",
"    </a>",
"    ]. Pacemaker syndrome describes the uncomfortable awareness of one's heart beat due to atrial contraction against a closed mitral valve or when atrial contraction occurs shortly after ventricular systole with incomplete atrial filling. Other situations in which a pacemaker may be considered include first degree AV block with concurrent neuromuscular disease (eg, myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb's dystrophy (limb-girdle), and peroneal muscular atrophy) due to the unpredictable risk of progressive AV conduction disturbances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/46/8931?source=see_link\">",
"       \"Patient information: Bradycardia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/26/44449?source=see_link\">",
"       \"Patient information: Heart block in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3778643\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrioventricular impulse transmission is delayed in first degree AV block, resulting in a PR interval longer than 200 msec (&gt;210 msec at slow heart rates). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While first degree AV block with a normal QRS duration (",
"      <a class=\"graphic graphic_waveform graphicRef67882 \" href=\"mobipreview.htm?11/45/11989\">",
"       waveform 1",
"      </a>",
"      ) can result from conduction delay in the atrium, the AV node, the bundle of His, or in the specialized infra-Hisian conduction system, the majority of cases with a normal QRS results from atrial or AV nodal delay. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sites of first degree AV block with a normal QRS duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First degree AV block with a wide QRS complex (&ge;120 msec) may be associated with delayed conduction in the AV node or bundle of His but most often involves the bundle branches (",
"      <a class=\"graphic graphic_waveform graphicRef75567 \" href=\"mobipreview.htm?9/62/10213\">",
"       waveform 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'First degree AV block with a wide QRS complex'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several clinical approaches to determining the site of first degree block, including electrocardiography (ECG), noninvasive evaluation in response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      or vagal maneuvers, and invasive electrophysiology studies (EPS). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical determination of the site of AV block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with first degree AV block do not require a permanent pacemaker, although there are certain situations in which a pacemaker may be appropriate. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment with a pacemaker'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/1\">",
"      SCHERF D, DIX JH. The effects of posture on A-V conduction. Am Heart J 1952; 43:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/2\">",
"      JOHNSON RL, AVERILL KH, LAMB LE. Electrocardiographic findings in 67,375 asymptomatic subjects. VII. Atrioventricular block. Am J Cardiol 1960; 6:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/3\">",
"      Viitasalo MT, Kala R, Eisalo A. Ambulatory electrocardiographic recording in endurance athletes. Br Heart J 1982; 47:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/4\">",
"      Graybiel A, McFarland RA, Gates DC, et al. Analysis of the electrocardiogram obtained from 1000 young healthy aviators. Am Heart J 1944; 27:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/5\">",
"      PACKARD JM, GRAETTINGER JS, GRAYBIEL A. Analysis of the electrocardiograms obtained from 1000 young healthy aviators; ten year follow-up. Circulation 1954; 10:384.",
"     </a>",
"    </li>",
"    <li>",
"     Narula OS. Atrioventricular block. In: Cardiac Arrhythmias: Electrophysiology, Diagnosis and Management, Williams &amp; Wilkins, Baltimore 1979. p.85.",
"    </li>",
"    <li>",
"     Peuch P, Groileau R, Guimond C. Incidence of different types of A-V block and their localization by His bundle recordings. In: The Conduction System of the Heart, Wellens HJJ, Lie KI, Janse MJ (Eds), Stenfert, Leiden, 1976. p.467.",
"    </li>",
"    <li>",
"     Peuch P. The value in intracardiac recordings. In: Cardiac Arrhythmias, Krikler D, Gododwin JF (Eds), Saunders, Philadelphia 1975. p.81.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/9\">",
"      Jacobsen JR, Gillette PC, Corbett BN, et al. Intracardiac electrography in endocardial cushion defects. Circulation 1976; 54:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/10\">",
"      Kastor JA, Goldreyer BN, Josephson ME, et al. Electrophysiologic characteristics of Ebstein's anomaly of the tricuspid valve. Circulation 1975; 52:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/11\">",
"      Sherron P, Torres-Arraut E, Tamer D, et al. Site of conduction delay and electrophysiologic significance of first-degree atrioventricular block in children with heart disease. Am J Cardiol 1985; 55:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/12\">",
"      Narula OS, Runge M, Samet P. Second-degree Wenckebach type AV block due to block within the atrium. Br Heart J 1972; 34:1127.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations, 2d ed, Lea &amp; Febiger, Philadelphia 1993.",
"    </li>",
"    <li>",
"     Narula OS, Gann D, Samet P. Prognostic value of H-V intervals. In: His Bundle Electrocardiography and Clinical Electrophysiology, Narula OS (Ed), F.A. Davis Company, Philadelphia 1975. p.437.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/15\">",
"      Narula OS, Samet P. Significance of first degree A-V block. Circulation 1971; 43:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/16\">",
"      Levites R, Haft JI. Significance of first degree heart block (prolonged P--R interval) in bifascicular block. Am J Cardiol 1974; 34:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/17\">",
"      Guimond C, Puech P. Intra-His bundle blocks (102 cases). Eur J Cardiol 1976; 4:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/18\">",
"      Dhingra RC, Palileo E, Strasberg B, et al. Significance of the HV interval in 517 patients with chronic bifascicular block. Circulation 1981; 64:1265.",
"     </a>",
"    </li>",
"    <li>",
"     Bar FW, Den Dulk K, Wellens HJJ. Atrioventricular dissociation. In: Comprehensive Electrocardiology: Theory and Practice in Health and Disease, MacFarlane PW, Lawrie TDV (Eds), Pergamon Press, New York 1989. p.933.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/20\">",
"      Scheinman MM, Peters RW, Modin G, et al. Prognostic value of infranodal conduction time in patients with chronic bundle branch block. Circulation 1977; 56:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/21\">",
"      Erikssen J, Otterstad JE. Natural course of a prolonged PR interval and the relation between PR and incidence of coronary heart disease. A 7-year follow-up study of 1832 apparently healthy men aged 40-59 years. Clin Cardiol 1984; 7:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/22\">",
"      Cheng S, Keyes MJ, Larson MG, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 2009; 301:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/23\">",
"      Magnani JW, Wang N, Nelson KP, et al. Electrocardiographic PR interval and adverse outcomes in older adults: the health, aging, and body composition study. Circ Arrhythm Electrophysiol 2013; 6:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/24\">",
"      Crisel RK, Farzaneh-Far R, Na B, Whooley MA. First-degree atrioventricular block is associated with heart failure and death in persons with stable coronary artery disease: data from the Heart and Soul Study. Eur Heart J 2011; 32:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41574/abstract/25\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 913 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-217.16.9.173-E29AE5AA73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41574=[""].join("\n");
var outline_f40_38_41574=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3778643\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SITES OF FIRST DEGREE AV BLOCK WITH A NORMAL QRS DURATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Atrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AV node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bundle of His",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infra-Hisian specialized conduction system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FIRST DEGREE AV BLOCK WITH A WIDE QRS COMPLEX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL DETERMINATION OF THE SITE OF AV BLOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3285434580\">",
"      Noninvasive evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3285434588\">",
"      Invasive evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment with a pacemaker",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3778643\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/913\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/913|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/21/31069\" title=\"figure 1\">",
"      Generation of ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/3/33852\" title=\"figure 2\">",
"      ECG and action potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/913|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?11/45/11989\" title=\"waveform 1\">",
"      ECG first degree AV block I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?9/62/10213\" title=\"waveform 2\">",
"      First degree AV block II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?6/17/6416\" title=\"waveform 3\">",
"      First degree AV block III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?30/53/31570\" title=\"waveform 4\">",
"      First degree AV block IV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17749?source=related_link\">",
"      ECG tutorial: Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37687?source=related_link\">",
"      ECG tutorial: Basic principles of ECG analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22328?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Bradyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39784?source=related_link\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12326?source=related_link\">",
"      Overview of invasive cardiac electrophysiology studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/46/8931?source=related_link\">",
"      Patient information: Bradycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/26/44449?source=related_link\">",
"      Patient information: Heart block in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10344?source=related_link\">",
"      Right bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21224?source=related_link\">",
"      Vagal maneuvers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_38_41575="Alcohol intake and pregnancy";
var content_f40_38_41575=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Alcohol intake and pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/38/41575/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41575/contributors\">",
"     Grace Chang, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/38/41575/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41575/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/38/41575/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41575/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/38/41575/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who drink alcohol come from all socioeconomic strata, ages, and races [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These individuals may also be using other addictive or illicit substances. Both the gravida and her family benefit from factual, nonjudgmental information about the maternal and fetal risks of alcohol use and, if necessary, from counseling regarding strategies for cessation. Pregnant women are typically highly motivated to modify their behavior to help their unborn child. In one national survey from the United States, the mean rate of pregnancy-related abstinence among users of alcohol was 74 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE OF ALCOHOL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and prevention (CDC) reported that 7.6 percent of pregnant women used alcohol and 1.4 percent admitted to binge drinking during the month prior to being interviewed during 2006-2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/4\">",
"     4",
"    </a>",
"    ]. This represents a small decrease from these rates prior to 2006 (12.2 and 1.8 percent, respectively). By comparison, 52 percent of nonpregnant women of childbearing age (18 to 44 years of age) reported alcohol use, and 15 percent reported binge drinking. Among pregnant women, the following characteristics were associated with the highest prevalence of prenatal alcohol use: age between 35 and 44 years (14.3 percent), college graduate (10.0 percent), employed (9.6 percent), and white (8.3 percent). Employed and unmarried pregnant women were two- to three-fold more likely to report binge drinking than unemployed and married pregnant women.",
"   </p>",
"   <p>",
"    Data from the National Birth Defects Prevention Study of 4088 women who delivered live born infants without birth defects between 1997 and 2002 indicate that 30.3 percent consumed alcohol at some time during pregnancy, of whom 8.3 percent reported binge drinking (at least four drinks on one occasion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of these women are also at risk for an alcohol-exposed pregnancy if they are sexually active and not using effective measures to prevent pregnancy. These data were supported by the Pregnancy Risk Assessment Monitoring System (PRAMS) survey conducted by the CDC in 2004, in which 50 percent of women stated they consumed alcohol in the three months prior to their most recent pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SAFE LEVEL OF ALCOHOL INTAKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Surgeon General of the United States and the Secretary of Health and Human Services recommend abstinence from alcohol for women planning pregnancy, at conception, and during pregnancy because a safe level of prenatal alcohol consumption has not been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/7\">",
"     7",
"    </a>",
"    ]. National guidelines in several other countries, including, but not limited to, Canada, Australia, New Zealand, France, and the United Kingdom, also recommend complete abstinence.",
"   </p>",
"   <p>",
"    There is no exact dose-response relationship between the amount of alcohol consumed during the prenatal period and the extent of damage caused by alcohol in the infant (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Perinatal outcome'",
"    </a>",
"    below). Infants whose mothers consume alcohol during pregnancy can manifest fetal alcohol effects (FAE), alcohol-related birth defects (ARBD), fetal alcohol syndrome (FAS), or they may be normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/8\">",
"     8",
"    </a>",
"    ]. The term fetal alcohol spectrum disorder (FASD) has been coined to describe the broad range of adverse sequelae in alcohol exposed offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/9\">",
"     9",
"    </a>",
"    ]. FAS represents the most severe sequelae of fetal alcohol exposure; however, there is a continuum of outcomes associated with prenatal exposure to alcohol.",
"   </p>",
"   <p>",
"    A systematic review did not find a significant increase in risk of low birthweight or birth of a small for gestational age infant for alcohol intake up to 10 g pure",
"    <span class=\"nowrap\">",
"     alcohol/day",
"    </span>",
"    (about one drink per day) or an increase in preterm birth for alcohol intake up to 18 g pure",
"    <span class=\"nowrap\">",
"     alcohol/day",
"    </span>",
"    (about 1.5 drinks per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the risk of these outcomes progressively increased and became statistically significant with greater alcohol consumption. This review did not evaluate the risk of alcohol-related fetal damage (FAE, ARBD, FAS, FASD), which is an important limitation to the conclusions of the meta-analysis. Furthermore, the studies included in the meta-analysis relied on self-reports of alcohol consumption and did not take patterns of alcohol use into account. As such, it did not provide definitive information about the risks associated with light to moderate prenatal alcohol.",
"   </p>",
"   <p>",
"    Subsequently, a series of studies from Denmark that evaluated the effects of maternal self-report of low to moderate alcohol consumption (&lt;9",
"    <span class=\"nowrap\">",
"     drinks/week)",
"    </span>",
"    in early to mid pregnancy on developmental outcomes (IQ, attention, executive function, motor function) in 5-year-old children did not find significant effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. However, there are several limitations to these data. The Danish studies did not conduct FAS diagnostic evaluations and they assessed only preschoolers, which can be misleading because these children were too young to measure the full impact alcohol may have had on their brains. For example, in a large well-designed study from Washington state that followed children up to age 18 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/16\">",
"     16",
"    </a>",
"    ]: although half of older children with FAS exhibited normal developmental scores as preschoolers, all had severe brain dysfunction confirmed by age 10; only 10 percent of children with FAS had attention problems by age 5 but 60 percent had attention problems by the age of 10; and only 30 percent of children with FAS had an IQ below normal, but 100 percent had severe dysfunction in other areas such as language, memory and activity level, which the Danish study did not assess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patterns of maternal alcohol consumption and socioeconomic and ethnic factors also affect outcome. As an example, binge drinking may exert a potentially greater negative effect than comparable consumption of low amounts of alcohol over several days (eg, four drinks in one sitting versus one drink a day for four days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], but this is also controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For unknown reasons, older maternal age, high parity, and African-American or Native American ethnicities appear to increase the risk of FAS. Other characteristics associated with women at higher risk for having an alcohol exposed pregnancy include low socioeconomic status, smoking, unmarried, unemployed, use of illicit drugs, history of sexual or physical abuse or neglect, history of incarceration, having a partner or family member who drinks heavily, is socially transient, and has psychologic stress or mental health disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alcohol freely crosses the placenta: fetal blood alcohol levels approach maternal levels within two hours of maternal intake. Elimination of alcohol relies primarily on maternal metabolic capacity, which varies widely among pregnant women and may help explain why similar amounts of ethanol consumption result in widely varying phenotypic presentations in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/23\">",
"     23",
"    </a>",
"    ]. Polymorphisms of the alcohol dehydrogenase gene could explain variations in blood alcohol levels among individuals ingesting the same amount of ethanol. Maternal, and possibly fetal, polymorphisms of the gene ADH1B appear to contribute to FASD susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/24\">",
"     24",
"    </a>",
"    ]. It is hypothesized that the gene affects peak blood alcohol levels that, in turn, correlate with the risk of adverse fetal effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. ADH1B polymorphisms may affect alcohol levels by affecting alcohol metabolism or alcohol intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/28\">",
"     28",
"    </a>",
"    ]. Expression of the cytochrome P450 E1 (CYP2E1) gene also affects alcohol metabolism, and may play a role in vulnerability to FAS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PERINATAL OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall rate of fetal alcohol syndrome (FAS) reported in studies varies because affected individuals are not consistently identified, while diagnostic guidelines have been developed to improve diagnosis and referral of these children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/22\">",
"     22",
"    </a>",
"    ]. The rate is comparable to, or above, other common developmental disabilities, such as Down syndrome or spina bifida.",
"   </p>",
"   <p>",
"    Alcohol appears to have negative effects throughout pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. A prospective study of 992 pregnant women who consumed alcohol during pregnancy observed that alcohol-related facial dysmorphology and growth deficiencies were increased in women with first trimester alcohol exposure and the risk was dose-related without evidence of a threshold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/29\">",
"     29",
"    </a>",
"    ]. Alcohol consumption in the second trimester affected birth weight and length and third trimester exposure affected length. In addition, a longitudinal study involving 595 children reported that alcohol exposure during the second trimester predicted deficits in reading, spelling, and arithmetic (as measured on the Wide Range Achievement Test &mdash; Revised) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/31\">",
"     31",
"    </a>",
"    ]. The effect of prenatal alcohol exposure persisted after controlling the analysis for the relationship between IQ and achievement.",
"   </p>",
"   <p>",
"    Stillbirth and FAS are the most severe consequences of prenatal alcohol exposure. In one large epidemiologic study, an increased rate of stillbirth was noted across all categories of alcohol intake, even after adjusting for confounders (eg, smoking, prepregnancy weight) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/32\">",
"     32",
"    </a>",
"    ]. The rate of death from fetoplacental dysfunction rose from 1.37 per 1000 births for women consuming less than one drink per week to 8.83 per 1000 births for women consuming greater than or equal to five drinks per week.",
"   </p>",
"   <p>",
"    The prevalence of FAS among offspring of moderate to heavy drinkers (1 to 2 oz absolute alcohol per day) and chronic alcoholics is 10 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/33\">",
"     33",
"    </a>",
"    ]. The diagnosis is based upon three criteria, all of which must be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]; maternal alcohol exposure may or may not be confirmed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth problems (confirmed prenatal or postnatal height or weight, or both, at or below the 10th percentile), documented at any one point in time (adjusted for age, sex, gestational age, and race or ethnicity)",
"     </li>",
"     <li>",
"      Facial dysmorphia (smooth philtrum, thin vermilion border, small palpebral fissures)",
"     </li>",
"     <li>",
"      Central nervous system abnormalities (structural abnormalities, neurological problems, below normal functional performance)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The typical FAS face has short palpebral fissures, a thin upper lip, an abnormal philtrum, and a hypoplastic midface. The spectrum of features that may be observed in FAS are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef76082 \" href=\"mobipreview.htm?28/41/29339\">",
"     table 1",
"    </a>",
"    ). These issues are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28746?source=see_link\">",
"     \"Infants of mothers with substance abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is continuing uncertainty about the effects of low and low to moderate levels of alcohol intake in pregnancy. Although several studies have not found adverse behavioral and developmental effects, these studies have several methodological limitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/8,34-37\">",
"     8,34-37",
"    </a>",
"    ]. Higher quality studies related to this type of drinking are needed. As discussed above, there is no confirmed \"safe\" threshold of alcohol exposure during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SCREENING FOR ALCOHOL MISUSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;All pregnant women should be screened for use of licit and illicit substances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Many screening options are possible, from self-administered questionnaires to analysis of biological samples taken from the pregnant woman or her offspring. A practical, effective approach is to interview each woman with respectful and sensitive use of neutrally worded questions. It is preferable to begin by asking about lawful substances, such as cigarette smoking and alcohol, followed by questions about illicit drugs.",
"   </p>",
"   <p>",
"    The typical questions asked about the quantity and frequency of alcohol use are less helpful in the assessment of prenatal alcohol consumption than in other populations. This discordancy is due to modification of alcohol consumption once pregnancy is recognized and the fact that traditional alcohol screening measures were developed in male alcoholics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition, admission of alcohol use during pregnancy can be stigmatizing; thus, women may be reluctant to admit to any amount of drinking.",
"   </p>",
"   <p>",
"    Clinicians can choose screening strategies that are appropriate for their clinical population and setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4101957\">",
"    <span class=\"h3\">",
"     T-ACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The T-ACE is a simple screening instrument for alcohol use designed specifically for the prenatal setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/41\">",
"     41",
"    </a>",
"    ]. It identifies a range of alcohol consumption from any current prenatal drinking, prepregnancy risk drinking defined as more than two drinks per drinking day, to lifetime alcohol diagnoses based on the Diagnostic and Statistical Manual of Mental Disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/42\">",
"     42",
"    </a>",
"    ]. The T-ACE questions are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How many drinks does it take for you to feel high (",
"      <strong>",
"       TOLERANCE",
"      </strong>",
"      )?",
"     </li>",
"     <li>",
"      Do you feel",
"      <strong>",
"       ANNOYED",
"      </strong>",
"      by people complaining about your drinking?",
"     </li>",
"     <li>",
"      Have you ever felt the need to",
"      <strong>",
"       CUT",
"      </strong>",
"      down on your drinking?",
"     </li>",
"     <li>",
"      Have you ever had a drink first thing in the morning (",
"      <strong>",
"       EYE-OPENER",
"      </strong>",
"      )?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One point is given for each affirmative answer to the",
"    <strong>",
"     A",
"    </strong>",
"    nnoy,",
"    <strong>",
"     C",
"    </strong>",
"    ut-down, and",
"    <strong>",
"     E",
"    </strong>",
"    ye-opener questions; 2 points are allotted if a woman reports tolerance to more than two drinks. A score of 2 or more is a positive score. The overall sensitivity (ie, the probability that a woman who is a risk drinker scores positive) of T-ACE is 69 percent, with specificity of 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4101964\">",
"    <span class=\"h3\">",
"     TWEAK",
"    </span>",
"    &nbsp;&mdash;&nbsp;TWEAK is another screening instrument used in pregnant women:",
"   </p>",
"   <p>",
"    &nbsp;T =",
"    <strong>",
"     TOLERANCE",
"    </strong>",
"    for alcohol",
"   </p>",
"   <p>",
"    &nbsp;W =",
"    <strong>",
"     WORRY",
"    </strong>",
"    or concern by family or friends about drinking behavior",
"   </p>",
"   <p>",
"    &nbsp;E =",
"    <strong>",
"     EYE OPENER",
"    </strong>",
"    , the need to have a drink in the morning",
"   </p>",
"   <p>",
"    &nbsp;A = \"blackouts\" or",
"    <strong>",
"     AMNESIA",
"    </strong>",
"    while drinking",
"   </p>",
"   <p>",
"    &nbsp;K = the self-perception of the need to",
"    <strong>",
"     CUT DOWN",
"    </strong>",
"    on alcohol use.",
"   </p>",
"   <p>",
"    Scores range from 0 to 7. The tolerance and worry questions each contribute 2 points and the other three questions contribute 1 point each. Any endorsement of the worry question is scored a 2; on the tolerance question, if three or more drinks are needed to feel high, the question is scored as a 2. Other versions of the",
"    <strong>",
"     TOLERANCE",
"    </strong>",
"    question ask:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How many drinks does it take before the alcohol makes you fall asleep or pass out?",
"     </li>",
"     <li>",
"      If you never drink till you pass out, what is the largest number of drinks you have or can hold?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the woman answers \"five or more drinks,\" these questions are given a score of 2 points.",
"   </p>",
"   <p>",
"    A total score of &ge;3 on the TWEAK is suggestive of heavy drinking patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. However, both the TWEAK and TACE tests can miss light drinking, and sensitivity varies by ethnic group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4101971\">",
"    <span class=\"h3\">",
"     AUDIT-C",
"    </span>",
"    &nbsp;&mdash;&nbsp;A third option for a brief screening questionnaire is the AUDIT-C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/46\">",
"     46",
"    </a>",
"    ]. In this system, a total score of &ge;3 points is positive for women.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How often have you had a drink containing alcohol in the past year?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Never: 0 points",
"     </li>",
"     <li>",
"      Monthly or less: 1 point",
"     </li>",
"     <li>",
"      Two to four times a month: 2 points",
"     </li>",
"     <li>",
"      Three times a week: 3 points",
"     </li>",
"     <li>",
"      Four times or more per week: 4 points",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How many drinks did you have on a typical day when you were drinking in the past year?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One or two: 0 points",
"     </li>",
"     <li>",
"      Three or four: 1 point",
"     </li>",
"     <li>",
"      Five or six: 2 points",
"     </li>",
"     <li>",
"      Seven to nine: 3 points",
"     </li>",
"     <li>",
"      10 or more: 4 points",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How often did you have six or more drinks on one occasion during the past year?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Never: 0 points",
"     </li>",
"     <li>",
"      Monthly or less: 1 point",
"     </li>",
"     <li>",
"      Monthly: 2 points",
"     </li>",
"     <li>",
"      Weekly: 3 points",
"     </li>",
"     <li>",
"      Daily or almost daily:4 points",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An in-depth discussion of screening and diagnosis of women with alcohol problems can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link&amp;anchor=H27630680#H27630680\">",
"     \"Screening for unhealthy use of alcohol and other drugs\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no agreement among research groups concerning the best method for analyzing biological samples or when these tests should be used in pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/47\">",
"     47",
"    </a>",
"    ]. Recent alcohol intake is evaluated by measuring the blood alcohol level; this level can be estimated by breathalyzer. Individual variability in ethanol pharmacokinetics makes interpretation of alcohol levels challenging. Chronic alcohol consumption may be suspected based on abnormalities of liver function tests, macrocytosis, anemia, or carbohydrate-deficient transferrin (which is affected by pregnancy). The value of maternal blood markers for detecting significant prenatal alcohol exposure is being examined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/48\">",
"     48",
"    </a>",
"    ]. Patient acceptability and cost of these analyses may limit widespread implementation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=see_link&amp;anchor=H27630680#H27630680\">",
"     \"Screening for unhealthy use of alcohol and other drugs\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Positive tests can have legal and economic implications. Women should give informed consent prior to laboratory testing; random testing is unethical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/33,49\">",
"     33,49",
"    </a>",
"    ]. Medically indicated alcohol testing without written consent is acceptable in women who are unconscious or show obvious signs of intoxication and need to be tested in order to provide the appropriate medical interventions. Clinicians should be aware of their state's requirements for testing and reporting drug test results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SCREEN POSITIVE WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consistent screening for alcohol use, followed by education, assessment, and treatment referral, if indicated, are effective and will help to ensure the best possible outcome for all pregnant women and their babies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/7,50\">",
"     7,50",
"    </a>",
"    ]. Linking substance abuse treatment with prenatal care has a positive effect on maternal and newborn health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/51\">",
"     51",
"    </a>",
"    ]. Maternal cessation of alcohol intake at any point during pregnancy is beneficial, as children born to women who stop drinking even late in gestation have better outcomes than those who continue to drink throughout pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A positive screen provides an opportunity to proceed with a careful, nonjudgmental assessment of the patient's current and past alcohol consumption. This focus on drinking behavior can be beneficial, as the assessment of alcohol intake itself and the counseling and support provided by a nonjudgmental clinician can motivate some women to abstain. This was illustrated in a trial that randomized 250 pregnant women with a positive alcohol screen to either comprehensive alcohol assessment only or to the same comprehensive assessment with a brief intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/53\">",
"     53",
"    </a>",
"    ]. Both groups of women reduced their antepartum alcohol consumption by one to two thirds and brief intervention helped abstinent women remain abstinent.",
"   </p>",
"   <p>",
"    Randomized and controlled trials show that even brief intervention for alcohol problems is more effective than no intervention, and often as effective as more extensive intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/54-59\">",
"     54-59",
"    </a>",
"    ]. Reported benefits of intervention include reduced consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], reduced risk for an alcohol-exposed pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/54\">",
"     54",
"    </a>",
"    ], higher rates of abstinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/55\">",
"     55",
"    </a>",
"    ], and improvement in fetal and newborn outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/55\">",
"     55",
"    </a>",
"    ]. In one randomized trial, including a partner chosen by the patient during treatment led to greater reduction in alcohol use, particularly among heavy drinkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some alcohol abusers require referral for in-depth counseling and treatment regimens. Women identified to have heavy drinking patterns and who are unlikely to reduce their consumption should be referred to professional alcohol treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREGNANCY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comprehensive prenatal care can ameliorate some of the maternal and neonatal complications of maternal substance abuse. The components of this care include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41575/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening of all pregnant women for alcohol use",
"     </li>",
"     <li>",
"      Counseling regarding the risks of alcohol use",
"     </li>",
"     <li>",
"      Assembling a multidisciplinary team of health care and social service providers to comprehensively assess gravidas who abuse alcohol, and their offspring",
"     </li>",
"     <li>",
"      Scheduling frequent prenatal visits to monitor maternal and fetal status and provide education and support",
"     </li>",
"     <li>",
"      Obtaining an early ultrasound examination to confirm gestational age and establish an accurate baseline for following fetal growth",
"     </li>",
"     <li>",
"      Beginning antepartum fetal surveillance if there is evidence of pregnancy complications (eg, growth restriction, third trimester bleeding, maternal withdrawal)",
"     </li>",
"     <li>",
"      Informing the pediatrician of the possibility of neonatal withdrawal",
"     </li>",
"     <li>",
"      Discouraging breastfeeding in women who continue to consume alcohol",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/46/17122?source=see_link\">",
"       \"Patient information: Alcohol and illegal drug use in pregnancy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/40/38529?source=see_link\">",
"       \"Patient information: Fetal alcohol syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than one-half of all women of childbearing age (18 to 44 years of age) report alcohol use, and one in eight report binge drinking in the past month. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence of alcohol use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alcohol appears to have negative effects throughout pregnancy. These effects include impaired growth problems, facial dysmorphia, and central nervous system abnormalities (structural abnormalities, neurological problems, below normal cognitive performance). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Perinatal outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no exact dose-response relationship between the amount of alcohol consumed during the prenatal period and the extent of damage caused by alcohol in the infant. We recommend abstinence from alcohol at conception and during pregnancy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Safe level of alcohol intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identification and counseling of women who use alcohol can decrease intake during pregnancy. Given that alcohol is a known teratogen and a safe level of intake during pregnancy has not been established, we recommend screening all pregnant women for any use of alcohol (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Screening for alcohol misuse'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Management of screen positive women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The T-ACE, TWEAK, or AUDIT-C screening tool can be used to identify women who may be at risk for prenatal alcohol use. Clinicians should choose screening strategies that are appropriate for their clinical population and setting. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Screening for alcohol misuse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant women who consume alcohol but are not heavy drinkers, we recommend a brief intervention (eg, educational session(s), motivational counseling) rather than no intervention or more extensive alcohol cessation programs (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Women with heavy drinking patterns who are unlikely to reduce their consumption should be referred to professional alcohol treatment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management of screen positive women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/1\">",
"      Chasnoff IJ, Landress HJ, Barrett ME. The prevalence of illicit-drug or alcohol use during pregnancy and discrepancies in mandatory reporting in Pinellas County, Florida. N Engl J Med 1990; 322:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/2\">",
"      Chasnoff IJ, McGourty RF, Bailey GW, et al. The 4P's Plus screen for substance use in pregnancy: clinical application and outcomes. J Perinatol 2005; 25:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/3\">",
"      Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstet Gynecol 2003; 101:374.",
"     </a>",
"    </li>",
"    <li>",
"     MMWR. Alcohol Use and Binge Drinking Among Women of Childbearing Age &mdash; United States, 2006&ndash;2010 file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6128a4.htm?s_cid=mm6128a4_e (Accessed on July 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/5\">",
"      Ethen MK, Ramadhani TA, Scheuerle AE, et al. Alcohol consumption by women before and during pregnancy. Matern Child Health J 2009; 13:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/6\">",
"      D'Angelo D, Williams L, Morrow B, et al. Preconception and interconception health status of women who recently gave birth to a live-born infant--Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 26 reporting areas, 2004. MMWR Surveill Summ 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     Surgeon General's Advisory on Alcohol Use in Pregnancy. www.hhs.gov/surgeongeneral/pressreleases/sg02222005.html. (Accessed December 14, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/8\">",
"      Henderson J, Gray R, Brocklehurst P. Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome. BJOG 2007; 114:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/9\">",
"      Koren G, Nulman I, Chudley AE, Loocke C. Fetal alcohol spectrum disorder. CMAJ 2003; 169:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/10\">",
"      Patra J, Bakker R, Irving H, et al. Dose-response relationship between alcohol consumption before and during pregnancy and the risks of low birthweight, preterm birth and small for gestational age (SGA)-a systematic review and meta-analyses. BJOG 2011; 118:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/11\">",
"      Falgreen Eriksen HL, Mortensen EL, Kilburn T, et al. The effects of low to moderate prenatal alcohol exposure in early pregnancy on IQ in 5-year-old children. BJOG 2012; 119:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/12\">",
"      Underbjerg M, Kesmodel US, Landr&oslash; NI, et al. The effects of low to moderate alcohol consumption and binge drinking in early pregnancy on selective and sustained attention in 5-year-old children. BJOG 2012; 119:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/13\">",
"      Skogerb&oslash; &Aring;, Kesmodel US, Wimberley T, et al. The effects of low to moderate alcohol consumption and binge drinking in early pregnancy on executive function in 5-year-old children. BJOG 2012; 119:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/14\">",
"      Kesmodel US, Bertrand J, St&oslash;vring H, et al. The effect of different alcohol drinking patterns in early to mid pregnancy on the child's intelligence, attention, and executive function. BJOG 2012; 119:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/15\">",
"      Bay B, St&oslash;vring H, Wimberley T, et al. Low to moderate alcohol intake during pregnancy and risk of psychomotor deficits. Alcohol Clin Exp Res 2012; 36:807.",
"     </a>",
"    </li>",
"    <li>",
"     file://depts.washington.edu/fasdpn/ (Accessed on August 30, 2012).",
"    </li>",
"    <li>",
"     Astley S, Grant T. Alcohol and Pregnancy: Another perspective on the Disputed Danish Studies file://depts.washington.edu/fasdpn/pdfs/astley-grant-Washington.pdf (Accessed on August 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/18\">",
"      Maier SE, West JR. Drinking patterns and alcohol-related birth defects. Alcohol Res Health 2001; 25:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/19\">",
"      Bailey BN, Delaney-Black V, Covington CY, et al. Prenatal exposure to binge drinking and cognitive and behavioral outcomes at age 7 years. Am J Obstet Gynecol 2004; 191:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/20\">",
"      Henderson J, Kesmodel U, Gray R. Systematic review of the fetal effects of prenatal binge-drinking. J Epidemiol Community Health 2007; 61:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/21\">",
"      Floyd RL, O'Connor MJ, Sokol RJ, et al. Recognition and prevention of fetal alcohol syndrome. Obstet Gynecol 2005; 106:1059.",
"     </a>",
"    </li>",
"    <li>",
"     Fetal Alcohol Syndrome: Guidelines for Referral and Diagnosis. National Center on Birth Defects and Developmental Disabilities Centers for Disease Control and Prevention Department of Health and Human Services. July 2004. available at www.cdc.gov/ncbddd/fas/default.htm (accessed Novemebr 10, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/23\">",
"      Burd L, Blair J, Dropps K. Prenatal alcohol exposure, blood alcohol concentrations and alcohol elimination rates for the mother, fetus and newborn. J Perinatol 2012; 32:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/24\">",
"      Warren KR, Li TK. Genetic polymorphisms: impact on the risk of fetal alcohol spectrum disorders. Birth Defects Res A Clin Mol Teratol 2005; 73:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/25\">",
"      Jacobson SW, Carr LG, Croxford J, et al. Protective effects of the alcohol dehydrogenase-ADH1B allele in children exposed to alcohol during pregnancy. J Pediatr 2006; 148:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/26\">",
"      McCarver DG, Thomasson HR, Martier SS, et al. Alcohol dehydrogenase-2*3 allele protects against alcohol-related birth defects among African Americans. J Pharmacol Exp Ther 1997; 283:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/27\">",
"      Stoler JM, Ryan LM, Holmes LB. Alcohol dehydrogenase 2 genotypes, maternal alcohol use, and infant outcome. J Pediatr 2002; 141:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/28\">",
"      Green RF, Stoler JM. Alcohol dehydrogenase 1B genotype and fetal alcohol syndrome: a HuGE minireview. Am J Obstet Gynecol 2007; 197:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/29\">",
"      Feldman HS, Jones KL, Lindsay S, et al. Prenatal alcohol exposure patterns and alcohol-related birth defects and growth deficiencies: a prospective study. Alcohol Clin Exp Res 2012; 36:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/30\">",
"      Coles, C. Critical periods for prenatal alcohol exposure. Alcohol Health and Research World 1994; 18:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/31\">",
"      Goldschmidt L, Richardson GA, Stoffer DS, et al. Prenatal alcohol exposure and academic achievement at age six: a nonlinear fit. Alcohol Clin Exp Res 1996; 20:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/32\">",
"      Kesmodel U, Wisborg K, Olsen SF, et al. Moderate alcohol intake during pregnancy and the risk of stillbirth and death in the first year of life. Am J Epidemiol 2002; 155:305.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Special issues in women's health. ACOG, Washington, DC 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/34\">",
"      Bay B, Kesmodel US. Prenatal alcohol exposure - a systematic review of the effects on child motor function. Acta Obstet Gynecol Scand 2011; 90:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/35\">",
"      O'Leary CM, Nassar N, Kurinczuk JJ, Bower C. The effect of maternal alcohol consumption on fetal growth and preterm birth. BJOG 2009; 116:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/36\">",
"      Kelly Y, Sacker A, Gray R, et al. Light drinking in pregnancy, a risk for behavioural problems and cognitive deficits at 3 years of age? Int J Epidemiol 2009; 38:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/37\">",
"      Todorow M, Moore TE, Koren G. Investigating the effects of low to moderate levels of prenatal alcohol exposure on child behaviour: a critical review. J Popul Ther Clin Pharmacol 2010; 17:e323.",
"     </a>",
"    </li>",
"    <li>",
"     Stratton, K, Howe, C, Battaglia, F (eds). Institute of Medicine Summary: Fetal Alcohol Syndrome Washington, DC: National Academy Press, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/39\">",
"      American College of Obstetricians and Gynecologists. Committee on Health Care for Underserved Women. Committee opinion no. 496: At-risk drinking and alcohol dependence: obstetric and gynecologic implications. Obstet Gynecol 2011; 118:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/40\">",
"      Babor TF, Kranzler HR, Lauerman RJ. Early detection of harmful alcohol consumption: comparison of clinical, laboratory, and self-report screening procedures. Addict Behav 1989; 14:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/41\">",
"      Sokol RJ, Martier SS, Ager JW. The T-ACE questions: practical prenatal detection of risk-drinking. Am J Obstet Gynecol 1989; 160:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/42\">",
"      Chang G, Wilkins-Haug L, Berman S, et al. Alcohol use and pregnancy: improving identification. Obstet Gynecol 1998; 91:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/43\">",
"      Chan AW, Pristach EA, Welte JW, Russell M. Use of the TWEAK test in screening for alcoholism/heavy drinking in three populations. Alcohol Clin Exp Res 1993; 17:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/44\">",
"      O'Connor MJ, Whaley SE. Alcohol use in pregnant low-income women. J Stud Alcohol 2003; 64:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/45\">",
"      Bradley KA, Boyd-Wickizer J, Powell SH, Burman ML. Alcohol screening questionnaires in women: a critical review. JAMA 1998; 280:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/46\">",
"      Burns E, Gray R, Smith LA. Brief screening questionnaires to identify problem drinking during pregnancy: a systematic review. Addiction 2010; 105:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/47\">",
"      Strano-Rossi S. Methods used to detect drug abuse in pregnancy: a brief review. Drug Alcohol Depend 1999; 53:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/48\">",
"      Stoler JM, Huntington KS, Peterson CM, et al. The prenatal detection of significant alcohol exposure with maternal blood markers. J Pediatr 1998; 133:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/49\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 422: at-risk drinking and illicit drug use: ethical issues in obstetric and gynecologic practice. Obstet Gynecol 2008; 112:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/50\">",
"      Rayburn WF, Bogenschutz MP. Pharmacotherapy for pregnant women with addictions. Am J Obstet Gynecol 2004; 191:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/51\">",
"      Goler NC, Armstrong MA, Taillac CJ, Osejo VM. Substance abuse treatment linked with prenatal visits improves perinatal outcomes: a new standard. J Perinatol 2008; 28:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/52\">",
"      Coles, DC, Smith, IE, Lancaster, JS, Falek, A. Persistence over the first month of neurobehavioral alterations in infants exposed to alcohol prenatally. Infant Behav Dev 1987; 10:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/53\">",
"      Chang G, Wilkins-Haug L, Berman S, Goetz MA. Brief intervention for alcohol use in pregnancy: a randomized trial. Addiction 1999; 94:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/54\">",
"      Floyd RL, Sobell M, Velasquez MM, et al. Preventing alcohol-exposed pregnancies: a randomized controlled trial. Am J Prev Med 2007; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/55\">",
"      O'Connor MJ, Whaley SE. Brief intervention for alcohol use by pregnant women. Am J Public Health 2007; 97:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/56\">",
"      Chang G, McNamara TK, Orav EJ, Wilkins-Haug L. Brief intervention for prenatal alcohol use: the role of drinking goal selection. J Subst Abuse Treat 2006; 31:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/57\">",
"      Ingersoll KS, Ceperich SD, Nettleman MD, et al. Reducing alcohol-exposed pregnancy risk in college women: initial outcomes of a clinical trial of a motivational intervention. J Subst Abuse Treat 2005; 29:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/58\">",
"      Chang G, McNamara TK, Orav EJ, et al. Brief intervention for prenatal alcohol use: a randomized trial. Obstet Gynecol 2005; 105:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41575/abstract/59\">",
"      Handmaker NS, Miller WR, Manicke M. Findings of a pilot study of motivational interviewing with pregnant drinkers. J Stud Alcohol 1999; 60:285.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4798 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41575=[""].join("\n");
var outline_f40_38_41575=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE OF ALCOHOL USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SAFE LEVEL OF ALCOHOL INTAKE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PERINATAL OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SCREENING FOR ALCOHOL MISUSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4101957\">",
"      - T-ACE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4101964\">",
"      - TWEAK",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4101971\">",
"      - AUDIT-C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT OF SCREEN POSITIVE WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREGNANCY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4798|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/41/29339\" title=\"table 1\">",
"      Fetal alcohol syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/46/17122?source=related_link\">",
"      Patient information: Alcohol and illegal drug use in pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/40/38529?source=related_link\">",
"      Patient information: Fetal alcohol syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_38_41576="Managing the side effects of tamoxifen";
var content_f40_38_41576=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Managing the side effects of tamoxifen",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/38/41576/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41576/contributors\">",
"     Suzanne D Conzen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/38/41576/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41576/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41576/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/38/41576/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41576/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/38/41576/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    are selective estrogen receptor modulators (SERMs) with both agonist and antagonist properties, depending on the individual target organ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These differences are probably because of variable effects on gene expression in different cell types. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    have antiestrogenic activity in breast tissue, reducing epithelial cell proliferation. This property has led to their clinical study as breast cancer chemopreventive agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, an important difference between the two drugs is their effect on the uterus, where",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    has an estrogen-like effect while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    acts as an estrogen antagonist. In apparent contrast to raloxifene, tamoxifen has been associated with endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], fibroids, polyps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/4-6\">",
"     4-6",
"    </a>",
"    ], and endometrial tumors (estrogen agonist effects) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. There are a number of other potential adverse effects associated with the administration of tamoxifen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to endometrial cancers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    can cause other side effects, including hot flashes (an estrogen antagonist effect), vaginal discharge, menstrual irregularities, sexual dysfunction, and blood clots.",
"   </p>",
"   <p>",
"    This topic review will cover management of the major side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . The use of tamoxifen as a hormonal treatment for breast cancer, both in the adjuvant setting and for advanced disease, and the use of tamoxifen and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    as chemopreventive agents in women at increased risk for breast cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HOT FLASHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hot flashes are one of the most common and bothersome side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ; they are believed to be due to a central nervous system antiestrogenic effect causing thermoregulatory dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/9\">",
"     9",
"    </a>",
"    ]. Up to 80 percent of women prescribed tamoxifen complain of hot flashes, and about 30 percent rate them as severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some risk factors for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    -induced hot flashes have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premenopausal women have a greater increase in hot flashes after starting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      compared to perimenopausal or postmenopausal women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/10-13\">",
"       10-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polymorphisms in drug metabolizing enzymes (cytochrome P450 enzyme, CYP2D6) decrease the conversion of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      to its most active metabolite (endoxifen), and they may influence the likelihood of tamoxifen-related hot flashes, although the available data are conflicting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=see_link&amp;anchor=H6#H6\">",
"       \"Mechanisms of action of selective estrogen receptor modulators\", section on 'Tamoxifen resistance in breast cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Likewise, coadministration of drugs that inhibit the activity of CYP2D6, such as the selective serotonin reuptake inhibitors (SSRIs), reduce",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      -related hot flashes. However, strong CYP2D6 inhibitors have the potential to adversely affect drug efficacy. A list of CYP2D6 inhibitors is available online. Among SSRIs, there is a gradient of potency for inhibition of CYP2D6; for example,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      &nbsp;and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      &nbsp;are strong CYP2D6 inhibitors, while",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      &nbsp;and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      &nbsp;are moderate inhibitors. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=see_link&amp;anchor=H6#H6\">",
"       \"Mechanisms of action of selective estrogen receptor modulators\", section on 'Tamoxifen resistance in breast cancer'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"       \"Menopausal hot flashes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inheritance of specific estrogen receptor genotypes may also influence the risk and severity of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      -induced hot flashes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While evaluation of genetic risk factors for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    -induced hot flashes such as these might hold promise for future selection of candidates for alternative therapeutic strategies when tamoxifen is indicated, genetic testing is not yet ready for clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THROMBOEMBOLIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies, including the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview analysis and two large breast cancer prevention trials have demonstrated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    use is associated with an increased rate of",
"    <strong>",
"     venous",
"    </strong>",
"    thromboembolic events, especially within the first two years, and that there is a significant additional procoagulant effect when tamoxifen is added to chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The relative risks of pulmonary embolism and deep vein thrombosis are increased two-to three-fold in older women receiving tamoxifen. Risk factors for tamoxifen-induced VTE include prior surgery, fracture, and immobilization. These data suggest that women receiving tamoxifen should discontinue use for several days prior to prolonged immobilization from anticipated surgery or travel. In addition, there is evidence that patients receiving tamoxifen who harbor a heterozygous Factor V Leiden mutation have a nearly fivefold risk of thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link&amp;anchor=H10#H10\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\", section on 'Tamoxifen and raloxifene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    may be associated with an increased incidence of arterial thromboembolism (ie, stroke) was raised in two NSABP randomized trials: P-1 (the breast cancer prevention trial) and NSABP B-24, a trial of tamoxifen for intraductal breast cancer. However, the available data are conflicting, and any increased risk of stroke may be counterbalanced by favorable effects on ischemic heart disease. This was shown in the most recent overview analysis of randomized trials of adjuvant tamoxifen from the Early Breast Cancer Trialists Collaborative Group (EBCTCG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/18\">",
"     18",
"    </a>",
"    ]. The non-significant excess of stroke deaths (three extra per 1000 women during the first 15 years) in women treated with tamoxifen was exactly balanced by a non-significant reduction in cardiac deaths (three fewer per 1000 women during the first 15 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, there was little net effect of tamoxifen on overall vascular mortality. This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link&amp;anchor=H10#H10\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\", section on 'Tamoxifen and raloxifene'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37561?source=see_link&amp;anchor=H562652190#H562652190\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\", section on 'Systemic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ENDOMETRIAL MALIGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    has been associated with an increased risk of both endometrial cancer and uterine sarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Endometrial cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an updated report of the P-1 study with seven years of follow-up, 53 cases of endometrial cancer occurred in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    group versus 17 in the placebo group (risk ratio 3.28) (",
"    <a class=\"graphic graphic_figure graphicRef80306 \" href=\"mobipreview.htm?22/7/22654\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, there were four cases of uterine sarcoma, three in the tamoxifen group. Of the 70 total endometrial cancers, 67 were localized (stage I). The majority presented with vaginal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/21\">",
"     21",
"    </a>",
"    ]. The increase in endometrial cancer was almost exclusively in women over the age of 50 years.",
"   </p>",
"   <p>",
"    A comparable risk ratio for endometrial cancer (2.7-fold increased risk) was found in a meta-analysis of 32 published randomized controlled trials in which a treatment arm containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    was compared to a similar control arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of developing endometrial cancer increases with longer treatment durations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], and decreases after treatment is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control study compared 816 patients with breast cancer who subsequently developed endometrial cancer, and 1067 controls with breast cancer but not endometrial cancer, both groups derived from population-based regional cancer registries in the United Kingdom [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/23\">",
"       23",
"      </a>",
"      ]. Compared with no treatment, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      was associated with a significantly higher risk of endometrial cancer (odds ratio [OR] 2.4) that increased over time (ORs for 2 to 4, 5 to 7, 8 to 9, and 10 to 17 years of therapy were 2.1, 2.5, 4.8, 7.9, respectively).",
"     </li>",
"     <li>",
"      Similarly, in the most recent EBCTCG overview analysis of individual patient data from 20 trials of approximately five years of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      versus no adjuvant tamoxifen, use of tamoxifen was associated with a significant 2.4-fold increased risk of uterine cancer, but there was no suggestion of any adverse effect on mortality from uterine cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A reduction in relative risk after treatment discontinuation was shown in the International Breast Cancer Study Group (IBIS)-I",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      chemoprevention trial, in which 7145 women at high risk for breast cancer were randomized to five years of tamoxifen or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/24\">",
"       24",
"      </a>",
"      ]. Thirteen of the 17 endometrial cancers in the tamoxifen group were diagnosed during active treatment (versus 3 of 11 in the placebo group). In contrast, during the follow-up period, four endometrial cancers were diagnosed in the tamoxifen group compared to eight in the placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Uterine sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although early studies failed to document an increased risk of uterine sarcoma in women treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/3,25,26\">",
"     3,25,26",
"    </a>",
"    ], long-term follow-up reports have disclosed a very small increased incidence of uterine sarcoma, particularly uterine carcinosarcoma or malignant mixed Mullerian tumors (MMMTs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2408?source=see_link\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/34/44585?source=see_link\">",
"     \"Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was illustrated in data derived from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute on 39,541 women diagnosed with breast cancer between 1980 and 2000 who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/30\">",
"     30",
"    </a>",
"    ]. Compared to the general SEER population, the relative risk of a subsequent uterine corpus cancer (observed-to-expected",
"    <span class=\"nowrap\">",
"     [O/E]",
"    </span>",
"    ratio) was 2.17, and was substantially higher for MMMTs than for endometrial adenocarcinomas",
"    <span class=\"nowrap\">",
"     (O/E",
"    </span>",
"    = 4.62 and 2.07, respectively). The relative risk of MMMT rose further in women surviving five years, while the risk of adenocarcinoma did not change appreciably",
"    <span class=\"nowrap\">",
"     (O/E",
"    </span>",
"    8.0 and 2.3, respectively). However, because of the rarity of MMMTs, this translated into a smaller excess absolute risk for MMMTs than for uterine adenocarcinomas (an additional 1.4 versus 8.4 cancers per 10,0000 women per year, respectively). Prognosis was poor among women diagnosed with MMMT, with 25 deaths among the 34 diagnosed women.",
"   </p>",
"   <p>",
"    As a result of these findings, the United States FDA issued a black box warning on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    because of its association with uterine sarcoma, which is intended mainly for women considering tamoxifen for ductal carcinoma in situ and as a chemopreventive agent where there is no proven survival benefit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37561?source=see_link\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    .) This warning does not apply to women with a history of invasive breast cancer since there is a proven survival benefit for adjuvant tamoxifen in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94636198\">",
"    <span class=\"h2\">",
"     Screening for uterine tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Obstetricians and Gynecologists has developed the following recommendations for monitoring women on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premenopausal women have no known increased risk of uterine cancer with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      and require no additional monitoring beyond routine gynecologic care.",
"     </li>",
"     <li>",
"      For postmenopausal women, perform an annual gynecologic examination.",
"     </li>",
"     <li>",
"      Monitor for symptoms of endometrial hyperplasia or cancer. Women should be educated to report any abnormal vaginal symptoms (eg, bloody discharge, spotting, staining, leukorrhea).",
"     </li>",
"     <li>",
"      Investigate any abnormal vaginal symptoms.",
"     </li>",
"     <li>",
"      Limit",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      use to five years duration because benefit beyond this time has not been demonstrated.",
"     </li>",
"     <li>",
"      If atypical endometrial hyperplasia develops, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      should be reassessed and appropriate gynecologic management should be initiated. Hysterectomy should be considered for women with atypical endometrial hyperplasia in whom tamoxifen therapy must be continued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9482501\">",
"    <span class=\"h3\">",
"     Gynecologic and ultrasound examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no evidence-based recommendations for uterine cancer screening in women taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ; investigators from the P-1 study recommend annual gynecologic examinations and a thorough evaluation of abnormal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/20\">",
"     20",
"    </a>",
"    ]. The utility of transvaginal ultrasound is unproven. One prospective study evaluated semiannual transvaginal ultrasound (TVUS) to screen for endometrial pathology in 247 asymptomatic women receiving tamoxifen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/33\">",
"     33",
"    </a>",
"    ]. The endometrial thickness increased from a mean of 3.5 mm pretreatment to 9.2 mm after three years of tamoxifen, a value that was significantly greater than controls (n=98) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/33\">",
"     33",
"    </a>",
"    ]. Even with a cutoff value of 10 mm for abnormal endometrial thickness, screening TVUS resulted in a high false positive rate and substantial iatrogenic morbidity. Histologically, endometrial cancer was detected in only one case, atrophy in 38 (73 percent), polyps in nine, and hyperplasia in four. Four of 52 hysteroscopy and D&amp;C procedures, which were prompted by abnormal TVUS findings, were complicated by uterine perforations.",
"   </p>",
"   <p>",
"    Furthermore, pelvic ultrasound should be interpreted with caution, as up to 25 percent of asymptomatic women on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    have ultrasonographic changes that are suggestive of endometrial cancer, but that are not associated with endometrial pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Endometrial polyps appear to be the most common endometrial pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9482508\">",
"    <span class=\"h3\">",
"     Endometrial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Likewise, routine endometrial biopsy in asymptomatic women on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    is not useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. A prospective study of semiannual screening office endometrial biopsies was performed in 159 asymptomatic women beginning adjuvant tamoxifen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/41\">",
"     41",
"    </a>",
"    ]. An average of 5.8 endometrial biopsies were performed per patient, and no cases of endometrial cancer were diagnosed. However, screening led to an increase in operative procedures; fourteen of 111 assessable patients (13 percent) underwent D&amp;C (all for benign pathology) and three underwent hysterectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9482672\">",
"    <span class=\"h2\">",
"     Endometrial protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial protection from the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    may be possible with local application of the levonorgestrel-releasing intrauterine device (LNG-IUD), a progestational agent. While LNG-IUD may prevent polyps and other endometrial issues among women taking tamoxifen, it may increase the risk of cancer recurrence; these data are reviewed below. Until more data becomes available, we suggest not administering LNG-IUD for endometrial protection. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2009 systematic review of two randomized trials of LNG-IUD versus endometrial surveillance in women on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      as adjuvant treatment for hormone-positive breast cancer, compared to surveillance, LNG-IUD use resulted in [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/42\">",
"       42",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A significant reduction in the incidence of endometrial polyps (1.6 versus 10.6 percent, respectively, odds ratio [OR] 0.14, 95% CI 0.03-0.61)",
"     </li>",
"     <li>",
"      A trend towards a lower incidence of endometrial hyperplasia (OR 0.30, 95% CI 0.01-7.44)",
"     </li>",
"     <li>",
"      A trend towards a lower incidence of endometrial fibroids (1.6 versus 4.1 percent, OR 0.37, 95% CI 0.07-1.95)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A European study retrospectively evaluated the risk of recurrence among women with breast cancer in LNG-IUD users (n=79) and nonusers (n=120), matched for age, breast cancer characteristics (ie, stage, grade), and previous treatments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/43\">",
"       43",
"      </a>",
"      ]. Compared to non-users, use of the LNG-IUD resulted in a slightly higher rate of breast cancer recurrence (22 versus 17 percent, OR 1.86, 95% 0.86-4.00). However, the timing of initiation of LNG-IUD before and during breast cancer treatment was associated with risk of recurrence:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women who initiated LNG-IUD at the time of the initial breast cancer diagnosis and continued to use it during treatment had a significantly increased risk of recurrence (hazard ratio [HR] for recurrence 3.4, 95% CI 1.01-11.4).",
"     </li>",
"     <li>",
"      Women who initiated LNG-IUD following completion of breast cancer treatment had a trend towards an increased risk of recurrence (HR 1.48, 95% CI 0.62-3.49).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more extensive discussion on contraception for women with breast cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link&amp;anchor=H269850350#H269850350\">",
"     \"Approach to the long-term survivor of breast cancer\", section on 'Contraception after breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7454824\">",
"    <span class=\"h1\">",
"     OTHER TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of non-uterine cancers has not been previously reported in women receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . However, a modest but significantly increased relative risk of gastrointestinal tumors (RR 1.31, 95% CI 1.01 to 1.69) was suggested in a meta-analysis of 16 randomized controlled trials comparing a tamoxifen-containing treatment arm with a similar control arm, in which the incidence of gastrointestinal tumors was reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/8\">",
"     8",
"    </a>",
"    ]. Most of this increased risk was derived from three individual Scandinavian trials; the majority of trials and the single largest study (NSABP P-1) did not report significant risk increases.",
"   </p>",
"   <p>",
"    Although data are limited,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    may",
"    <strong>",
"     reduce",
"    </strong>",
"    the risk of ovarian cancer. This was illustrated in a retrospective study of 152 breast cancer patients undergoing oophorectomy, 44 of whom were receiving tamoxifen, nine had previously received tamoxifen, and 99 had never received tamoxifen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/44\">",
"     44",
"    </a>",
"    ]. There was no difference in the frequency of benign ovarian tumors or functional ovarian cysts based upon tamoxifen exposure. However, tamoxifen-treated women were less likely to have ovarian cancer (0 of 53 versus 10 of 99 patients in the tamoxifen and non-tamoxifen groups, respectively). Further studies are required to better define the effect of tamoxifen on ovarian cancer risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CORONARY HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    has favorable effects on the lipid profile that may influence coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/45-51\">",
"     45-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial in 57 normal postmenopausal women,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      in a dose of 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      led to significant reductions in total and LDL-cholesterol (12 and 19 percent, respectively) and an 18 percent fall in fibrinogen levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/45\">",
"       45",
"      </a>",
"      ]. There was no change in HDL-cholesterol.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      reduces arterial LDL oxidation and LDL degradation, reflecting an estrogen-agonist effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. However, unlike estrogen it does not enhance the endothelium-dependent vasodilation response of atherosclerotic coronary arteries, reflecting its estrogen-antagonist effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    might reduce the risk of coronary heart disease (CHD), biochemical data can be misleading, as has been learned from the Women's Health Initiative.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    was associated with a modest though significant reduction in CHD events in a meta-analysis of 12 trials in which a treatment arm containing tamoxifen was compared to a similar control arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/8\">",
"     8",
"    </a>",
"    ], and in five secondary analyses of clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. However, there were relatively few events reported in these studies, and CHD was not a prospective endpoint in any. In one of the trials, the significant reduction in cardiovascular events and cardiovascular death associated with five as compared to two years of adjuvant tamoxifen was limited to women 50 to 59 years of age and not older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, other data suggest that the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    is not associated with a beneficial cardiovascular effect:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The NSABP P-1 trial prospectively evaluated the occurrence of cardiovascular events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/57\">",
"       57",
"      </a>",
"      ]. Cardiovascular follow-up was available for 13,194 women, 1048 of whom had prior CHD. The rate of cardiovascular events (fatal myocardial infarction [MI], Q-wave MI, non-Q-wave MI, unstable angina, or severe angina requiring revascularization) was not significantly different in women assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      compared with those receiving placebo, independent of preexisting CHD. It has been suggested that the large proportion of younger women enrolled on this trial may have obscured the benefit of tamoxifen in terms of cardiovascular disease outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar conclusion was reached in a case control study of 11,045 women enrolled in a single HMO who developed breast cancer over a 20 year period, 134 of whom had a subsequent myocardial infarction (MI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/59\">",
"       59",
"      </a>",
"      ]. Compared to 262 control women who were MI-free and matched for year of birth and breast cancer diagnosis, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      was not associated with a lower risk of MI.",
"     </li>",
"     <li>",
"      As noted above, in the most recent overview analysis of randomized trials of adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      from the EBCTCG, there was a statistically non-significant reduction in cardiac deaths (three fewer per 1000 women during the first 15 years) in women treated with tamoxifen that was counterbalanced by a non-significant excess of stroke deaths (three extra per 1000 women) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On balance, the available data support the view that in postmenopausal women both with and without CHD, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    associated with either a beneficial or adverse cardiovascular effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EYE PROBLEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    has been associated with an increased risk of cataracts in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/20,60\">",
"     20,60",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/61\">",
"     61",
"    </a>",
"    ]. The rate of cataract development was slightly but significantly higher in women taking tamoxifen in the P-1 study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/20\">",
"     20",
"    </a>",
"    ]. However, there was no increase in the risk of serious eye disease (eg, macular degeneration).",
"   </p>",
"   <p>",
"    Although this appears to be a rare problem, routine annual ocular examination is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7454115\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    is a selective estrogen receptor modulator (SERM) with both estrogen agonist and antagonist activities. In the uterus, it has been associated with an increased risk of uterine cancer. Other side effects associated with the use of tamoxifen include hot flashes, vaginal discharge, menstrual irregularities, sexual dysfunction, and blood clots. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hot flashes are one of the most common and bothersome side effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      . Coadministration of drugs that inhibit the activity of CYP2D6, such as the selective serotonin reuptake inhibitors (SSRIs), reduce tamoxifen-related hot flashes. However, strong CYP2D6 inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      &nbsp;and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ) have the potential to adversely affect drug efficacy, and their use is best avoided.&nbsp;(See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hot flashes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The relative risks of pulmonary embolism and deep vein thrombosis are increased two- to threefold in older women receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      ; the risk is higher in women who have inherited a Factor V Leiden mutation. Women receiving tamoxifen should discontinue use for several days prior to prolonged immobilization from anticipated surgery or travel. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Thromboembolic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      has been associated with an increased risk of endometrial cancer and uterine sarcoma. These risks prompted the United States FDA to issue a black box warning that is intended mainly for women considering tamoxifen for ductal carcinoma in situ and as a chemopreventive agent where there is no proven survival benefit. The warning does not apply to women with a history of invasive breast cancer since there is a proven survival benefit for adjuvant tamoxifen. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Endometrial malignancies'",
"      </a>",
"      above.).",
"      <br/>",
"      <br/>",
"      There are no evidence-based recommendations for uterine cancer screening in women taking tamoxifen. The American College of Obstetricians and Gynecologists recommend the following for monitoring women on tamoxifen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41576/abstract/32\">",
"       32",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H94636198\">",
"       'Screening for uterine tumors'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Premenopausal women have no known increased risk of uterine cancer with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      and require no additional monitoring beyond routine gynecologic care.",
"     </li>",
"     <li>",
"      For postmenopausal women, perform an annual gynecologic examination.",
"     </li>",
"     <li>",
"      Monitor for symptoms of endometrial hyperplasia or cancer. Women should be educated to report any abnormal vaginal symptoms (eg, bloody discharge, spotting, staining, leukorrhea).",
"     </li>",
"     <li>",
"      Investigate any abnormal vaginal symptoms.",
"     </li>",
"     <li>",
"      Limit",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      use to five years duration; benefit beyond this time has not been proven, and may be harmful.",
"     </li>",
"     <li>",
"      If atypical endometrial hyperplasia develops, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      should be reassessed and appropriate gynecologic management should be initiated. Hysterectomy should be considered for women with atypical endometrial hyperplasia in whom tamoxifen therapy must be continued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Further studies are required to better define the effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      on risk of other cancers, including gastrointestinal and ovarian cancer. (See",
"      <a class=\"local\" href=\"#H7454824\">",
"       'Other tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      has some favorable actions on lipid profiles that suggest a potential protective effect against coronary heart disease (CHD). However, the available data from clinical suggest that in postmenopausal women both with and without CHD, the use of tamoxifen is",
"      <strong>",
"       not",
"      </strong>",
"      associated with either a beneficial or adverse cardiovascular effect when the drug is used for adjuvant treatment of early breast cancer or as a chemopreventive agent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      has been associated with a slightly increased risk of cataracts, although this appears to be a rare problem. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Eye problems'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/1\">",
"      Cosman F, Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 1999; 20:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/2\">",
"      Riggs BL, Hartmann LC. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med 2003; 348:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/3\">",
"      Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/4\">",
"      Chalas E, Costantino JP, Wickerham DL, et al. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 2005; 192:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/5\">",
"      Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994; 343:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/6\">",
"      Lahti E, Blanco G, Kauppila A, et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/7\">",
"      Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/8\">",
"      Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003; 18:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/9\">",
"      Stearns V, Ullmer L, L&oacute;pez JF, et al. Hot flushes. Lancet 2002; 360:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/10\">",
"      Day R, National Surgical Adjuvant Breast and Bowel Projet P-1 study (NSABP-1). Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann N Y Acad Sci 2001; 949:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/11\">",
"      Jin Y, Hayes DF, Li L, et al. Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 2008; 26:5849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/12\">",
"      Crandall C, Petersen L, Ganz PA, Greendale GA. Association of breast cancer and its therapy with menopause-related symptoms. Menopause 2004; 11:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/13\">",
"      Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 2003; 45:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/14\">",
"      Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23:9312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/15\">",
"      Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006; 24:3708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/16\">",
"      Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/17\">",
"      Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/18\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/19\">",
"      Garber JE, Halabi S, Tolaney SM, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst 2010; 102:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/20\">",
"      Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/21\">",
"      Runowicz CD. Gynecologic surveillance of women on tamoxifen: first do no harm. J Clin Oncol 2000; 18:3457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/22\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/23\">",
"      Swerdlow AJ, Jones ME, British Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 2005; 97:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/24\">",
"      Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99:272.",
"     </a>",
"    </li>",
"    <li>",
"     National Prescription Audit and National Prescription Audit Plus. Plymouth meeting, Pa. IMS Health, 1978-2001 (database).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/26\">",
"      Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/27\">",
"      Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002; 20:2758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/28\">",
"      Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002; 346:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/29\">",
"      Bergman L, Beelen ML, Gallee MP, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 2000; 356:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/30\">",
"      Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004; 96:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/31\">",
"      Saadat M, Truong PT, Kader HA, et al. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen. Cancer 2007; 110:31.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Tamoxifen and endometrial cancer. ACOG Committee Opinion 336. ACOG June 2006; Washington, DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/33\">",
"      Gerber B, Krause A, M&uuml;ller H, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000; 18:3464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/34\">",
"      Dijkhuizen FP, Br&ouml;lmann HA, Oddens BJ, et al. Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Maturitas 1996; 25:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/35\">",
"      Bertelli G, Venturini M, Del Mastro L, et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 1998; 47:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/36\">",
"      Cecchini S, Ciatto S, Bonardi R, et al. Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol Oncol 1996; 60:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/37\">",
"      Fung MF, Reid A, Faught W, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 2003; 91:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/38\">",
"      Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004; 94:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/39\">",
"      Love CD, Muir BB, Scrimgeour JB, et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999; 17:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/40\">",
"      Seoud M, Shamseddine A, Khalil A, et al. Tamoxifen and endometrial pathologies: a prospective study. Gynecol Oncol 1999; 75:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/41\">",
"      Barakat RR, Gilewski TA, Almadrones L, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 2000; 18:3459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/42\">",
"      Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev 2009; :CD007245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/43\">",
"      Trinh XB, Tjalma WA, Makar AP, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 2008; 90:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/44\">",
"      McGonigle KF, Vasilev SA, Odom-Maryon T, Simpson JF. Ovarian histopathology in breast cancer patients receiving tamoxifen. Gynecol Oncol 1999; 73:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/45\">",
"      Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995; 80:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/46\">",
"      Williams JK, Wagner JD, Li Z, et al. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol 1997; 17:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/47\">",
"      Guetta V, Lush RM, Figg WD, et al. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol 1995; 76:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/48\">",
"      Williams JK, Honor&eacute; EK, Adams MR. Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries in nonhuman primates. Circulation 1997; 96:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/49\">",
"      Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998; 83:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/50\">",
"      Hayes DF, Skaar TC, Rae JM, et al. Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. Clin Pharmacol Ther 2010; 88:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/51\">",
"      Hozumi Y, Suemasu K, Takei H, et al. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. Ann Oncol 2011; 22:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/52\">",
"      Costantino JP, Kuller LH, Ives DG, et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997; 89:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/53\">",
"      McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991; 303:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/54\">",
"      Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993; 85:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/55\">",
"      Nordenskj&ouml;ld B, Rosell J, Rutqvist LE, et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 2005; 97:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/56\">",
"      Hackshaw A, Roughton M, Forsyth S, et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 2011; 29:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/57\">",
"      Reis SE, Costantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 2001; 93:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/58\">",
"      Pritchard KI, Sousa B. Long-term follow-up of women in trials of adjuvant therapy for breast cancer: is it still important? J Clin Oncol 2011; 29:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/59\">",
"      Geiger AM, Chen W, Bernstein L. Myocardial infarction risk and tamoxifen therapy for breast cancer. Br J Cancer 2005; 92:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/60\">",
"      Gianni L, Panzini I, Li S, et al. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer 2006; 106:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41576/abstract/61\">",
"      Bradbury BD, Lash TL, Kaye JA, Jick SS. Tamoxifen and cataracts: a null association. Breast Cancer Res Treat 2004; 87:189.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 764 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-219.243.220.100-85C35604D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41576=[""].join("\n");
var outline_f40_38_41576=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7454115\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HOT FLASHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THROMBOEMBOLIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ENDOMETRIAL MALIGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Uterine sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94636198\">",
"      Screening for uterine tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9482501\">",
"      - Gynecologic and ultrasound examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9482508\">",
"      - Endometrial biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9482672\">",
"      Endometrial protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7454824\">",
"      OTHER TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CORONARY HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EYE PROBLEMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7454115\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/764\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/764|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/7/22654\" title=\"figure 1\">",
"      Estimates of the benefits and risks of tamoxifen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/34/44585?source=related_link\">",
"      Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37561?source=related_link\">",
"      Ductal carcinoma in situ: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2408?source=related_link\">",
"      Uterine sarcoma: Classification, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_38_41577="Zollinger Ellison Light";
var content_f40_38_41577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Zollinger-Ellison syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power light micrograph of a gastric body biopsy from a patient with Zollinger-Ellison syndrome. The mucosa has an abnormally thick pit compartment and an expanded glandular compartment with much of the expansion due to an excess of parietal cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41577=[""].join("\n");
var outline_f40_38_41577=null;
var title_f40_38_41578="Overview of the therapy and prognosis of systemic lupus erythematosus in adults";
var content_f40_38_41578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/38/41578/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41578/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41578/contributors\">",
"     Daniel J Wallace, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/38/41578/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41578/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/38/41578/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/38/41578/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/38/41578/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic lupus erythematosus (SLE) is a chronic, occasionally life-threatening, multisystem disorder. Patients suffer from a wide array of symptoms and have a variable prognosis that depends upon the severity and type of organ involvement. The diagnosis of SLE should be confirmed prior to initiating treatment (",
"    <a class=\"graphic graphic_table graphicRef86633 \" href=\"mobipreview.htm?1/31/1535\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the uncertain course, effective treatment requires ongoing patient-doctor communication to correctly interpret laboratory tests, to alleviate symptoms, to prevent and treat relapses, to lessen side effects related to drug therapy, to improve adherence with medications, and to coordinate care with the patient&rsquo;s primary care provider [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the general issues related to the treatment and prognosis of patients with SLE. The treatment of specific organ involvement is discussed separately. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETERMINATION OF DISEASE ACTIVITY AND SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An effective therapeutic regimen first requires confirmation of the diagnosis and the accurate determination of both disease activity and severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Disease activity usually refers to the degree of inflammation, while the degree of severity depends upon the level of organ dysfunction and upon the organ&rsquo;s relative importance. The degree of irreversible organ dysfunction has been referred to as the &ldquo;damage index&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of severe organ dysfunction does not necessarily imply ongoing inflammation. As an example, marked proteinuria and a decreasing glomerular filtration rate may result either from active inflammation or from scarred nephrons in the absence of active inflammatory disease. The ability to differentiate between these two possibilities is extremely important, since immunosuppressive therapy is not indicated in the latter setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinically useful markers of activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease activity is assessed using a combination of the clinical history, physical examination, organ-specific functional tests, and serologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/7-11,13-15\">",
"     7-11,13-15",
"    </a>",
"    ]. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active SLE (particularly lupus nephritis) is often preceded by a rise in immunoglobulin G (IgG) anti-double-stranded deoxyribonucleic acid (dsDNA) titers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/16-20\">",
"       16-20",
"      </a>",
"      ], by a fall in complement levels (especially CH50, C3, and C4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/17,19,20\">",
"       17,19,20",
"      </a>",
"      ], and by an elevation in complement split and activation products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/17,19-21\">",
"       17,19-21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Persistently low serum levels of complement C1q are associated with continued activity of proliferative glomerulonephritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increases in the erythrocyte sedimentation rate (ESR) and in the serum C-reactive protein (CRP) concentration are also commonly seen within this setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/23-26\">",
"       23-26",
"      </a>",
"      ], and, in one study, increases in the CRP were associated with a broad range of particular clinical features and with disease activity or organ damage in certain systems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/27\">",
"       27",
"      </a>",
"      ]. The association of increased CRP with disease activity was noted particularly with constitutional, eye, pulmonary, gastrointestinal, and neurologic disease activity, but elevated CRP was not associated with an index of organ damage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/28\">",
"       28",
"      </a>",
"      ]. There are conflicting data on the diagnostic value of a marked elevation of CRP in distinguishing active lupus from infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/24,29\">",
"       24,29",
"      </a>",
"      ], but a markedly elevated level of CRP in a patient with SLE should raise the suspicion for infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, not all patients with these serologic markers have active disease, and these markers do not necessarily predict disease exacerbation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/25\">",
"     25",
"    </a>",
"    ]. In one study, for example, 12 percent of patients with hypocomplementemia and elevated anti-DNA antibody titers had no clinical evidence of active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/30\">",
"     30",
"    </a>",
"    ]. We favor an approach in which such patients are closely monitored; therapy is adjusted if there are signs of clinical worsening of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Frequency of laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency with which monitoring laboratory tests are performed is tailored to each patient. In general, patients with more active disease are monitored more frequently, while those with inactive disease require less frequent monitoring. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient with active lupus nephritis may have a battery of tests done once weekly.",
"     </li>",
"     <li>",
"      For someone with a reduction in glomerular filtration rate whose disease is stable and who is free of proteinuria, testing every two to three months may be appropriate.",
"     </li>",
"     <li>",
"      A patient with previously active nephritis, a normal glomerular filtration rate, and no proteinuria, whose SLE is otherwise quiescent, may be tested every four to six months.",
"     </li>",
"     <li>",
"      Someone with no history of renal involvement and with quiescent disease may be retested every 6 to 12 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following laboratory tests are suggested for monitoring in a patient with a previous history of renal involvement who is currently free of proteinuria and who has a normal creatinine clearance:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate",
"     </li>",
"     <li>",
"      C-reactive protein",
"     </li>",
"     <li>",
"      Urinalysis with examination of urinary sediment",
"     </li>",
"     <li>",
"      Spot (untimed) urine protein and creatinine",
"     </li>",
"     <li>",
"      Serum creatinine and estimated glomerular filtration rate (eGFR)",
"     </li>",
"     <li>",
"      Serum albumin",
"     </li>",
"     <li>",
"      Anti-dsDNA",
"     </li>",
"     <li>",
"      Complement (CH50, C3, and C4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients without a history of lupus nephritis, the spot (untimed) urine protein and creatinine, as well as the serum albumin, are unnecessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Investigational markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous investigations of other immunologic tests as indicators of disease activity have been reported, including antibodies to C1q and to nucleosomes, complement activation products, soluble T-cell activation markers, serum levels of various cytokines and cytokine receptors, angiogenic factors, adhesion molecules, chemokines, and cell surface makers of immunologic activation (eg, erythrocyte- or reticulocyte-bound C4d) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gene expression profiling and proteomic approaches may eventually provide additional indices of disease activity. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased expression of genes activated by interferon in peripheral blood mononuclear cells has been noted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Active disease may be associated with a constellation of autoantibodies that can be detected using glomerular proteomic arrays [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A proteomic approach identified a pattern of proteins that was both sensitive and specific for active nephritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased amounts of erythrocyte-bound C4d were correlated with increased disease activity in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/35\">",
"       35",
"      </a>",
"      ] but not in another [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Urinary biomarkers for nephritis include interleukin-6, neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein, micro-ribonucleic acid (miRNA), and transforming growth factor-&beta; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The usefulness of the investigational markers of disease activity noted above either has been unconfirmed or has generally not been proven to be as useful as monitoring complement and anti-double stranded DNA antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Disease activity indices",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of research protocol disease activity or damage measures or indices, including the Systemic Lupus Erythematosus (SLE) Disease Activity Index (SLEDAI), the Safety of Estrogens in Lupus Erythematosus: National Assessment-SLEDAI (SELENA-SLEDAI), the Systemic Lupus Activity Measure (SLAM), the British Isles Lupus Assessment Group (BILAG), the European Consensus Lupus Activity Measurement (ECLAM), and others, have been designed in an attempt to better monitor disease activity and to assess trial outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/35,38-44\">",
"     35,38-44",
"    </a>",
"    ]. They all use a combination of history, examination, and laboratory data; these protocols may have general applicability to clinical practice if simplified. The particular outcome measure used in a trial, even for organ-specific disease such as lupus nephritis, can influence apparent trial outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trials are also using combinations of indices to create composite assessment measures for determining trial outcomes. Examples include the SRI (Systemic Lupus Erythematosus Response Index), used in the pivotal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"     belimumab",
"    </a>",
"    trials, and the BICLA (BILAG-based Combined Lupus Assessment), used in a trial of epratuzumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H48780341\">",
"     'Belimumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENERAL TREATMENT CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the pattern and severity of organ involvement determines specific drug therapy, a number of general issues are applicable to every patient with SLE. We emphasize the importance of adherence to medication regimens, of maintenance of good sleep hygiene, and of follow-through with recommended testing. Patients should also be informed of the availability of resource information relating to the treating center and to lupus support organizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/6,47\">",
"     6,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sun protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoid exposure to direct or reflected sunlight and other sources of ultraviolet (UV) light (eg, fluorescent and halogen lights). Use sunscreens, preferably those that block both UV-A and UV-B, with a high skin protection factor (SPF). A sunscreen with a SPF of 55 or greater is suggested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diet and nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data exist concerning the effect of dietary modification in SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Of two studies performed by one group of investigators, the larger trial randomly assigned 60 patients to receive either 1.8 grams of eicosapentaenoic acid (EPA) and 1.2 grams of docosahexanoic acid (DHA) or placebo, daily, for 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/49\">",
"     49",
"    </a>",
"    ]. Those on fish oil had a significantly greater reduction in an index of disease activity (the revised SLAM [SLAM-R]) and improvement in endothelial function, as assessed by flow-mediated arterial dilation, than did the placebo group. These findings await independent confirmation; thus, we do not recommend fish oil supplements in the treatment of SLE.",
"   </p>",
"   <p>",
"    A conservative approach is to recommend a balanced diet consisting of carbohydrates, proteins, and fats. However, the diet should be modified based upon disease activity and upon the response to therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with active inflammatory disease and fever may require an increase in caloric intake.",
"     </li>",
"     <li>",
"      Glucocorticoids enhance appetite, resulting in potentially significant weight gain. Hunger can be somewhat lessened by the ingestion of water, antacids, proton pump inhibitors,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      histamine H2 blockers. A low calorie diet should be instituted if there is significant weight gain.",
"     </li>",
"     <li>",
"      Hyperlipidemia may be induced by the nephrotic syndrome or by the administration of glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"       \"Lipid abnormalities in nephrotic syndrome\"",
"      </a>",
"      .) In one report, increasing the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      by 10 mg per day was associated with an elevation in serum cholesterol of 7.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/51\">",
"       51",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients with hyperlipidemia should be encouraged to eat a low-fat diet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/52\">",
"       52",
"      </a>",
"      ]. A lipid-lowering agent (usually a statin) should be considered if serum cholesterol remains above the recommended values despite a change in diet. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamins are rarely needed when patients eat a balanced diet. However, a daily multivitamin should be taken by patients who are not able to obtain an adequate diet or who are dieting to lose weight.",
"     </li>",
"     <li>",
"      The majority of patients with SLE have low serum levels of 25-hydroxyvitamin D (calcidiol) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/53\">",
"       53",
"      </a>",
"      ], probably due, at least in part, to avoidance of sun exposure. Patients with low vitamin D levels should be treated with supplemental vitamin D. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23753?source=see_link\">",
"       \"Musculoskeletal manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients on long-term glucocorticoids and postmenopausal women should ingest 800 units of vitamin D plus 1500 mg of calcium per day",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      should ingest a bisphosphonate to minimize the degree of bone loss. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Herbal remedies are of unproven benefit and may cause harm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with hypertension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nephritis, dietary measures such as salt restriction may be required. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=see_link\">",
"       \"Salt intake, salt restriction, and essential hypertension\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=see_link\">",
"       \"Diet in the treatment and prevention of hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who are overweight, measures to encourage weight loss should be instituted. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inactivity produced by acute illness causes a rapid loss of muscle mass, bone demineralization, and loss of stamina resulting in a sense of fatigue. This can usually be treated with isometric and graded exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. In selected refractory cases, relief can be obtained with antimalarial drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking may increase the risk of developing SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/58\">",
"     58",
"    </a>",
"    ], and smokers in general have more active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/59\">",
"     59",
"    </a>",
"    ]. Patients should be counseled not to smoke or to quit smoking and should be provided with help to do so.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    is less effective in smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"     \"Patient information: Quitting smoking (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We advise that patients should receive appropriate immunizations prior to the institution of immunosuppressive therapies. It had been previously thought that immunization could exacerbate SLE. However, influenza vaccine and pneumococcal vaccines are safe, but resultant antibody titers are somewhat less in patients with SLE than in controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Use of glucocorticoids, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , or other immunosuppressive agents may contribute to the blunted antibody response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=see_link&amp;anchor=H18#H18\">",
"     \"Glucocorticoid effects on the immune system\", section on 'Impact on vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, it is inadvisable to immunize potentially immunosuppressed patients (including those treated with glucocorticoids alone at doses equivalent to &ge;20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for more than two weeks) with live vaccines (eg, measles, mumps, rubella, polio, varicella, and vaccinia [smallpox]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the issue of efficacy of vaccination with hepatitis B (HepB) vaccine has not been completely resolved, the risks posed by HepB vaccine to patients with SLE must, at most, be very small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/61,63\">",
"     61,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylaxis for Pneumocystis pneumonia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Systemic lupus erythematosus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anecdotal reports of increased toxicity following therapeutic ionizing radiation have made radiation oncologists wary of treating patients with SLE and other collagen vascular disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/64\">",
"     64",
"    </a>",
"    ]. Patients with scleroderma may be at greater risk. However, if needed, radiation therapy may be used in patients with SLE to treat malignant disease.",
"   </p>",
"   <p>",
"    Among the studies and reviews that have addressed the safety and toxicity of radiation therapy in patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/47,65-68\">",
"     47,65-68",
"    </a>",
"    ] the following are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two observational series have included 19 patients with SLE among those with &ldquo;collagen vascular diseases&rdquo; receiving radiation therapy for cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. No unusually severe local reactions in the skin or subcutaneous tissues in the radiation portal were noted in those with lupus.",
"     </li>",
"     <li>",
"      One study included 17 patients with SLE who received radiation therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/47\">",
"       47",
"      </a>",
"      ]. Four patients had a grade 3 or higher toxicity at 5 to 10 years. There was a trend toward greater toxicity with more severe disease and with more extensive organ involvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who have an overlap of scleroderma with SLE appear to be at highest risk of marked fibrotic reaction to radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treating comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated atherosclerosis, pulmonary hypertension, and antiphospholipid antibodies, as well as osteopenia or osteoporosis, are among the comorbid conditions which can be treated and for which screening tests are appropriately used. These comorbid disorders, for which patients with SLE have an increased risk, include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accelerated atherosclerosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=see_link&amp;anchor=H15#H15\">",
"       \"Coronary heart disease in systemic lupus erythematosus\", section on 'Prevention and treatment'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pulmonary hypertension &mdash; Although an imperfect screening test, Doppler echocardiography is usually used as the initial noninvasive study for pulmonary hypertension. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=see_link\">",
"       \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antiphospholipid antibodies &mdash; The presence of antiphospholipid antibodies is assessed by assays for antibodies to cardiolipin (aCL), for antibodies to beta 2 glycoprotein-1 (anti-&szlig;2 glycoprotein-I), and for the presence of lupus anticoagulant (LA) activity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27096?source=see_link\">",
"       \"Diagnosis of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osteopenia or osteoporosis &mdash; Bone mineral density determination may detect the presence of osteopenia or osteoporosis and may allow dietary or medical interventions to prevent or reverse bone demineralization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link\">",
"       \"Screening for osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Avoidance of specific medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that sulfonamide-containing antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , sulfisoxazole) may cause exacerbations and should, therefore, be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/69\">",
"     69",
"    </a>",
"    ]. This impression with regard to sulfa-containing agents was supported by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control study of 145 patients with SLE and 104 controls, in which adverse reactions to sulfonamide-containing antibiotics were more than twice as frequent in those with SLE (52 versus 19 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A study of 417 patients with SLE, among whom 114 (27 percent) had a history of sulfonamide allergy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/71\">",
"       71",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, medications that cause drug-induced lupus, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , do not cause exacerbations of idiopathic SLE. This observation is a presumed reflection of the pathogenetic differences between the two disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    can also cause drug-induced lupus. We advise against its use in patients with SLE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pregnancy and contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy should be avoided during active disease (especially with significant organ impairment) due to the high risk of miscarriage and exacerbation of SLE. Women with SLE should be counseled not to become pregnant until the disease has been quiescent for at least six months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=see_link\">",
"     \"Pregnancy in women with systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral contraceptives containing high-dose estrogens can cause exacerbations of SLE. However, this complication rarely occurs with the current use of low-dose estrogen or progesterone-containing compounds. Patients with migraine headaches, Raynaud phenomenon, a history of phlebitis, or antiphospholipid antibodies probably should not be treated with oral contraceptives. Hormone replacement therapy in postmenopausal women may be associated with a modest increase in the rate of flares, and decisions about use of estrogen for postmenopausal symptoms must be carefully considered weighing the potential benefits against risks of thrombotic events and of breast and uterine cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16646?source=see_link\">",
"     \"Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnant patients with active lupus are generally managed with glucocorticoids. Other drugs used during pregnancy include nonsteroidal antiinflammatory drugs (avoided during early pregnancy and in the third trimester) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (probably safe).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    are contraindicated, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    can be cautiously used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=see_link\">",
"     \"Pregnancy in women with systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT OF SPECIFIC ORGAN INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medications are commonly used in the treatment of SLE, including nonsteroidal antiinflammatory drugs (NSAIDs), antimalarials (primarily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    ), glucocorticoids, and immunosuppressive agents (including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"     belimumab",
"    </a>",
"    ). Patient compliance with recommended treatment is, as expected, associated with better outcomes than noncompliance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    What follows is a general overview of which drugs are preferred in selected clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical therapies are often useful for cutaneous manifestations of lupus and reduce the risk of side effects that are associated with systemic use of NSAIDs, glucocorticoids, or immunosuppressants.",
"     </li>",
"     <li>",
"      NSAIDs are generally effective for musculoskeletal complaints, fever, headaches, and mild serositis.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       Naproxen",
"      </a>",
"      may have greater relative cardiovascular safety than other NSAIDs.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"       Celecoxib",
"      </a>",
"      has been used in SLE patients, even in those with &ldquo;sulfa&rdquo; allergy, without precipitating any allergic response but should be administered with caution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/74\">",
"       74",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23753?source=see_link\">",
"       \"Musculoskeletal manifestations of systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of selective COX-2 inhibitors\", section on 'Sulfonamide allergy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antimalarials are most useful for skin manifestations and for musculoskeletal complaints. In addition, in long-term studies, the use of antimalarials, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , prevented major damage to the kidneys and central nervous system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/75\">",
"       75",
"      </a>",
"      ]. Their use may also reduce the risk of disease flares, though this is less clear for renal and central nervous system (CNS) manifestations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/76\">",
"       76",
"      </a>",
"      ]. Antimalarials and their use in SLE are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link\">",
"       \"Antimalarial drugs in the treatment of rheumatic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic glucocorticoids (eg, high doses of 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent or intermittent intravenous &ldquo;pulses&rdquo; of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      ) used alone or in combination with immunosuppressive agents are generally reserved for patients with significant organ involvement, particularly renal and CNS disease. There is a paucity of data to support the use of intravenous &ldquo;pulse&rdquo; versus daily oral glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/77\">",
"       77",
"      </a>",
"      ]. Patients with organ-threatening disease (eg, cardiopulmonary, hepatic, renal, hemolytic anemia, immune thrombocytopenia) are usually given the above-mentioned oral doses, whereas non-organ-threatening disease (eg, cutaneous, musculoskeletal, constitutional) patients usually respond to 5 to 15 mg of prednisone (or equivalent) daily until a glucocorticoid-sparing agent or antimalarial can take effect.",
"     </li>",
"     <li>",
"      Immunosuppressive medications other than glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/78\">",
"       78",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ) are generally reserved for patients with significant organ involvement",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      for patients who have had an inadequate response to glucocorticoids. The use of cyclophosphamide and other immunosuppressive agents in SLE is discussed in greater detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link\">",
"       \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=see_link\">",
"       \"Clinical features and therapy of membranous lupus nephritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=see_link\">",
"       \"Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=see_link\">",
"       \"Neurologic manifestations of systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/34/42534?source=see_link\">",
"       \"Pulmonary manifestations of systemic lupus erythematosus in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5928?source=see_link\">",
"       \"Gastrointestinal manifestations of systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/60/11210?source=see_link\">",
"       \"Pulmonary manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31498?source=see_link\">",
"       \"Management of refractory discoid lupus and subacute cutaneous lupus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14106?source=see_link\">",
"       \"Hematologic manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22456?source=see_link\">",
"       \"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/46/38631?source=see_link\">",
"       \"Neuropsychiatric manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Immunosuppressive agents such as mycophenolate, azathioprine, or cyclophosphamide are given with glucocorticoids to patients with more than mild lupus nephritis, and cyclophosphamide is given to those with alveolar hemorrhage, to those with systemic vasculitis, and to most patients with significant CNS involvement. Lower doses of glucocorticoids (eg, &le;10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) may be used for symptomatic relief of severe arthralgia, arthritis, or serositis while awaiting a therapeutic effect from other medications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link\">",
"       \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=see_link\">",
"       \"Neurologic manifestations of systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/60/11210?source=see_link\">",
"       \"Pulmonary manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"       Belimumab",
"      </a>",
"      is available in the United States for the treatment of patients with active SLE who are receiving standard therapy, such as NSAIDs, glucocorticoids, antimalarials,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunosuppressives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/79\">",
"       79",
"      </a>",
"      ]. However, it has not been adequately studied in patients with severe active lupus nephritis or with CNS lupus or in patients who have previously used",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      or who have recently used intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      . The role of belimumab in SLE treatment is uncertain. (See",
"      <a class=\"local\" href=\"#H48780341\">",
"       'Belimumab'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA sulfate) are major circulating androgens, and dietary supplements containing these androgenic steroids are widely available. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/263?source=see_link\">",
"       \"Dehydroepiandrosterone and its sulfate\"",
"      </a>",
"      .) Women with systemic lupus erythematosus have low serum DHEA and DHEA sulfate concentrations, even prior to initiating chronic glucocorticoid therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/80\">",
"       80",
"      </a>",
"      ]. A 2007 meta-analysis concluded that DHEA probably leads to little or no important difference in disease activity in people with mild to moderate SLE; it may improve overall well being but does so at the expense of androgenic side effects including acne, hair growth, and menstrual changes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/81\">",
"       81",
"      </a>",
"      ]. In addition, because the purity and potency of available dietary supplements are uncontrolled, use of DHEA or DHEA sulfate supplements is not recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of agents have been used in patients resistant to more well-established therapeutic approaches, including biologic agents that target either B cells or T cells.",
"   </p>",
"   <p>",
"    Patients with severe organ involvement who are resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy generally do poorly. The optimal approach to such patients is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48780341\">",
"    <span class=\"h2\">",
"     Belimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"     Belimumab",
"    </a>",
"    (Benlysta, formerly termed Lymphostat-B) is a fully human monoclonal antibody that inhibits the biologic activity of the soluble form of a B-cell survival factor, B-lymphocyte stimulator or BLyS (also known as B-cell activating factor belonging to the tumor necrosis factor [TNF] family [BAFF]); belimumab has become available in the United States for the treatment of patients with active autoantibody-positive SLE who are receiving standard therapy, including NSAIDs, glucocorticoids, antimalarials, or immunosuppressives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/79,82-86\">",
"     79,82-86",
"    </a>",
"    ]. It has not been evaluated in patients with severe active lupus nephritis or with severe active central nervous system lupus, nor has it been studied in combination with other biologics or intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Also, the use of belimumab is not recommended by the manufacturer in these situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/87\">",
"     87",
"    </a>",
"    ]. However, the role of belimumab in SLE treatment is evolving. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=see_link&amp;anchor=H10#H10\">",
"     \"The humoral immune response\", section on 'TACI, BAFF and APRIL'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the available data and upon our clinical experience, we suggest limiting the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"     belimumab",
"    </a>",
"    to patients who are similar to those enrolled in the two major trials, such as those with active musculoskeletal or cutaneous disease. The dose regimen recommended by the manufacturer is 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at two-week intervals for the first three doses and at four-week intervals thereafter.",
"   </p>",
"   <p>",
"    We advise limiting its use to patients who require at least 10 mg daily of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    along with antimalarials and with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    to maintain control of disease activity or to patients who are intolerant of such medications. We do not recommend its use for the purpose of treating severe active lupus nephritis or severe active CNS lupus until efficacy has been shown for these indications. Live vaccines should not be given concurrently with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"     belimumab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Levels of BLyS are elevated in some patients with SLE, and it may play a role in the pathogenesis of lupus by promoting the formation and survival of memory B cells and plasmablasts making autoantibodies. Inhibition of BLyS can reduce the numbers of B cells and short-lived plasma cells and can decrease anti-double stranded DNA antibody titers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37562?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and pathogenesis of systemic lupus erythematosus\", section on 'Immune abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two randomized, multinational trials (the BLISS-52 trial and BLISS-76 trial) involving a total of 1684 patients demonstrated the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"     belimumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. In the BLISS-52 trial, 867 patients with active lupus and with a positive antinuclear antibody (ANA) or anti-double-stranded DNA antibody were randomly assigned to receive belimumab 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (administered intravenously on days 0, 14, and 28 and every 28 days until 48 weeks) or placebo infusions, together with their standard care, including NSAIDs, antimalarials, glucocorticoids, and immunosuppressives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/83\">",
"     83",
"    </a>",
"    ]. Outcomes were assessed with a novel endpoint, the SLE responder index (SRI), which was developed based upon a retrospective analysis of data from an earlier randomized trial of belimumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/88\">",
"     88",
"    </a>",
"    ]. Patients were defined as responders based upon the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall improvement in disease activity of at least four points on the SLE Disease Activity Index (SLEDAI) as modified for the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) trial (the SELENA-SLEDAI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A lack of significant disease progression in any single dimension or organ system, as indicated by the absence of a new British Isles Lupus Assessment Group (BILAG) A organ domain score and by no more than one new BILAG B organ domain score [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/89,90\">",
"       89,90",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      No worsening (less than a 0.3 out of 3 increase) in the Physician&rsquo;s Global Assessment (PGA) compared with baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A significantly higher likelihood of achieving an SRI at one year was observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"     belimumab",
"    </a>",
"    (10 or 1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    compared with placebo (58 and 51 percent versus 44 percent, odds ratios (OR) 1.83, 95% CI 1.3-2.59, and 1.55, 95% CI 1.1-2.19, respectively). Additionally, belimumab was glucocorticoid-sparing. Those with a baseline dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    greater than 7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    who received belimumab were significantly more likely, compared with patients receiving placebo, to experience a sustained reduction in glucocorticoid doses (28 and 24 percent versus 15 percent, OR 1.96, 95% CI 1.25-3.07, and 1.6, 95% CI 1.01-2.53, respectively).",
"   </p>",
"   <p>",
"    Similar but more modest benefit was described at 52 weeks in a preliminary report of the other large randomized trial (BLISS-76), although, at 76 weeks, the degree of benefit was no longer statistically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall adverse event rates were similar in the patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"     belimumab",
"    </a>",
"    (10 or 1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or placebo in the published BLISS-52 trial, including serious infections, which were seen in 4 to 8 percent of patients. However, the FDA reported that, during all clinical studies and trials of the drug, more deaths and serious infections occurred with belimumab compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/79\">",
"     79",
"    </a>",
"    ]. Severe or serious hypersensitivity reactions were seen on infusion days in two patients in each belimumab group (less than 1 percent) but in none of the patients receiving placebo in the BLISS-52 trial. The most common adverse reactions in the clinical trials (occurring in at least 5 percent of patients) were nausea, diarrhea, and fever. Nasopharyngitis, bronchitis, insomnia, pain in the extremities, depression, migraine, and pharyngitis were also commonly reported.",
"   </p>",
"   <p>",
"    Post hoc analyses have further examined the results of these trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/91-94\">",
"     91-94",
"    </a>",
"    ]. A greater likelihood of improving with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"     belimumab",
"    </a>",
"    compared with placebo was associated with more active disease, anti-double stranded DNA antibodies, low complement levels, and use of glucocorticoids at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/91\">",
"     91",
"    </a>",
"    ]. Patients with musculoskeletal and mucocutaneous involvement were more likely to improve with belimumab compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/92\">",
"     92",
"    </a>",
"    ]. Use of the drug was also associated with a tendency for levels of IgG and of anti-DNA antibodies to decrease and for complement levels to normalize [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/93\">",
"     93",
"    </a>",
"    ]. Patients with active lupus nephritis receiving belimumab in addition to MMF showed a statistically nonsignificant trend toward greater improvement compared with patients on MMF without belimumab, although patients with severe active nephritis were excluded from the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several limitations to the available data regarding the benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"     belimumab",
"    </a>",
"    in SLE:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The subset of patients of African heritage and of African-Americans in the two major trials did not respond to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"       belimumab",
"      </a>",
"      , although insufficient numbers of such patients were enrolled to draw definite conclusions; additional studies in this population will be performed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who had received prior B-cell targeted therapy, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , or who had received intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      within the preceding six months were excluded from the trials.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"       Belimumab",
"      </a>",
"      has not been compared with any other active therapeutic agent used in the treatment of SLE, nor has it been studied in combination with other biologic agents or with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Patients with severe active lupus nephritis or severe active CNS lupus were excluded from the trials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, further studies are required to define the clinical utility of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"     belimumab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334601\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal anti-B lymphocyte antibodies may be beneficial for patients with disease that is resistant to other therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/95\">",
"     95",
"    </a>",
"    ]. However, concern has arisen from case reports of a possible association of the use of the chimeric anti-CD20 monoclonal antibody agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , with fatal progressive multifocal leukoencephalopathy (PML) due to reactivation of latent infection with the JC virus; such reports in two patients with SLE caused the United States Food and Drug Administration (FDA) to issue an alert to health providers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Both patients had received other immunosuppressive therapies. Other case reports of PML in patients treated for other diseases with rituximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/97-101\">",
"     97-101",
"    </a>",
"    ] suggest that B-cell depleting therapies should be used cautiously. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/7/44151?source=see_link\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17336?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334608\">",
"    <span class=\"h3\">",
"     Rituximab, cyclophosphamide, and glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of the B-cell depleting chimeric monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and high-dose glucocorticoids, as used in the treatment of lymphoma, has shown some promise in uncontrolled, observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/102-105\">",
"     102-105",
"    </a>",
"    ]. The potential benefits and adverse effects were illustrated in a large study of this combination in 90 patients with SLE refractory to conventional treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/103\">",
"     103",
"    </a>",
"    ]. Following rituximab infusion, patients were followed for 3 to 40 months. A &ldquo;meaningful&rdquo; decrease in disease activity was noted in 80 percent, and infusions were well-tolerated in 90 percent of patients. However, adverse events (ascribed to hypersensitivity to the chimeric antibody) occurred in 10 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334615\">",
"    <span class=\"h3\">",
"     Rituximab without cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite promising reports from uncontrolled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/106-109\">",
"     106-109",
"    </a>",
"    ], a placebo-controlled, randomized trial of 257 patients with active SLE (EXPLORER trial), which excluded those with nephritis, noted no significant difference in outcomes between those who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    plus two infusions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and those who received prednisone plus placebo infusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvement in lupus nephritis following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    treatment was noted in a series of 10 patients; five achieved a complete remission a median of three months after beginning rituximab treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/111\">",
"     111",
"    </a>",
"    ]. Eight patients experienced partial remissions at a median of two months. However, a large randomized study with a similar design to EXPLORER of rituximab in patients with lupus nephritis (LUNAR trial) was not successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/112\">",
"     112",
"    </a>",
"    ]. This may have been due to patients in both study arms having been given highly effective therapy with large doses of glucocorticoids and immunosuppressive agents, and the open label extension part of the protocol was halted due to concern relating to PML.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hematopoietic stem cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proposed mechanism of action of hematopoietic stem cell transplantation is that it provides a period free from memory T-cell influence, during which maturation of new lymphocyte progenitors can occur without recruitment to anti-self activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link&amp;anchor=H16#H16\">",
"     \"The adaptive cellular immune response\", section on 'Memory T cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Results from this approach are limited and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-dose chemotherapy followed by autologous stem cell transplantation administered to 50 patients with glomerulonephritis, cerebritis, transverse myelitis, autoimmune cytopenia, catastrophic antiphospholipid syndrome,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vasculitis despite intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/113\">",
"       113",
"      </a>",
"      ]. The overall five-year survival was 84 percent, and the probability of disease survival at five years was 50 percent. Treatment related mortality, in an intention to treat analysis, was 4 percent.",
"     </li>",
"     <li>",
"      Results from the European Registry of autologous stem cell transplantation for SLE, which were notable for induction of remission of disease activity in 33 of 50 cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/114\">",
"       114",
"      </a>",
"      ]. However, one-third of the patients relapsed at a median of six months. Survival was 62 percent at 48 months, with a treatment-related mortality of 12 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Autologous stem cell transplantation remains complex, costly, and, despite improvements in treatment-related mortality, risky. Additional study, including direct comparison with more conventional treatment approaches in randomized controlled trials, is needed before any recommendation can be made regarding the role of stem cell transplantation in the treatment of SLE. Use of allogenic stem cells is an interesting alternative for which there are insufficient data to assess efficacy or safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Immunoablation alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoablation without bone marrow or stem cell support has also been effective in some patients with moderate to severe SLE refractory to glucocorticoids and immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/115\">",
"     115",
"    </a>",
"    ]. However, safety concerns caused the US National Institutes of Health to halt their trial that was examining the effectiveness of immunoablation alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    (or ciclosporin) inhibits the transcription process that is normally associated with T-cell activation (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link&amp;anchor=H3#H3\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Mechanism of action'",
"    </a>",
"    ). Addition of cyclosporine may allow a reduction in the use of glucocorticoids. As an example, an unblinded study randomly assigned 89 patients with SLE, who were taking &ge;15 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    per day and who required the addition or change of a glucocorticoid-sparing drug, to receive either cyclosporine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    allowed reduction in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    dose at the end of one year of study. There was no statistically significant difference between cyclosporine and azathioprine in the reduction in dose (mean decrease in daily prednisolone dose of 9 mg and 10.7 mg, respectively, a difference of -1.7 mg [95% CI -4.4 to +0.9]).",
"   </p>",
"   <p>",
"    Similar rates of study drug discontinuation were noted for each group. Discontinuations due to lack of efficacy and due to side effects were also similar. In this study, neither severe hypertension nor irreversible renal injury occurred in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -treated subjects. However, hypertension was noted more frequently in patients who received cyclosporine (49 versus 14 percent), as was an increase in the serum creatinine (13 versus 2 percent). When cyclosporine is used in clinical practice, these side effects must be anticipated. Frequent monitoring of blood pressure and renal function is necessary for appropriate dose titration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Other agents in clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other therapeutic approaches have been tried or are under investigation in SLE, some of which are available for use in other immune-mediated conditions including rheumatoid arthritis. These include intravenous immunoglobulin;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ; LJP 394; anti-C5 complement monoclonal antibody; anti-interleukin (IL)-10; B-cell depleting agents, including small molecular immunopharmaceutical anti-CD20 and epratuzumab; atacicept; mizoribine; immunoadsorption, via perfusion of patients&rsquo; blood through a column of immobilized C1q or polyclonal sheep anti-human immunoglobulin; recombinant human IL-1 receptor antagonist (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    ); recombinant monoclonal antibody that inhibits ligand binding to the human interleukin-6 receptor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    ); spliceosomal peptide P140; non-coding (micro)RNA molecules; interferon-alpha and -gamma inhibitors; an anti-TNF monoclonal antibody (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ); and a T-cell costimulation blocker (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/45,46,116-139\">",
"     45,46,116-139",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLE can run a varied clinical course, ranging from a relatively benign illness to a rapidly progressive disease with fulminant organ failure and death. Most patients have a relapsing and remitting course, which may be associated with the use of high-dose glucocorticoids during the treatment of severe flares.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Patient survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The five-year survival rate in SLE has dramatically increased since the mid-20th century from approximately 40 percent in the 1950s to more than 90 percent in studies beginning after 1980 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/140-142\">",
"     140-142",
"    </a>",
"    ], a trend that has continued into the early 21st century [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of survival can be ranked on the basis of organ involvement (skin and musculoskeletal are best, central nervous system and kidney are worst) and on the number of American College of Rheumatology criteria for SLE (",
"    <a class=\"graphic graphic_table graphicRef73334 \" href=\"mobipreview.htm?2/47/2813\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/144\">",
"     144",
"    </a>",
"    ]. Older age, male sex, poverty, and a low complement may also be poor prognostic factors, as was noted in a cohort of North American patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/142\">",
"     142",
"    </a>",
"    ]. However, increasing age was not a predictor of an increased mortality rate in one Chinese cohort of 442 patients when compared with an age-adjusted population mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/145\">",
"     145",
"    </a>",
"    ]. Measures of disease activity and accumulated organ damage may also be predictive of increased mortality while use of antimalarial drugs may reduce mortality rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The improvement in patient survival is probably due to multiple factors. These include increased disease recognition with more sensitive diagnostic tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/146\">",
"     146",
"    </a>",
"    ], earlier diagnosis or treatment, the inclusion of milder cases, increasingly judicious therapy, and prompt treatment of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2002 report from the Centers for Disease Control in the United States, deaths due to SLE varied among different population groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/148\">",
"     148",
"    </a>",
"    ]. As examples, the proportion of deaths due to SLE was more than five times higher in women than men and was more than three times higher in black compared with white women. More than one-third of deaths due to lupus occurred in people aged 15 to 44 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Causes of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major cause of death in the first few years of illness is active disease (eg, CNS, renal, or cardiovascular disease) or infection due to immunosuppression, while late deaths are caused by the illness (eg, end-stage renal disease), by treatment complications (including infection and coronary disease), by non-Hodgkin lymphoma, and by lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/147,149-153\">",
"     147,149-153",
"    </a>",
"    ]. The frequency of the different causes of death can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest study included survival data and causes of death in a total of 9547 patients who were followed for an average of 8.1 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/153\">",
"       153",
"      </a>",
"      ]. Standardized mortality rates (SMR) of SLE patients to expected rates for a age- and sex-adjusted population were noted for circulatory disease (SMR 1.7), especially heart disease (SMR 1.7); for non-Hodgkin lymphoma (SMR 2.8); for lung cancer (SMR 19.4); for infections (SMR 9.0), especially pneumonia (SMR 7.2); and for renal disease (SMR 4.3). Those at particularly high risk for mortality were younger, female, and black, with disease duration of less than one year.",
"     </li>",
"     <li>",
"      One study evaluated the causes of death in 408 patients with SLE followed over a mean period of 11 years; 144 (35 percent) died [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/154\">",
"       154",
"      </a>",
"      ]. The major causes of death were active lupus (34 percent), infection (22 percent), cardiovascular disease (16 percent), and cancer (6 percent). Deaths that resulted directly from SLE and infection were common among younger patients; the risk of death directly due to SLE was highest in the first three years after diagnosis.",
"     </li>",
"     <li>",
"      Another prospective study followed 1000 patients for 10 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/141\">",
"       141",
"      </a>",
"      ]. The most frequent causes of death were active SLE (26 percent), infection (25 percent), and thromboses (26 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/141\">",
"       141",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of 4747 Swedish patients who were diagnosed with SLE between 1964 and 1995, the proportions of deaths due to cardiovascular events, SLE, and malignant disease were 42 percent, 21 percent, and 12 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/155\">",
"       155",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serious infection is most often due to immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29706?source=see_link\">",
"     \"Secondary immune deficiency induced by drugs and biologics\"",
"    </a>",
"    .) Patients at particular risk are those treated with both glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , especially if the white blood cell count is less than",
"    <span class=\"nowrap\">",
"     3000/microL",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if high-dose glucocorticoids are given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/156,157\">",
"     156,157",
"    </a>",
"    ]. Lymphopenia",
"    <span class=\"nowrap\">",
"     (&lt;1000/microL)",
"    </span>",
"    at presentation may be an independent risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/158\">",
"     158",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Premature coronary artery disease is being increasingly recognized as a cause of late mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=see_link\">",
"     \"Coronary heart disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Is cancer risk increased?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the relation of SLE to malignancy was previously unclear because conflicting data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/153,159-164\">",
"     153,159-164",
"    </a>",
"    ], a clear increase of certain malignancies in patients with SLE was subsequently recognized.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased risk in patients with SLE, predominantly for that of non-Hodgkin type lymphoma, which was found in a 2005 meta-analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/165\">",
"       165",
"      </a>",
"      ]. Non-Hodgkin lymphoma in patients with SLE is often an aggressive histologic subtype, especially diffuse large B-cell lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/166,167\">",
"       166,167",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An association with Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/168\">",
"       168",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An increase in lung cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/168\">",
"       168",
"      </a>",
"      ]. Smoking was a predictor for lung cancer in women with SLE.",
"     </li>",
"     <li>",
"      A twofold increase in the incidence of breast cancer when compared with an age- and gender-matched segment of the population (standardized incidence ratio of 2.1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/169\">",
"       169",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An increase of squamous skin cancer among 238 patients with SLE in Iceland [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/170\">",
"       170",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An increased frequency of abnormal cervical Papanicolaou (Pap) smears in women with SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/171\">",
"       171",
"      </a>",
"      ]. The risk factors for the development of an abnormal Pap smear include a history of sexually transmitted diseases, the use of oral contraceptives, and the use of immunosuppressive drugs.",
"     </li>",
"     <li>",
"      An increased incidence of cervical cancer in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/163\">",
"       163",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An increased risk of vaginal or vulvar cancer, which was seen in one study (RR 5.7) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/159\">",
"       159",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antimalarial drug use may be associated with a reduced risk of cancer. This is suggested by the results of an observational study of 235 Spanish patients, among whom two-thirds were treated at some time with an antimalarial drug while one-third were never treated with one of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/172\">",
"     172",
"    </a>",
"    ]. After adjustment for other risk factors, use of antimalarial drugs was associated with a statistically significant (85 percent) reduction in the relative risk of malignant disease. Further study of the influence of antimalarial drug use on the incidence of cancer did not confirm these initial results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/168\">",
"     168",
"    </a>",
"    ]. These agents are used to treat some specific types of organ involvement. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Treatment of specific organ involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although some data suggest that the use of immunosuppressive drugs may be associated with the later development of hematologic malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/173\">",
"     173",
"    </a>",
"    ], there is insufficient information to conclude whether or not the use of immunosuppressive medications in patients with SLE increases their risk for malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/168\">",
"     168",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor prognostic factors for survival in SLE include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/141,144,151,154,159,174-180\">",
"     141,144,151,154,159,174-180",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Renal disease (especially diffuse proliferative glomerulonephritis)",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Male sex",
"     </li>",
"     <li>",
"      Young age",
"     </li>",
"     <li>",
"      Older age at presentation",
"     </li>",
"     <li>",
"      Poor socioeconomic status",
"     </li>",
"     <li>",
"      Black race, which may primarily reflect low socioeconomic status",
"     </li>",
"     <li>",
"      Presence of antiphospholipid antibodies",
"     </li>",
"     <li>",
"      Antiphospholipid syndrome",
"     </li>",
"     <li>",
"      High overall disease activity (eg, hemolytic anemia, thrombotic thrombocytopenic purpura [TTP], alveolar hemorrhage, pulmonary hypertension, mesenteric vasculitis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite a reduction in the risk of premature death, patients with SLE are at risk for significant morbidity due both to active disease and to the side effects of drugs such as glucocorticoids and cytotoxic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/181\">",
"     181",
"    </a>",
"    ]. Glucocorticoid-induced avascular necrosis of the hips and knees, osteoporosis, fatigue, and cognitive dysfunction have become particularly important problems as patients live longer with their illness with a concomitant increase in total glucocorticoid exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/182\">",
"     182",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors that may be associated with a shorter delay between disease onset and organ damage include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/183\">",
"     183",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hispanic ethnicity",
"     </li>",
"     <li>",
"      Greater disease activity",
"     </li>",
"     <li>",
"      A history of thrombotic events",
"     </li>",
"     <li>",
"      Glucocorticoid use of less than 10 mg per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glucocorticoid use at doses equivalent to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &ge;10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was associated with a longer time from SLE onset to organ damage, but, as noted above, long-term use of higher doses of glucocorticoids has significant risks that must be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Clinical remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;After appropriate therapy, some patients go into a clinical remission, requiring no treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/184,185\">",
"     184,185",
"    </a>",
"    ]. The frequency with which this occurs was addressed in two long-term follow-up studies.",
"   </p>",
"   <p>",
"    In one study of 667 patients, the following were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/184\">",
"     184",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 25 percent had at least one treatment-free clinical remission lasting for at least one year. The mean duration of remission was 4.6 years, which represents an underestimate since one-half of the patients were still in remission at the end of follow-up.",
"     </li>",
"     <li>",
"      A long history of SLE or the presence of renal or neuropsychiatric disease did not preclude remission.",
"     </li>",
"     <li>",
"      Among the 48 percent of patients who relapsed after achieving remission, one-half did not achieve a subsequent remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a second study of 703 patients, 46 achieved complete clinical remission of at least one-year duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/38/41578/abstract/186\">",
"     186",
"    </a>",
"    ]. However, of these, only 12 were still in remission after five years.",
"   </p>",
"   <p>",
"    These observations demonstrate that remission is uncommon, and, even when achieved, it is frequently not sustained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/42/22178?source=see_link\">",
"       \"Patient information: Lupus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=see_link\">",
"       \"Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/42/36518?source=see_link\">",
"       \"Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11414608\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An effective therapeutic regimen for the treatment of systemic lupus erythematosus (SLE) first requires the accurate determination of both disease activity and severity. Disease activity usually refers to the degree of inflammation, while the degree of severity depends upon the level of organ dysfunction and upon the organ&rsquo;s relative importance. The degree of irreversible organ disfunction has been referred to as the &ldquo;damage index.&rdquo; Disease activity is assessed using a combination of the clinical history, physical examination, organ-specific functional tests, and serologic studies. The frequency with which monitoring laboratory tests are performed is tailored to each patient, generally depending upon the level of disease activity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Determination of disease activity and severity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinically useful markers of activity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Frequency of laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pattern and severity of organ involvement determines specific drug therapy, but a number of general issues are applicable to every patient with SLE. Adherence to medication regimens, maintenance of good sleep hygiene, and follow-through with recommended testing are of particular importance. Patients should also be informed of the availability of resource information relating to the treating center and to lupus patient support organizations. Other important issues include protection from sunlight and from other sources of ultraviolet light; a balanced approach to diet and nutrition, considering clinical needs; exercise; smoking cessation; immunizations; treatment of comorbid conditions; avoidance of certain medications; and avoidance of pregnancy during active disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General treatment considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of medications are commonly used in the treatment of SLE, including nonsteroidal antiinflammatory drugs (NSAIDs), antimalarials (primarily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      ), glucocorticoids, and agents that are immunosuppressive or immunomodulatory (including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"       belimumab",
"      </a>",
"      ). Certain drugs are preferred in selected clinical settings. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment of specific organ involvement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe organ involvement who are resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      therapy generally do poorly. The optimal approach to such patients is uncertain. A number of investigational strategies are under investigation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SLE can run a varied clinical course, ranging from a relatively benign illness to a rapidly progressive disease with fulminant organ failure and death. Most patients have a relapsing and remitting course, which may be associated with the use of high-dose glucocorticoids during the treatment of severe flares. The five-year survival rate has improved to greater than 90 percent due to multiple factors. The major cause of death in the first few years of illness is active disease or infection due to immunosuppression, while causes of late deaths include the illness, treatment complications, non-Hodgkin lymphoma, and lung cancer. There is an increase in the frequency of certain malignancies in patients with SLE. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Patient survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite a reduction in the risk of premature death, patients with SLE are at risk for significant morbidity due both to active disease and to the side effects of drugs such as glucocorticoids and cytotoxic agents. After appropriate therapy, some patients go into a clinical remission, requiring no treatment. However, remission is uncommon, and, even when achieved, it is frequently not sustained. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Morbidity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H38\">",
"       'Clinical remission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/1\">",
"      Strand V. New therapies for systemic lupus erythematosus. Rheum Dis Clin North Am 2000; 26:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/2\">",
"      Smolen JS. Therapy of systemic lupus erythematosus: a look into the future. Arthritis Res 2002; 4 Suppl 3:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/3\">",
"      Gescuk BD, Davis JC Jr. Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol 2002; 14:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/4\">",
"      Ginzler EM, Moldovan I. Systemic lupus erythematosus trials: successes and issues. Curr Opin Rheumatol 2004; 16:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/5\">",
"      Goldblatt F, Isenberg DA. New therapies for systemic lupus erythematosus. Clin Exp Immunol 2005; 140:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/6\">",
"      Wallace DJ. Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox. Lupus 2008; 17:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/7\">",
"      Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/8\">",
"      Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/9\">",
"      Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/10\">",
"      Bencivelli W, Vitali C, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/11\">",
"      Gladman DD, Iba&ntilde;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/12\">",
"      Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/13\">",
"      Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 2004; 50:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/14\">",
"      Liu CC, Manzi S, Ahearn JM. Biomarkers for systemic lupus erythematosus: a review and perspective. Curr Opin Rheumatol 2005; 17:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/15\">",
"      Jolly M. Pitfalls and opportunities in measuring patient outcomes in lupus. Curr Rheumatol Rep 2010; 12:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/16\">",
"      Bootsma H, Spronk PE, Ter Borg EJ, et al. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation. Ann Rheum Dis 1997; 56:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/17\">",
"      Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981; 60:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/18\">",
"      Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/19\">",
"      Linnik MD, Hu JZ, Heilbrunn KR, et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/20\">",
"      Kao AH, Navratil JS, Ruffing MJ, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum 2010; 62:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/21\">",
"      Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44:2350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/22\">",
"      Gunnarsson I, Sundelin B, Heimb&uuml;rger M, et al. Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria. J Rheumatol 2002; 29:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/23\">",
"      Roy S, Tan KT. Pyrexia and normal C-reactive protein (CRP) in patients with systemic lupus erythematosus: always consider the possibility of infection in febrile patients with systemic lupus erythematosus regardless of CRP levels. Rheumatology (Oxford) 2001; 40:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/24\">",
"      Suh CH, Jeong YS, Park HC, et al. Risk factors for infection and role of C-reactive protein in Korean patients with systemic lupus erythematosus. Clin Exp Rheumatol 2001; 19:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/25\">",
"      Esdaile JM, Abrahamowicz M, Joseph L, et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996; 39:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/26\">",
"      Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008; 59:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/27\">",
"      Lee SS, Singh S, Link K, Petri M. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008; 38:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/28\">",
"      Bertoli AM, Vil&aacute; LM, Reveille JD, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage. J Rheumatol 2008; 35:2355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/29\">",
"      Barnes EV, Narain S, Naranjo A, et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005; 14:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/30\">",
"      Walz LeBlanc BA, Gladman DD, Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares. J Rheumatol 1994; 21:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/31\">",
"      R&ouml;nnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006; 54:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/32\">",
"      Alcorta DA, Barnes DA, Dooley MA, et al. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int 2007; 72:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/33\">",
"      Li QZ, Zhen QL, Xie C, et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest 2005; 115:3428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/34\">",
"      Mosley K, Tam FW, Edwards RJ, et al. Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford) 2006; 45:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/35\">",
"      Liu CC, Manzi S, Danchenko N, Ahearn JM. New advances in measurement of complement activation: lessons of systemic lupus erythematosus. Curr Rheumatol Rep 2004; 6:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/36\">",
"      Singh V, Mahoney JA, Petri M. Erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. J Rheumatol 2008; 35:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/37\">",
"      Reyes-Thomas J, Blanco I, Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol 2011; 40:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/38\">",
"      Haq I, Isenberg DA. How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice? Best Pract Res Clin Rheumatol 2002; 16:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/39\">",
"      Merrill JT. Measuring disease activity in systemic lupus: progress and problems. J Rheumatol 2002; 29:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/40\">",
"      Rahman A, Hiepe F. Anti-DNA antibodies--overview of assays and clinical correlations. Lupus 2002; 11:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/41\">",
"      Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 2004; 50:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/42\">",
"      Yee CS, Farewell V, Isenberg DA, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 2007; 56:4113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/43\">",
"      Yee CS, McElhone K, Teh LS, Gordon C. Assessment of disease activity and quality of life in systemic lupus erythematosus - New aspects. Best Pract Res Clin Rheumatol 2009; 23:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/44\">",
"      Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/45\">",
"      Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012; 64:3660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/46\">",
"      Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/47\">",
"      Gold DG, Miller RC, Pinn ME, et al. Chronic toxicity risk after radiotherapy for patients with systemic sclerosis (systemic scleroderma) or systemic lupus erythematosus: association with connective tissue disorder severity. Radiother Oncol 2008; 87:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/48\">",
"      Duffy EM, Meenagh GK, McMillan SA, et al. The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol 2004; 31:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/49\">",
"      Wright SA, O'Prey FM, McHenry MT, et al. A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis 2008; 67:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/50\">",
"      Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987; 83:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/51\">",
"      Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/52\">",
"      Hearth-Holmes M, Baethge BA, Broadwell L, Wolf RE. Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus. J Rheumatol 1995; 22:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/53\">",
"      Toloza SM, Cole DE, Gladman DD, et al. Vitamin D insufficiency in a large female SLE cohort. Lupus 2010; 19:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/54\">",
"      Herbal roulette. Consumer Reports 1995; 60:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/55\">",
"      Robb-Nicholson LC, Daltroy L, Eaton H, et al. Effects of aerobic conditioning in lupus fatigue: a pilot study. Br J Rheumatol 1989; 28:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/56\">",
"      Tench CM, McCarthy J, McCurdie I, et al. Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology (Oxford) 2003; 42:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/57\">",
"      Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/58\">",
"      Formica MK, Palmer JR, Rosenberg L, McAlindon TE. Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black Women's Health Study. J Rheumatol 2003; 30:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/59\">",
"      Ghaussy NO, Sibbitt W Jr, Bankhurst AD, Qualls CR. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 2003; 30:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/60\">",
"      Leroux G, Costedoat-Chalumeau N, Hulot JS, et al. Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. Ann Rheum Dis 2007; 66:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/61\">",
"      O'Neill SG, Isenberg DA. Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus 2006; 15:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/62\">",
"      Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998; 41:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/63\">",
"      Kuruma KA, Borba EF, Lopes MH, et al. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 2007; 16:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/64\">",
"      De Naeyer B, De Meerleer G, Braems S, et al. Collagen vascular diseases and radiation therapy: a critical review. Int J Radiat Oncol Biol Phys 1999; 44:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/65\">",
"      Ross JG, Hussey DH, Mayr NA, Davis CS. Acute and late reactions to radiation therapy in patients with collagen vascular diseases. Cancer 1993; 71:3744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/66\">",
"      Rakfal SM, Deutsch M. Radiotherapy for malignancies associated with lupus: case reports of acute and late reactions. Am J Clin Oncol 1998; 21:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/67\">",
"      Lin A, Abu-Isa E, Griffith KA, Ben-Josef E. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer 2008; 113:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/68\">",
"      H&ouml;lscher T, Bentzen SM, Baumann M. Influence of connective tissue diseases on the expression of radiation side effects: a systematic review. Radiother Oncol 2006; 78:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/69\">",
"      Petri M, Allbritton J. Antibiotic allergy in systemic lupus erythematosus: a case-control study. J Rheumatol 1992; 19:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/70\">",
"      Pope J, Jerome D, Fenlon D, et al. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol 2003; 30:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/71\">",
"      Jeffries M, Bruner G, Glenn S, et al. Sulpha allergy in lupus patients: a clinical perspective. Lupus 2008; 17:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/72\">",
"      Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/73\">",
"      Chambers SA, Rahman A, Isenberg DA. Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/74\">",
"      Lander SA, Wallace DJ, Weisman MH. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus 2002; 11:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/75\">",
"      Fessler BJ, Alarc&oacute;n GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/76\">",
"      A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med 1991; 324:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/77\">",
"      Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 2007; 16:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/78\">",
"      Fortin PR, Abrahamowicz M, Ferland D, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008; 59:1796.",
"     </a>",
"    </li>",
"    <li>",
"     FDA news release. FDA approves Benlysta to treat lupus. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246489.htm (Accessed on March 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/80\">",
"      Suzuki T, Suzuki N, Engleman EG, et al. Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995; 99:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/81\">",
"      Crosbie D, Black C, McIntyre L, et al. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database Syst Rev 2007; :CD005114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/82\">",
"      Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/83\">",
"      Navarra SV, Guzm&aacute;n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/84\">",
"      van Vollenhoven RF, Zamani O, Wallace DJ, et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. Ann Rheum Dis 2010; 69(suppl3):74.",
"     </a>",
"    </li>",
"    <li>",
"     FDA briefing information, belimumab (BENLYSTA), for the November 16, 2010 meeting of the Arthritis Advisory Committee www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/ucm233578.htm (Accessed on March 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/86\">",
"      Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008; 10:R109.",
"     </a>",
"    </li>",
"    <li>",
"     Benlysta (belimumab): Full prescribing information. file://us.gsk.com/products/assets/us_benlysta.pdf (Accessed on April 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/88\">",
"      Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009; 61:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/89\">",
"      Isenberg DA, Gordon C, BILAG Group. British Isles Lupus Assessment Group. From BILAG to BLIPS--disease activity assessment in lupus past, present and future. Lupus 2000; 9:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/90\">",
"      Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/91\">",
"      van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 71:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/92\">",
"      Manzi S, S&aacute;nchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012; 71:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/93\">",
"      Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/94\">",
"      Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013; 22:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/95\">",
"      Tieng AT, Peeva E. B-cell-directed therapies in systemic lupus erythematosus. Semin Arthritis Rheum 2008; 38:218.",
"     </a>",
"    </li>",
"    <li>",
"     FDA alert [12/18/2006]. Rituximab (marketed as Rituxan) Information. www.fda.gov/cder/drug/InfoSheets/HCP/rituximab.pdf (Accessed on December 21, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/97\">",
"      Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/98\">",
"      Garc&iacute;a-Su&aacute;rez J, de Miguel D, Krsnik I, et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005; 80:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/99\">",
"      Steurer M, Clausen J, Gotwald T, et al. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation 2003; 76:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/100\">",
"      Matteucci P, Magni M, Di Nicola M, et al. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 2002; 100:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/101\">",
"      Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/102\">",
"      Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007; 66:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/103\">",
"      Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005; 17:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/104\">",
"      Ng KP, Leandro MJ, Edwards JC, et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006; 65:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/105\">",
"      J&oacute;nsd&oacute;ttir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008; 67:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/106\">",
"      Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50:2580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/107\">",
"      Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/108\">",
"      Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54:2970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/109\">",
"      Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/110\">",
"      Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/111\">",
"      Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52:501.",
"     </a>",
"    </li>",
"    <li>",
"     Furie R, Looney RJ, Rovin B, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): Results form the randomized, double-blind Phase III Lunar study (abstract). Presented at the 2009 scientific meeting of the ACR.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/113\">",
"      Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/114\">",
"      Tyndall A. Cellular therapy of systemic lupus erythematosus. Lupus 2009; 18:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/115\">",
"      Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003; 48:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/116\">",
"      Griffiths B, Emery P, Ryan V, et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford) 2010; 49:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/117\">",
"      Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56:4142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/118\">",
"      Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis. Nat Rev Rheumatol 2009; 5:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/119\">",
"      Jacobi AM, Goldenberg DM, Hiepe F, et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008; 67:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/120\">",
"      Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:3077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/121\">",
"      Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of Ocrelizumab, a humanized ani CD20 antibody, in patients with active proliferative lupus nephritis (LN): Results from the randomized, double-blind Phase III, BELONG study. Arthritis Rheum 2010; 62:S606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/122\">",
"      &Oslash;stergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010; 62:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/123\">",
"      Fleischmann R, Cohen S, Pardo P, et al. SAT0188 B cell depletion in subjects with controlled systemic lupus erythematosus (SLE) after intravenous or subcutaneous administration of SBI-087. Ann Rheum Dis 2010; 69(supp 3).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/124\">",
"      Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/125\">",
"      Muller S, Monneaux F, Schall N, et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum 2008; 58:3873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/126\">",
"      Wallace DJ, Petri M, Olsen N, et al. MEDI-545, an interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum 2007; 56:S526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/127\">",
"      Schroeder JO, Zeuner RA, Euler HH, L&ouml;ffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996; 23:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/128\">",
"      McMurray RW, Weidensaul D, Allen SH, Walker SE. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 1995; 22:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/129\">",
"      Hackshaw KV, Shi Y, Brandwein SR, et al. A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus. J Rheumatol 1995; 22:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/130\">",
"      Fernandez D, Bonilla E, Mirza N, et al. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/131\">",
"      Wallace DJ, Tumlin JA. LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus 2004; 13:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/132\">",
"      Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009; 48:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/133\">",
"      Pfueller B, Wolbart K, Bruns A, et al. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum 2001; 44:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/134\">",
"      Stummvoll GH, Aringer M, Smolen JS, et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 2005; 64:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/135\">",
"      Ostendorf B, Iking-Konert C, Kurz K, et al. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005; 64:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/136\">",
"      Yumura W, Suganuma S, Uchida K, et al. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol 2005; 64:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/137\">",
"      Rigby RJ, Vinuesa CG. SiLEncing SLE: the power and promise of small noncoding RNAs. Curr Opin Rheumatol 2008; 20:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/138\">",
"      Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/139\">",
"      Uppal SS, Hayat SJ, Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009; 18:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/140\">",
"      Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001; 13:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/141\">",
"      Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/142\">",
"      Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006; 85:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/143\">",
"      Urowitz MB, Gladman DD, Tom BD, et al. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008; 35:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/144\">",
"      Callahan LF, Pincus T. Mortality in the rheumatic diseases. Arthritis Care Res 1995; 8:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/145\">",
"      Mok CC, To CH, Ho LY, Yu KL. Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. J Rheumatol 2008; 35:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/146\">",
"      Seleznick MJ, Fries JF. Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum 1991; 21:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/147\">",
"      Ward MM, Pyun E, Studenski S. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996; 156:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/148\">",
"      Centers for Disease Control and Prevention (CDC). Trends in deaths from systemic lupus erythematosus--United States, 1979-1998. MMWR Morb Mortal Wkly Rep 2002; 51:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/149\">",
"      Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 1985; 55:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/150\">",
"      Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995; 22:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/151\">",
"      Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 1995; 22:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/152\">",
"      Moss KE, Ioannou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002; 61:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/153\">",
"      Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/154\">",
"      Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum 1995; 38:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/155\">",
"      Bj&ouml;rn&aring;dal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004; 31:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/156\">",
"      Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996; 39:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/157\">",
"      Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003; 15:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/158\">",
"      Ng WL, Chu CM, Wu AK, et al. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM 2006; 99:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/159\">",
"      Mellemkjaer L, Andersen V, Linet MS, et al. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/160\">",
"      Sweeney DM, Manzi S, Janosky J, et al. Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol 1995; 22:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/161\">",
"      Nived O, Bengtsson A, J&ouml;nsen A, et al. Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 2001; 10:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/162\">",
"      Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996; 39:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/163\">",
"      Ramsey-Goldman R, Mattai SA, Schilling E, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 1998; 46:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/164\">",
"      Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005; 52:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/165\">",
"      Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/166\">",
"      Bernatsky S, Ramsey-Goldman R, Rajan R, et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005; 64:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/167\">",
"      L&ouml;fstr&ouml;m B, Backlin C, Sundstr&ouml;m C, et al. A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 2007; 66:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/168\">",
"      Gayed M, Bernatsky S, Ramsey-Goldman R, et al. Lupus and cancer. Lupus 2009; 18:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/169\">",
"      Bernatsky S, Clarke A, Ramsey-Goldman R, et al. Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/170\">",
"      Ragnarsson O, Gr&ouml;ndal G, Steinsson K. Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 2003; 12:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/171\">",
"      Bernatsky S, Ramsey-Goldman R, Gordon C, et al. Factors associated with abnormal Pap results in systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/172\">",
"      Ruiz-Irastorza G, Ugarte A, Egurbide MV, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 2007; 66:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/173\">",
"      Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 2008; 67:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/174\">",
"      Barron KS, Silverman ED, Gonzales J, Reveille JD. Clinical, serologic, and immunogenetic studies in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1993; 36:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/175\">",
"      Miller MH, Urowitz MB, Gladman DD, Killinger DW. Systemic lupus erythematosus in males. Medicine (Baltimore) 1983; 62:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/176\">",
"      McLaughlin JR, Bombardier C, Farewell VT, et al. Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 1994; 37:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/177\">",
"      Drenkard C, Villa AR, Alarc&oacute;n-Segovia D, P&eacute;rez-V&aacute;zquez ME. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 1994; 21:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/178\">",
"      Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/179\">",
"      Walsh SJ, Algert C, Gregorio DI, et al. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol 1995; 22:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/180\">",
"      Wadee S, Tikly M, Hopley M. Causes and predictors of death in South Africans with systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/181\">",
"      Stoll T, Sutcliffe N, Mach J, et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study. Rheumatology (Oxford) 2004; 43:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/182\">",
"      Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/183\">",
"      Toloza SM, Roseman JM, Alarc&oacute;n GS, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis Rheum 2004; 50:3177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/184\">",
"      Drenkard C, Villa AR, Garcia-Padilla C, et al. Remission of systematic lupus erythematosus. Medicine (Baltimore) 1996; 75:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/185\">",
"      Heller CA, Schur PH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol 1985; 12:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/38/41578/abstract/186\">",
"      Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005; 32:1467.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4675 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-4BCC47CC64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41578=[""].join("\n");
var outline_f40_38_41578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11414608\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETERMINATION OF DISEASE ACTIVITY AND SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinically useful markers of activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Frequency of laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Investigational markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Disease activity indices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENERAL TREATMENT CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sun protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diet and nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treating comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Avoidance of specific medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pregnancy and contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT OF SPECIFIC ORGAN INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48780341\">",
"      Belimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H334601\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H334608\">",
"      - Rituximab, cyclophosphamide, and glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H334615\">",
"      - Rituximab without cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hematopoietic stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Immunoablation alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Other agents in clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Patient survival",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Causes of death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Is cancer risk increased?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Clinical remission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11414608\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/4675\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4675|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/31/1535\" title=\"table 1\">",
"      Classification criteria for SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/47/2813\" title=\"table 2\">",
"      ACR criteria for SLE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=related_link\">",
"      Clinical features and therapy of membranous lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=related_link\">",
"      Coronary heart disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/263?source=related_link\">",
"      Dehydroepiandrosterone and its sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27096?source=related_link\">",
"      Diagnosis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=related_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37562?source=related_link\">",
"      Epidemiology and pathogenesis of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5928?source=related_link\">",
"      Gastrointestinal manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31498?source=related_link\">",
"      Management of refractory discoid lupus and subacute cutaneous lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/16/16646?source=related_link\">",
"      Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23753?source=related_link\">",
"      Musculoskeletal manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=related_link\">",
"      Neurologic manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/46/38631?source=related_link\">",
"      Neuropsychiatric manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/59/22456?source=related_link\">",
"      Non-coronary cardiac manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/42/22178?source=related_link\">",
"      Patient information: Lupus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=related_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/42/36518?source=related_link\">",
"      Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=related_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17336?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/60/11210?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/34/42534?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=related_link\">",
"      Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_38_41579="Oligosymptomatic celiac disease";
var content_f40_38_41579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical and laboratory findings in 82 oligosymptomatic Italian children with celiac disease detected by screening",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Iron deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        With anemia",
"       </td>",
"       <td class=\"sublist_other\">",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Without anemia",
"       </td>",
"       <td class=\"sublist_other\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent abdominal pain",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mood changes",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent aphthous stomatitis",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor appetite",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent diarrhea",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short stature",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal distention",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constipation",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pubertal delay",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoalbuminemia",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Catassi C, Fabiani E, R&auml;tsch IM, et al. The coeliac iceberg in Italy: a multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr 1996; 412(Suppl):29.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41579=[""].join("\n");
var outline_f40_38_41579=null;
var title_f40_38_41580="CRT vs chemo LAPC";
var content_f40_38_41580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Trials of chemotherapy versus chemoradiotherapy followed by chemotherapy in locally advanced pancreatic cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Au, year",
"       </td>",
"       <td class=\"subtitle1\">",
"        5-FU plus arms",
"       </td>",
"       <td class=\"subtitle1\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\">",
"        RT dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Hazel J; 1981",
"       </td>",
"       <td>",
"        5-FU + methyl-CCNU",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        Median OS 7.8 versus 7.3 months (NSS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         RT + 5-FU 500 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         weekly",
"        </p>",
"        <p>",
"         Post CRT: 5-FU + methyl-CCNU",
"        </p>",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        46 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Klaassen D; 1985",
"       </td>",
"       <td>",
"        5-FU weekly bolus",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        Median OS 8.2 versus 8.3 months (NSS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         RT + 5-FU 600 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         &nbsp;days 1 to 3&nbsp;only",
"        </p>",
"        <p>",
"         Post CRT: 5-FU weekly bolus",
"        </p>",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        40 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        GITSG; 1988",
"       </td>",
"       <td>",
"        5-FU + streptozocin + mitomycin",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        Median OS significantly better with CRT (42&nbsp;versus 32 weeks)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         RT + 5-FU 350 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         per day, first&nbsp;three + last&nbsp;three days RT",
"        </p>",
"        <p>",
"         Post CRT: 5-FU + streptozocin + mitomycin",
"        </p>",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        54 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <p>",
"         Chauffert B; 2006",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        Gemcitabine",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        Median OS significantly better with chemotherapy alone (14.3&nbsp;versus 8.4 months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         RT + infus 5-FU + cisplatin&nbsp;days 1 to 5&nbsp;every week",
"        </p>",
"        <p>",
"         Post CRT: Gemcitabine",
"        </p>",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        60 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Loehrer P; 2011&nbsp;",
"       </td>",
"       <td>",
"        Gemcitabine&nbsp;",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RT plus gemcitabine&nbsp;",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        &nbsp;50.4 Gy",
"       </td>",
"       <td>",
"        Median OS significantly better with&nbsp;CRT (11.1&nbsp;versus 9.2 months)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     5-FU: 5-fluorouracil; CRT: chemoradiotherapy; GITSG: Gastrointestinal Tumor Study Group; OS: overall survival; NSS: differences not statistically significant; RT: radiation therapy.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41580=[""].join("\n");
var outline_f40_38_41580=null;
var title_f40_38_41581="Glucocorticoid binding in asthma";
var content_f40_38_41581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Glucocorticoid binding in steroid-sensitive and steroid-resistant asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 374px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scatchard analysis of glucocorticoid receptor binding to glucocorticoid response element (GRE) oligonucleotide in nuclear extracts from peripheral blood mononuclear cells isolated from a glucocorticoid-sensitive and a glucocorticoid-resistant patient. This plot is typical of three such determinations in each group of patients. Nuclear extracts were prepared after incubation with dexamethasone (1 &micro;m) for 30 min, and 32P-labeled GRE oligonucleotide was separated by nondenaturing gel electrophoresis and counted directly. Specific binding was determined by subtraction of nonspecific binding in the presence of excess unlabeled GRE oligonucleotide.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Adcock I, Lane S, Brown C, et al, J Immunol 1995; 154:3503.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41581=[""].join("\n");
var outline_f40_38_41581=null;
var title_f40_38_41582="Pathogenesis of secondary hyperparathyroidism";
var content_f40_38_41582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Schematic depiction of factors that contribute to secondary hyperparathyroidism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 399px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The figure shows that renal injury, increased dietary phosphate load, and increased calcitriol levels stimulate increased FGF23 secretion by the osteocytes in the early stages CKD. The increase in FGF-23 helps to maintain normal phosphorus balance by increasing urinary phosphate excretion and by inhibiting 1,25(OH)2D synthesis. However, the trade-off for this seemingly beneficial adaptation is that the decreased 1,25(OH)2D levels stimulates PTH secretion. Hypocalcemia, which results from various factors shown in the figure, also stimulates PTH secretion. However, the direct effects of phosphate retention on increased PTH secretion becomes more apparent in the advanced stages of CKD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Wajeh Y Qunibi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41582=[""].join("\n");
var outline_f40_38_41582=null;
var title_f40_38_41583="Squamous debris";
var content_f40_38_41583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Old tympanostomy tube with squamous debris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extrusion of most tubes is initiated by the continual shedding of squamous debris from the epithelium of the tympanic membrane. As debris accumulates under the outer flange of the tube, the pressure causes the flange to lift up from the surface of the membrane, as depicted above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isaacson G, Rosenfeld RM. Care of the child with tympanostomy tubes. A visual guide for the pediatrician. Pediatrics 1994; 93:924. Copyright &copy; 1994 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_38_41583=[""].join("\n");
var outline_f40_38_41583=null;
